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Abstract 
The class II cytokine family consists of structurally homologous receptors and their 
ligands, including type I and type II interferons (IFNs), interleukin-10 (IL-10) and IL-10 
related factors, such as IL-24, IL-26 and IL-22. They exert a broad range of functions on 
the immune system, such as anti-viral, anti-inflammatory and immuno-regulatory 
effects.  The recent sequencing and annotation of the human genome led to identification 
of several additional members of this cytokine family, including interferon-1 (or IL-
29),2 (IL-28A) and 3 (IL-28B).  An understanding of the function and biological 
relevance of these novel class II cytokines is important to expand our knowledge of the 
immune system and to potentially open the door for new therapeutic possibilities. This 
thesis aimed to analyse how the expression of the human IFN-1 gene is regulated and 
what role this cytokine plays during acute and chronic inflammation.  It revealed that the 
gene is rapidly and strongly induced in human monocyte-derived dendritic cells in 
response to LPS.  Using a combination of RNA-interference and over-expression studies, 
it was found that this induction was strongly dependent on specific transcription factors 
of the NF-B and Interferon Regulatory Factor (IRF) families, such as RelA and IRF3/7.  
Furthermore, gene reporter and bio-informatic analyses suggested that IRF3/7 activity is 
mediated via interactions with the proximal part of the IFN-1 promoter, whereas the 
majority of RelA activity is mediated via a distal cluster of putative NF-B binding sites 
located between -1106 and -1901 nucleotides upstream of the gene.  A combination of 
electrophoretic mobility shift assay and chromatin immunoprecipitation confirmed that 
RelA could efficiently bind to binding sites within this cluster.  Interestingly, these distal 
NF-B binding sites in the IFN-1 promoter are contained within transposable elements 
of Alu and LTR families, and the evolutionary significance of this is discussed.  This 
thesis also shows that a specific chain of the IFN-1 receptor complex (IFN-R1) is 
expressed in a cell-type specific manner, with primary human myeloid cells and 
synoviocytes derived from rheumatoid arthritis patients expressing only a modest level of 
the receptor.  Consequently IFN-1 had limited effect on inflammatory cytokine 
production by these cells.  The role of this restricted IFN system and its potential 
therapeutic benefits in inflammatory diseases will be discussed.  
  3 
Acknowledgements 
 
There are so many people who have been incredibly helpful and supportive over the last 
four years. 
 
First and foremost, I will be eternally indebted to Irina for her superb guidance and 
supervision throughout my PhD.  It has been a privilege and pleasure to have known and 
worked with her.  I also thank Brian for sharing his keen scientific insight and critical 
discussions.   
 
I would also like to thank Brain, Matt, Grisha, Alessandra, Richard, Andy, Fergie and 
particularly Irina, for taking their time to critically read this thesis and making many 
helpful suggestions.   
 
I also wish to thank everyone in my group, and on the ground floor, for making my time 
here so enjoyable and rewarding.   
 
Most of all I want to extend my thanks and love to my family, who has given me the best 
upbringing anyone could hope for, and to Eva, particularly for showing enormous 
patience over the last six months and always and putting up with my chronically 
depressive state of mind!  Without her constant love, support and optimism I cannot 
imagine how I would have got everything finished!  THANK YOU HONEY!!! 
 
 
 
 
 
 
 
 
 
 
 
 
  4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This thesis is dedicated to the memory of my beloved Grandma,  
Maisie Finlayson 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  5 
Table of contents 
 
 
Title page          1  
Abstract          2      
Acknowledgements         3      
Table of contents         5      
List of figures         13 
Abbreviations         16 
       
Chapter 1  Introduction                                   18                                                
1.1    The immune system      19 
1.2    Cells involved in the immune response   21 
1.2.1    Neutrophils       21 
1.2.2    Monocytes       21 
1.2.3    Macrophages       21 
1.2.4    Dendritic cells        22 
1.2.5    T-lymphocytes       24 
1.2.5.1    Helper T-lymphocytes      25 
1.2.5.2    Cytotoxic T-lymphocytes      26 
1.2.6     B-cells        27 
1.3    Innate immunity is activated by pattern recognition          
   receptors       27 
1.3.1    Toll-like receptors      28 
1.3.1.1    TLR4        29 
1.3.1.2    TLR3, 7, 8, and 9       30 
1.3.1.3    TLR1, 2, 6, and 5       30 
1.3.2    TLR expression in leukocytes     30 
1.3.3    Proximal TLR signaling      31 
1.3.3.1    MyD88-dependent pathway     32 
1.3.3.2    MyD88-independent pathway     32 
1.4    NF-κB and IRF transcription factors are key    
   regulators of TLR gene expression    33 
1.4.1    NF-κB        33 
1.4.1.1    NF-κB proteins       34 
  6 
1.4.1.2    NF-κB-DNA binding      35 
1.4.1.3    Inhibitor of NF-κB proteins     36 
1.4.1.4    The IKK complex       37 
1.4.1.5    Activation of NF-κB by the canonical pathway   37 
1.4.1.6    Activation of NF-κB by the non-canonical pathway   38 
1.4.1.7    Signalling to NF-κB via the MyD88-dependent pathway  38 
1.4.1.8    Signalling to NF-κB via the TRIF-dependent pathway   40 
1.4.1.9    Termination of the NF-κB response     40 
1.4.2   Interferon regulatory factors     41 
1.4.2.1    IRF structure        41 
1.4.2.2    IRF protein function      42 
1.4.2.3    IRF-DNA binding      44 
1.4.2.4    Activation of IRFs by viruses     44 
1.4.2.5    Signalling to IRFs via the TRIF pathway    45 
1.4.2.6    Signalling to IRFs via the MyD88 pathway    46 
1.4.3    NF-κB and IRFs can interact to regulate gene expression  47 
1.5    Sustained activation of innate immunity can result    
   in auto-immune disease     48 
1.5.1    Pathology of RA       49 
1.5.2    Etiology of RA       50 
1.5.3    RA treatment       51 
1.6    Class II cytokines exert a broad range of effects on   
   the immune system      51 
1.6.1    Type I IFNs       53 
1.6.1.1    Type I IFNs and their receptor     53 
1.6.1.2    Biological activities of type I IFNs     54 
1.6.1.3    Regulation of IFN-β in response to viruses    56 
1.6.1.4    Induction of IFN-α genes following virus infection        58 
1.6.1.5    Regulation of IFN-β in response to LPS    59 
1.6.2    Type II IFNs       59 
1.6.3    IL-10         60 
1.6.4    IL-10 related factors      61 
1.6.4.1    IL-22 and IL-26       61 
1.6.4.2    IL-19, IL-20 and IL-24      62 
1.6.5    IFN-λs        62 
1.6.5.1    Biological functions of IFN-λs     63  
1.6.5.2    IFN-λR expression is cell specific     65 
  7 
1.6.5.3    IFN-λs are induced by viral infection and specific TLR activation 66  
1.6.5.4    Regulation of type III IFNs       66 
1.7    Aims        68 
 
Chapter 2   Materials and methods     69 
2.1 Materials       70 
2.1.1    Human cell lines       70 
2.1.2    Taqman primer probes       70 
2.1.3   Antibodies       71 
2.1.3.1   ELISA antibodies       71 
2.1.3.2    Western blot antibodies      71 
2.1.3.3    Chromatin immuno-precipitation antibodies    72 
2.1.4    siRNA oligonucleotides      73 
2.1.5    Primers        72 
2.1.5.1    Primer sequences for generation of IRF expression constructs  72 
2.1.5.2  Primer sequences for generation of IFN-1 luciferase gene  
 reporter constructs      74 
2.1.5.3    Primer sequences for EMSA assays     74 
2.1.5.4    Primer sequences for chromatin immuno-precipitation   75 
2.2    Buffers and solutions      77 
2.2.1  Isolation of synoviocytes derived from inflamed membranes  
 of rheumatoid arthritis patients     77 
2.2.2  Western blotting       77 
2.2.3  EMSA        78 
2.2.4  Chromatin immuno-precipitation     78 
2.3    Methods       80 
2.3.1    Cell culture       80 
2.3.1.1    Maintenance of cell lines      80 
2.1.3.2    Cryopreservation of cells      80 
2.3.2    Isolation and differentiation of primary human myeloid cells  80 
2.3.2.1    Isolation of human peripheral blood mononuclear cells  80 
2.3.2.2    Isolation of human monocytes     81 
2.3.2.3    In vitro differentiation of human monocytes into dendritic cells 81 
2.3.2.4    In vitro differentiation of human monocytes into macrophages   81 
2.3.3  Isolation of synoviocytes derived from inflamed membranes  
 of rheumatoid arthritis patients      82 
  8 
2.3.3.1    Macrophage isolation       82 
2.3.3.2    Lymphocyte and fibroblast isolation     83 
2.3.3.3    FACS analysis of isolated cellular populations   84 
2.3.4    Analysis of collagen induced arthritis in IFN-R1 knock-out mice 84 
2.3.4.   Induction of CIA       84 
2.3.4.2    Clinical score       84 
2.3.4.3    RNA extraction from paws      85 
2.3.5    Quantitative real-time PCR     85 
2.3.5.1    RNA extraction and quantification     85 
2.3.5.2    cDNA synthesis       85 
2.3.5.3    Quantitative real-time PCR 2 standard curve method   86 
2.3.6    ELISA        87 
2.3.7    Western blotting       88 
2.3.7.1    Preparation of whole cell protein extracts    88 
2.3.7.2    Preparation of nuclear and cytoplasmic protein extracts  88 
2.3.7.3    Protein quantification: BCA assay     89 
2.3.7.4    SDS-PAGE       89 
2.3.7.5    Protein transfer       89 
2.3.7.6    Immuno-blotting and protein detection    90 
2.3.8    Cloning and generation of genetic constructs    90 
2.3.8.1    Generation of wild-type and dominant-negative IRF-3, 5 and 7  
   constructs        90 
2.3.8.2    Generation of human IFN-1 gene reporter constructs  91 
2.3.8.3    Generation of PO cDNA clone     93 
2.3.8.4    PCR        93 
2.3.8.5    Restriction digests      93 
2.3.8.6    Dephosphorylation of digested vectors    93 
2.3.8.7   Blunt-ending of 5’ and 3’ overhangs    94 
2.3.8.8    DNA purification       94 
2.3.8.9    DNA ligation       94 
2.3.8.10    Transformation of chemically competent cells   94 
2.3.8.11    Amplification and isolation of plasmids    95 
2.3.8.12    Identification of positive clones     95 
2.3.9    Transfection and adenoviral infection of cell cultures   95 
2.3.9.1    Transfection of siRNA oligonucleotides into cell lines   95 
2.3.9.2    Transfection of siRNA oligonucleotides into MDDCs   96 
2.3.9.3    Transfection of plasmids into cell lines     96 
  9 
2.3.9.4    Adenoviral infection of primary human myeloid cells   96 
2.3.10    Luciferase gene reporter assays     97 
2.3.11    EMSA        97 
2.3.11.1    DNA probe design and labeling     98 
2.3.11.2    Nuclear protein extract preparation    98 
2.3.11.3    Binding reaction and gel run     99 
2.3.12    Chromatin immuno-precipitation     99 
2.3.12.1    Preparation of nuclear extracts     100 
2.3.12.2    Sonication       100 
2.3.12.3    Immuno-precipitation      101 
2.3.12.4    DNA purification       101 
2.3.12.5    Real-time PCR analysis      101 
2.3.13   MTT cytotoxic assay      102 
2.3.14    Purification of recombinant proteins     102 
2.3.15    Bio-informatic analysis      103 
2.3.16    Statistical analyses      103 
      
 
Chapter 3   Does IFN-λ1 have a role in inflammation?   104 
3.1   Introduction       105 
3.2    Characterising the role of IFN- in acute  
   inflammation       106 
3.2.1    Human myeloid cells differentially express IFN-1 in response  
   to LPS        106 
3.2.2    MDDCs and M-CSF macrophages express low levels of IFN-R1  108 
3.2.3  IFN-λ1 does not modulate LPS-induced pro-inflammatory  
 cytokine expression in MDDCs or M-CSF macrophages  110 
3.2.4  IFN-λ1 does not modulate inflammatory cytokine production in  
 A549 cells       113 
3.2.5    IFN-λ1 and IFN-α regulate similar target genes in A549 cells  114 
3.3  Expression of IFN- in synovial tissue derived  
 from rheumatoid arthritis patients    117 
3.3.1  Characterisation of IFN-λ1 expression in synovial tissue  
 derived from rheumatoid arthritis patients    117 
3.3.2    Separation of cell types found within synovial tissue   119 
3.3.3  IFN-λ1 expression in distinct synoviocyte populations  122 
  10 
3.3.4  Characterisation of IFN-R1 expression in synovial tissue  
 derived from rheumatoid arthritis patients    124 
3.3.5  Effect of IFN-λ1 treatment on spontaneous cytokine  
 expression from inflamed synoviocyte cultures   125 
3.4  Characterisation of collagen induced arthritis  
 in IFN-λR1 knock out mice       127 
3.4.1  Female IFN-λR1 knock-out mice develop severe arthritic  
 symptoms in collagen induced arthritis    127 
3.4.2  Levels of cytokine expression are similar in the paws of  
 wild-type and IFN-λR1 knock-out mice    129 
3.5    Discussion       131 
 
Chapter 4  Key role of RelA and IRF3 in IFN-λ1 induction  137 
4.1    Introduction       138 
4.2  Characterisation of MDDC as a system to investigate  
 LPS-induced IFN-λ1 expression    139 
4.2.1    IFN-λ1 and IFN-β are expressed with similar kinetics   139 
4.2.2    IFN-λ1 mRNA induction in MDDCs is transcriptionally regulated  140 
4.2.3    NF-κB and IRF3 undergo rapid nuclear translocation in MDDCs 142 
4.3 Characterising TLR-expressing 293 cells as a model  
 system to understand IFN-λ1 transcriptional regulation 144 
4.3.1  IFN-λ1 is inducible in TLR-expressing 293 cells   144 
4.3.2    TLR3/4-293s express NF-κB and IRF3     146 
4.4  siRNA-mediated knockdown of RelA and IRF3  
 inhibits IFN-λ1 induction     148 
4.4.1  Optimisation of siRNA to knockdown specific NF-κB and IRF  
 proteins in TLR3-293s      148 
4.4.2  Functional effect of NF-κB/IRF3 knockdown on IFN-λ1 induction  
 in TLR3-293s        149 
4.4.3  Functional effect of NF-κB/IRF3 knockdown on IFN-λ1 induction  
 in TLR4-293s        151 
4.4.4    Validation of RNAi knockdown     153 
4.4.5    IFN-λ1 induction is dependent on RelA and IRF3 in MDDCs  153 
4.5  Validation of role of RelA and IRF3 in IFN-λ1 gene  
 induction in MDDCs      155 
  11 
4.5.1    IκBα DN inhibits IFN-λ1 gene induction    155 
4.5.2    Generation of IRF DN constructs     157 
4.5.3    Effect of DN IRF constructs on IFN-λ1 induction in MDDCs  160 
4.6  Over-expression of specific NF-κB and IRF proteins  
 to investigate IFN-λ1 induction    162 
4.6.1  RelA, IRF3 and IRF7 over-expression induces IFN-λ1 production  
 in TLR3-293 cells      162 
4.6.2    RelA can weakly synergise with IRF3 and IRF7 respectively  163 
4.6.3    Effect of over-expressing RelA and IRF3 in MDDCs   164 
4.7    Discussion       167 
 
Chapter 5 Functional κB sites in the IFN-1 promoter are  
 embedded in transposable elements   173 
5.1 Introduction       174 
5.2    Distal regulatory elements are required for maximal   
   IFN-λ1 gene activation     175 
5.2.1    Rationale for design of IFN-λ1 reporter constructs   175 
5.2.2  Positive regulatory elements are located within 5ΚB upstream  
 of the IFN-λ1 TSS      177 
5.2.3  Regulatory elements essential for IFN-λ1 gene induction are located  
 within the first -1901 nt upstream of the TSS   178 
5.2.4  Validation of IFN-λ1 -1901 reporter as a model of the endogenous 
  IFN-λ1 gene        179 
5.3  Identification of putative NF-κB and IRF binding  
 sites within the -1901 nucleotides upstream  
 of the IFN-λ1 gene      180 
5.4  RelA binding to the distal cluster of κB sites is a key  
 regulatory event in TLR4-mediated IFN-λ1 gene  
 activation        182 
5.4.1  RelA-mediated IFN-λ1 induction is mediated mainly via the  
 distal promoter region between -1106 and-1901 nucleotides  
 upstream of the TSS      182 
5.4.2  Mutation of individual putative κB sites does not  
 diminish IFN-λ1 -1901 reporter activity    183 
  12 
5.4.3  Mutation of multiple putative NF-κB binding sites inhibits  
 IFN-λ1 -1901 reporter activity     185 
5.4.4  Design of primer sequences to analyse the IFN-λ1 promoter  
 by chromatin immuno-precipitation     186 
5.4.5  RelA is rapidly recruited to the distal κB cluster in  
 LPS-treated MDDCs      189 
5.4.6  Multiple AluS elements containing κB sites are present  
 within the IFN-λ1 genomic locus     190 
5.5  Biochemical characterisation of distal cluster of  
 putative NF-κB sites      192 
5.5.1  Five of six κB sites in the IFN-λ1 promoter region efficiently  
 bind RelAp50 complexes      192 
5.5.2.    κB sites bind RelA/p50 complexes with similar affinities  193 
5.5.3  Five of six κB sites in the IFN-λ1 promoter region efficiently  
 NF-κB complexes in LPS-induced MDDCs    195 
5.5.4    ISRE2 site efficiently binds IRF3     196 
5.6    Discussion       198 
 
Chapter 6  Concluding discussion     204 
 
Chapter 7  References       214 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  13 
 
List of Figures 
 
 
Figure 1.1  Simplified overview of immune system activation in response to    
  infection        20    
Figure 1.2  Simplified overview of DC subtype development in vivo.   24 
Figure 1.3  Human Toll-like receptors, ligands and adaptors.    29 
Figure 1.4  Schematic representation of (A) NF-κB, (B) IκB and (c) IKK family members    35                                      
Figure 1.5  Simplified overview of Myd88 and TRIF-dependent signalling to NF-κB        39                  
Figure 1.6  Schematic representations of IRF family members    42  
Figure 1.7  Simplified overview of Myd88 and TRIF-dependent signalling to IRFs  46 
Figure 1.8  Schematic representation of healthy versus rheumatoid arthritis joint  49 
Figure 1.9  Schematic representation of class II cytokine receptors and ligands  53 
 
 
Figure 2.1.   A representative IFN-1 standard curve     86 
Figure 2.2   Cloning strategy employed for generation of HA-tagged wt and dn IRF-3,     
 IRF- 5, and IRF-7 adeno-viral constructs     91 
Figure 2.3   Cloning strategy employed for generation of IFN- gene promoter constructs 92 
 
 
 
Figure 3.1  Schematic illustration of generation of cell types used to model  
 acute inflammation       106 
Figure 3.2  LPS activates the IFN-1 gene in primary human myeloid cells  107 
Figure 3.3  M-CSF macrophages and MDDCs do not express high levels of functional  
 IFN-receptor        109 
Figure 3.4  IFN-1 does not modulate LPS-induced TNF or IL-6 production in M-CSF  
 macrophages        111 
Figure 3.5  IFN-1 does not modulate LPS-induced TNF or IL-6 production in MDDCs 112 
Figure 3.6  Effect of IFN-1 receptor activation on inflammatory cytokine protein  
 production in A549 cells       114 
Figure 3.7  IFN-1 and IFN- regulate similar target genes in A549 cells   115 
Figure 3.8 TNF is able to synergise with IFN-λ1 and IFN-α to activate interferon  
 stimulated genes and the IFN-λ1 gene  in A549 cells    116 
Figure 3.9  Low levels of IFN-1 are spontaneously expressed in rheumatoid synoviocytes 118 
  14 
Figure 3.10  Overview of synoviocyte separation procedure    120 
Figure 3.11  Assessment of synoviocyte isolation efficiency    121 
Figure 3.12  Summary of purity of synoviocyte populations following cell  
 isolation procedure       122 
Figure 3.13  Expression of (A) IFN-1, (B) TNF and (C) IL-10 in distinct populations  
 of synoviocytes        123 
Figure 3.14  IFN-R1 expression in RA synoviocytes is similar to that in myeloid cells 125 
Figure 3.15  IFN-1 does not modulate spontaneous cytokine production from cultured  
 synovial membranes derived from rheumatoid arthritis patients  126 
Figure 3.16  Female, but not male, IFN-λR1 knock-out mice develop significantly higher  
 clinical score compared to wild-type mice in collagen induced arthritis  128 
Figure 3.17  Cytokine expression is similar in arthritic paws of wild-type and IFN-λR1  
 knock-out mice with collagen induced arthritis    130 
 
 
 
Figure 4.1  Kinetics of LPS-induced IFN-1 induction in human MDDCs   140 
Figure 4.2  IFN-1 gene is regulated at the level of transcription    142 
Figure 4.3  LPS stimulation of MDDCs results in nuclear translocation of NF-κB  
  and IRF3        143 
Figure 4.4  Kinetics of induction of IFN-1 in TLR3-293s and TLR4-293s  145 
Figure 4.5  NF-κB subunits and IRF3 are expressed and undergo stimulus-dependent  
 translocation in TLR3- and TLR4-293s     147 
Figure 4.6  Efficient knock-down of NF-κB subunits and IRF3 in TLR3-293s by siRNA 149 
Figure 4.7   Knockdown of RelA and IRF3 significantly inhibits IFN-1 induction in  
 TLR3-293 cells        150 
Figure 4.8  RelA and IRF3 knock-down inhibits IFN-1 induction in TLR4-293s  152 
Figure 4.9   Validation of involvement of RelA and IRF3 in IFN-1 induction in  
 TLR3-293s using multiple siRNA reagents     153  
Figure 4.10  IFN-1 induction in response to LPS is dependent on RelA and IRF3  
  in MDDCs        154 
Figure 4.11  Over-expression of IBSR inhibits LPS-induced IFN-1 induction  
  in MDDC        157 
Figure 4.12  Generation of IRF DN expression constructs     159 
Figure 4.13  Effect of DN IRF3 and DN IRF5 over-expression on LPS-induced IFN-1  
 expression in MDDCs       161 
Figure 4.14  RelA, IRF3 and IRF7 selectively upregulate IFN-1 protein expression  
  15 
 in TLR3-293s        164 
Figure 4.15  Over-expression of IRF3 significantly increases LPS-induced IFN-1  
 protein expression in MDDCs      166 
 
 
Figure 5.1   Rationale for design of IFN-λ1 gene reporter constructs   176 
Figure 5.2   IFN-λ1 -5086 reporter construct had significantly more activity than the   
 -1106 reporter construct in (A) MDDCs, (B) M-CSF macrophages and  
 (C) GM-CSF macrophages      177 
Figure 5.3   IFN-λ1 -1901 reporter has significantly more activity compared to the -1106   
 reporter construct in (A) TLR4-293s and (B) TLR3-293s   178 
Figure 5.4  The behaviour of the IFN-λ1 -1901 reporter is similar to the endogenous 
 IFN-λ1 gene in response to NF-κB and IRF protein over-expression in  
 TLR3-293s        180 
Figure 5.5   Four putative NF-κB binding sites are located between -1106 and -1901  
 upstream of the IFN-λ1 transcription start site    181 
Figure 5.6  RelA and IRF3/7 activate IFN-λ1 via spatially separated (distal and proximal)  
 promoter elements in (A) TLR4-293s and (B) TLR3-293s   183 
Figure 5.7  Mutation of individual NF-κB binding sties does not diminish IFN-λ1 -1901  
 reporter activity in TLR4-293s      185 
Figure 5.8  Mutation of two NF-κB binding sties in the IFN-λ1 distal promoter region  
 inhibits IFN-λ1 -1901 reporter activity in TLR4-293s    186 
Figure 5.9  Primer design for analysis of IFN-λ1 promoter region by chromatin  
 immuno-precipitation       188 
Figure 5.10  RelA is rapidly recruited to the distal cluster of B sites in the IFN-1  
 promoter region        190 
Figure 5.11  Alu S subfamily elements in the IFN-1 gene locus    191 
Figure 5.12  Most putative NF-κB binding sites in the IFN-λ1 promoter region can  
 efficiently bind RelAp50       193 
Figure 5.13  Distal κB sites bind RelAp50 more efficiently then proximal κB site in the  
 IFN-λ1 promoter region       194 
Figure 5.14  Distal κB sites bind NF-κB in LPS-induced MDDCs    196 
Figure 5.15  ISRE2 site efficiently binds recombinant IRF3 in vitro   197 
 
 
 
 
 
  16 
 
Abbreviations 
 
CIA   collegan induced arthritis 
CMV   cytomegalo virus 
DC   dendritic cell 
DMEM  Dulbecco modified eagle medium 
DN   dominant negative 
EDTA   ethylenediaminetetraacetic acid 
ELISA   enzyme linked immunosorbent assay 
EMCV   encephalomyocarditis virus 
FACS   Fluorescence activated cell sorter 
FCS   foetal calf serum 
GFP   green fluorescent protein 
GM-CSF  granulocyte macrophage colony stimulating factor 
HBSS   hanks balanced salt solution 
HEK   human embryonic kidney 
HSV-1   herpes simplex virus type 1 
HRP   horse radish peroxidase 
HVS   herpesvirus saimiri 
IFN   interferon 
IB SR  Inhibitor of NF-kappaB super represor 
IL-   interleukin 
IL1-ra   interleukin-1 receptor antagonist 
IRAK   IL-1R associated kinase 
IRF   interferon regulatory factor 
ISG   interferon stimulated gene 
B   kappaB 
kB    kilobase 
LPS   lipopolysaccharide 
MAL   MyD88-adaptor-like protein 
M-CSF  macrophage colony stimulating factor 
  17 
MEF   mouse embryonic fibroblast 
MEKK3  mitogen-activated protein kinase kinase kinase 3 
MMP   matrix metallo proteinase 
moDC   monocyte-derived dentritic cell 
moMPH  monocyte-derived macrophage 
MPH   macrophage 
MyD88  Myeloid differentiation primary response gene 88 
NDV   Newcastle disease virus 
NF-κB   nuclear factor-κB 
Nt   nucleotide 
PBMC   peripheral blood mononuclear cell 
PBS   phosphate buffered saline 
RA   rheumatoid arthritis 
RIP1   receptor interacting protein 1 
RPMI   Roswell Park Memorial Institute 
SDS   sodium dodecyl sulphate 
STAT   signal transducer and activator of transcription 
TAK1   TGF-activated kinase 1 
TLR   toll-like receptor 
TLSS   translation start site 
TNF   tumour necrosis factor 
TRAF   TNF Receptor Associated Factor 
TRIF   TIR-domain-containing adapter-inducing interferon-β 
TSS   transcription start site 
VSV   vesicular stomatitis virus 
wt   wild type 
 
Chapter 1  Introduction     
 18 
 
 
 
 
 
 
Chapter 1: 
 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1  Introduction     
 19 
1.1 The immune system 
Micro-organisms, such as viruses, bacteria, fungi and parasites, have the potential to 
cause disease and threaten host viability.  Moreover, different classes of invading 
pathogens present distinct challenges to the host.  Accordingly, the human immune 
system has evolved sophisticated mechanisms to discriminate between, and eliminate, 
infectious agents or pathogens (Figure 1.1 – pathogen detection).  However, these 
mechanisms must be tightly regulated, as excessive or inappropriate activation of the 
immune system can be detrimental to the host and result in the development of auto-
immune diseases.  Immune responses can be broadly divided into innate (Figure 1.1 – 
innate response) and adaptive (Figure 1.1 – adaptive response).  All multi-cellular 
organisms possess innate immunity, whereas adaptive immunity appeared during the 
evolution of vertebrates.  Innate immunity is an immediate and relatively non-specific 
response, whereas adaptive immunity is highly specific for a particular pathogen, but can 
take hours, or even days, to become effective at pathogen clearance.   
 
The innate and adaptive immune systems differ greatly in their mechanism of activation.  
The innate immune system is triggered by so-called pattern recognition receptors (PRRs) 
that are encoded in the germline. PRRs recognise molecular structures that are both 
common and integral to broad ranges of microorganisms.  Receptor binding results in the 
initiation of gene expression programs and the release of chemokines, cytokines and 
inflammatory mediators (Figure 1.1 – inflammatory mediators).  Inflammation is a key 
innate defense mechanism that is characterised by heat, redness, swelling and pain, and 
serves to immediately localize and destroy invading pathogens.  Inflammatory mediators 
increase the blood flow and permeability of local blood vessels.  In addition, they induce 
the up-regulation of cell adhesion molecules, such as selectins and integrins on 
endothelial cells and circulating leukocytes, which facilitates leukocyte extravasation into 
adjacent tissue.  Extravasated cells then migrate along a chemotractant gradient to the site 
of infection. 
 
The hallmark of adaptive immunity is clonally selected T-lymphocytes and B-
lymphocytes.  Activation of these cells is dependent upon the innate immune system, and 
Chapter 1  Introduction     
 20 
occurs through highly variable, non-germline encoded receptors that bind a specific 
antigen (Figure 1.1 – antigen presentation).  The antigens are presented as peptide 
fragments in the context of major histocompatability complex molecules (MHC) by 
specialised antigen presenting cells (APCs) such as macrophages and dendritic cells 
(DCs).  T-lymphocyte and B-lymphocyte activation is associated with cell proliferation 
and differentiation into effector cells.  The functions and cellular components of the 
innate and adaptive immune systems are described below and summarized in figure1.1.    
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Figure 1.1 Simplified overview of immune system activation in response to infection.  The order of 
events is indicated by numbers.  1. Pathogen detection by tissue resident DC and macrophages 2. 
Release of inflammatory mediators.  3. Recruitment of innate immune cells to site of infection.  4.  
Migration of DCs to peripheral lymphoid organs and activation of T- and B-cells.  5.  Migration of T- 
and B-cells from peripheral lymphoid organs to site of infection.  See text for more details. DC = 
dendritic cells; MØ = macrophage; Neutro = neutrophil; MO = monocyte NK = natural killer cell; CTL 
= cytotoxic T-cell; Th0 = naïve T-helper cell; Th1 = T-helper 1 cell; Th17 = T-helper 17 cell; Th2 = T-
helper 2 cell. 
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1.2 Cells involved in the immune response 
 
1.2.1 Neutrophils 
Neutrophils (Figure 1.1 – Neutro) are by far the most abundant leukocyte and account for 
~60% of circulating white blood cells.  They are among the first circulating cell type to 
be recruited following an inflammatory insult, where they ingest pathogens and apoptotic 
cells by phagocytosis. Neutrophils are characterised by the presence of granular 
structures within their cytoplasm, which contain anti-microbial products and reactive 
oxygen species.  Once activated, neutrophils undergo degranulation, whereby the granule 
contents are released into the extracellular environment (Segal, 2005).    
 
1.2.2 Monocytes 
Monocytes (Figure 1.1 – MO) are derived from CD34+ myeloid progenitors and 
comprise approximately 5-10% of circulating leukocytes.  They can be divided into 
subpopulations which differ in size, cell surface expression markers, chemokine receptors 
and functional activities (reviewed in (Grage-Griebenow et al., 2001)).  For example, 
cells expressing high levels of CD14 produce higher levels of pro-inflammatory 
cytokines upon challenge,(Ziegler-Heitbrock et al., 1992), whereas monocytes expressing 
low levels of CD14 and CD16 express higher levels of MHC class II molecules (Ziegler-
Heitbrock et al., 1993).  In mice, monocytes have been shown to be recruited by, and 
play a key role in the clearance of, a broad range of infectious agents such as intracellular 
bacteria and fungi (Serbina et al., 2008).  Monocytes are also the precursors of tissue 
resident macrophages and dendritic cells, which play crucial roles in the maintenance of 
tissue homeostasis and pathogen surveillance.  Moreover, during an inflammatory 
response monocytes recruited from the blood can differentiate into macrophages or DCs 
in situ, which then act to limit the growth of the pathogen and activate the adaptive 
immune system. 
 
1.2.3 Macrophages 
In vivo, macrophages (Figure 1.1 – MØ) are present within most tissues and exhibit a 
diverse number of phenotypes which reflect the physiological demands of their specific 
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microenvironments.  For instance, alveolar macrophages express high levels of pattern 
recognition receptors since the respiratory tract is a common route of entry for bacterial 
and viral infections.  Tissue resident macrophages are important mediators of tissue 
homeostasis, since their high phagocytic activity contributes to the clearance of apoptotic 
or senescent cells.  Macrophages that are recruited to the site of infection perform several 
important functions including phagocytosis, release of anti-microbial products and 
reactive oxygen species as well as the presentation of antigens to memory T-cells and B-
cells.  Experiments using monocyte-derived macrophages that have been differentiated in 
vitro have led to the notion that macrophages can take on multiple activation states.  
Classical activation is achieved by culture with IFN-γ and LPS.  This causes the release 
of pro-inflammatory cytokines such as TNF and IL-1, reactive oxygen species and anti-
microbial peptides in addition to up-regulation of MHC class II and co-stimulatory 
molecules.  Alternative activation, by contrast, can be induced by the Th2 cytokines IL-4 
or IL-13, and results in the induction of anti-parasite responses, humoral immunity and 
tissue repair (Martinez et al., 2008).  Deactivation of macrophage activity is also 
important for the resolution of inflammation to prevent damage to host tissues.  The 
cytokine IL-10 is the most potent mediator of macrophage deactivation and results in the 
inhibition of pro-inflammatory cytokine release and down-regulation of MHC class II 
(Gordon, 2003; Gordon and Taylor, 2005).   
 
1.2.4 Dendritic cells  
Dendritic cells (Figure 1.1 – DC) can be described as the conductors of an immune 
response.  Not only do they contribute to activation of the innate immune system, they 
are also the major APC, and therefore crucial for effective induction of adaptive 
immunity.  DCs also induce immunological tolerance in potentially auto-reactive T-cells 
that have escaped negative selection in the thymus (see section 1.2.5).  In vivo, immature 
tissue resident DCs are continually sampling the micro-environment for pathogens such 
as viruses or bacteria by phagocytosis or macropinocytosis (Inaba et al., 1993; Reis e 
Sousa et al., 1993; Sallusto et al., 1995).  In the absence of infectious agents, DCs 
migrate into the lymph nodes at a basal rate where they present antigens to T-cells, which 
then become inactive or apoptotic.  However, following infection DCs mature and release 
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a plethora of inflammatory mediators, and up-regulate the chemokine receptor CCR7, 
which induces rapid migration into lymph nodes.  It is this migratory capacity that 
separates DCs from other APCs in their ability to stimulate naïve T-cells.  DC maturation 
is accompanied by up-regulation of MHC class II and co-stimulatory molecules and 
increased antigen presentation to naïve T-cells.  Based on the nature of the APC, 
activated T-cell clones then differentiate into the appropriate effector cell type and 
undergo rounds of proliferation before migrating to the site of infection.  This 
requirement for T-cell proliferation is responsible for the delay in the adaptive immune 
response compared to the innate immune response.  
 
Like macrophages, DCs are resident within most tissues and are highly heterogeneous in 
nature.  Under non-infectious/inflammatory conditions, DCs can be divided into 
conventional DCs (cDCs) and pre-DCs (reviewed in (Shortman and Naik, 2007)).  cDCs 
exhibit DC morphology and function, while pre-DCs do not, although minimal cell 
division is required to obtain a full DC phenotype.  Different types of pre-DCs include 
plasmacytoid DCs (pDCs), which are specialised for the combat of viral infection and 
release huge amounts of type I interferons (IFNs) upon detection of viruses, and the 
immediate precursors of steady-state splenic cDCs.  In addition, monocytes can also 
serve as pre-DCs in response to microbial or inflammatory stimuli.  In fact most studies 
on human DCs have been performed on monocyte derived DCs (MDDCs) that have been 
differentiated in vitro by culture in the presence of GM-CSF and IL-4 (Sallusto and 
Lanzavecchia, 1994).  cDCs can be further sub-divided into distinct populations based on 
the tissue of location.  For example Langerhans cells can be found in the epidermis, while 
interstitial DCs are located in the dermis.  Furthermore, three different populations of 
murine splenic cDCs have been described based on the expression of CD4 and CD8: 
CD4+ DCs; CD8+ DCs; and double negative (DN) DCs.  The functional significance of 
these cDC subsets are unclear, however microarray data indicates that they differ in their 
basal gene expression profiles (Edwards et al., 2003).  CD4+ and CD8+ cDCs were 
found to differ by >200 individual genes, whereas CD4+ and DN cDCs only differed by 
~25 genes, suggesting that CD8+ cDCs are more distantly related to the other two sub-
populations.  The pathways that lead to these different DC subtypes in vivo are complex 
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and not completely understood, but they appear to be more flexible than other leukocytes.  
All immune cell types are derived from multi-potent haematopoietic stem cells (HSC) in 
the bone marrow.  Early HSCs differentiation can be broadly divided into common 
myeloid precursor cells (CMPs) or common lymphoid precursor cells (CLPs), which 
have a strong bias towards forming neutrophils/macrophages or T-cells/B-cells 
respectively.  Remarkably, however, it was demonstrated that both CLPs and CMPs have 
the capacity to form different DC populations in cell culture (Chicha et al., 2004; Manz et 
al., 2001), although it remains unclear if this reflects the situation in vivo. 
 
 
Figure 1.2 Simplified overview of DC subtype development in vivo. See section 1.1.2.4 for details.  
Abbreviations: HSC (haematopoietic stem cell); pDC (plasmacytoid DC); cDC (conventional DC); I DC 
(interstitial DC); LC (Langerhans cell).  Figure adapted from Shortman et al. 2007. Nat Rev Immunol. 
7(1):19-30 
 
 
1.2.5 T-lymphocytes 
The defining feature of T-lymphocytes, or T-cells, is expression of the so-called T-cell 
receptor (Haskins et al., 1984).  The T-cell receptor is a transmembrane immunoglobulin 
protein that is capable of recognising an almost unlimited number of foreign antigens 
derived from pathogens.  The molecular diversity of the T-cell receptor occurs because 
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the genes that encode the T-cell receptor are subjected to random mutation and 
recombination events (Schatz et al., 1992).  T-cells are generated from common 
lymphoid precursors in the bone marrow, which then migrate to the thymus where they 
undergo the final stages of their differentiation.  Since the process that generates the T-
cell receptor is random, there is a high probability that it may react with self antigens 
from the host.  This could result in the inappropriate, and potentially detrimental, 
activation of T-cells that attack the host‟s own cells and tissues.  To reduce this 
possibility, T-cells undergo negative selection in the thymus, whereby APCs present self 
antigens in the thymus.  If the T-cell receptor reacts too strongly to self antigen the T-cell 
undergoes apoptosis.  The remaining T-cells then differentiate into either cytotoxic T-
lymphocytes (CTLs) (Figure 1.1 – CTL) or helper T-cells (Th cells) (Figure 1.1 – Th), 
defined by the expression of the CD8 or CD4 receptors respectively, and migrate to 
peripheral lymphoid organs where they survey the environment for foreign antigens 
(Germain, 2002). 
 
1.2.5.1 Helper T-lymphocytes 
Upon activation, naïve helper T-cells turn into effector cells.  Helper-T cells require two 
distinct signals in order to become activated.  In addition to T-cell receptor activation, 
which occurs from APCs by MHC class II molecules, Th-cells need activation by co-
stimulatory molecules, such as CD80 and CD86 (Slavik et al., 1999).  These co-
stimulatory molecules are not constitutively expressed, but are induced in APCs by 
specific signals such as toll-like receptor (TLR) or type I interferon (IFN) receptor 
activation (discussed later).  If helper T-cells do not receive both activation signals, they 
either undergo apoptosis or become anergic.  This process of peripheral tolerance helps to 
prevent auto-reactive T-cells that escape negative selection in the thymus from inducing 
auto-immunity.  Classically, helper T-cells can become either Th1 or Th2 cells, which 
contribute to cell-mediated and humoral-mediated immunity respectively (Cherwinski et 
al., 1987; Santana and Rosenstein, 2003).   
 
IL-12 is the key factor that drives the Th1 phenotype (Hsieh et al., 1993).  Th1 cells 
characteristically secrete large amounts of IFN-γ which acts on macrophages, cytotoxic 
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T-cells and natural killer (NK) cells to increase their respective effector functions 
(Ackerman et al., 2002).  A Th2 phenotype, on the other hand, is produced when naïve T-
cells are activated in the presence of IL-4.  Th2 cells regulate B-cell behaviour, including 
antibody production, and are characterised by the secretion of IL-4, IL-5 and IL-13 
(Abbas et al., 1996).  More recently, two additional helper T-cell subsets have been 
characterised: Th17 cells and regulatory T-cells (Tregs).  A Th17 response, which is 
characterised by the production of IL-17 and IL-22 from activated T-cells, can be 
triggered by a wide of range of bacterial agents (Alexopoulou et al., 2001; Infante-Duarte 
et al., 2000; Mangan et al., 2006).  Moreover, Th17 cells have attracted much attention 
recently as their activity has been implicated in a number of auto-immune diseases such 
as rheumatoid arthritis (Kirkham et al., 2006), psoriasis (Krueger et al., 2007) and 
inflammatory bowel disease (Duerr et al., 2006).  It has been shown that Th17 cells are 
produced when naïve T-cells are activated in the presence of TGF- and either IL-6 or 
IL-21 (Bettelli et al., 2006; Veldhoen et al., 2006).  Tregs are subdivided into naturally 
occurring Tregs (nTregs) or inducible Tregs (iTregs).  nTregs are generated in the thymus 
and characterised by the expression of CD4, CD25, and the transcription factor FOXP3, 
while iTregs are generated from naïve CD4
+
CD252
-
 T-cells activated in the presence of 
IL-10 and/or TGF (Chen et al., 2003; Groux et al., 1997).  Tregs are major producers of 
anti-inflammatory cytokines such as IL-10, and suppress the activity of auto-reactive T-
cells that may cause auto-immunity (Horwitz et al., 2003; Sakaguchi, 2000).   
 
1.2.5.2 Cytotoxic T-lymphocytes 
Like helper T-cells, CTLs require T-cell receptor and co-stimulatory receptor stimulation 
to become activated once they leave the thymus, otherwise they become anergic or 
apoptotic in the periphery.   In contrast, however, the T-cell receptor on CTLs is 
stimulated by antigens presented in the context of MHC class I, a function performed by 
almost all nucleated cells (Bevan, 1995).  CTLs are crucial for combating intracellular 
pathogens such as bacteria and viruses, as well as protecting against tumour cells.  
Following activation, CTLs can directly induce apoptosis in the infected cell by several 
mechanisms (Berke, 1994).  For example, CTLs express a protein called perforin which 
punctures a hole in the plasma membrane of virally infected cells.  CTLs then secrete 
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specific serine proteases into the pore, which activates caspase enzymes and ultimately 
stimulates apoptotic pathways leading to cell death (Kagi et al., 1994; Lowin et al., 
1994). 
 
1.2.6  B-cells 
Immature B-cells (Figure 1.1 – B) are also generated from common lymphoid precursor 
cells in the bone marrow, but unlike T-cells, undergo maturation in the spleen.  The major 
function of B-cells is antibody production.  Antibodies are soluble immunoglobulin 
proteins that are composed of two light chains and two heavy chains (Davies and 
Metzger, 1983).  The light chain contains a hyper-variable region at the tip that allows it 
to recognise a large number of antigens, and is therefore analogous to the TCR (Di Noia 
and Neuberger, 2007).  The light chains usually bind to anti-microbial products, or the 
microbes themselves, which serves to neutralise their effects and alert other components 
of the immune system.  By contrast there are only a limited number of heavy chains, 
which dictate the isotype of the antibody. Different antibody isotopes induce different 
effector responses, for example activation of complement or opsonisation (Heyman, 
2000).  Isotype switching occurs when the heavy chain of the antibody is substituted for a 
different type, while the light chain remains unchanged.  The result of this process is that 
the antibody will still recognise the same antigen, but because it is of a different isotype, 
distinct effector functions will be induced (Esser and Radbruch, 1990).  In addition to 
antibody production, B-cells are also capable of presenting antigens to helper T-cells 
(Bishop and Hostager, 2001).   
 
 
1.3 Innate immunity is activated by pattern recognition receptors 
Until recently, the mechanism through which pathogens initially triggered an immune 
response remained obscure.  However, in the late 1980s, Charles Janeway proposed the 
existence of germline encoded receptors that recognise so-called pathogen associated 
molecular patterns (PAMPs); molecular structures that are commonly found on, and 
integral to, pathogenic microorganisms, but absent from host cells (Janeway, 1989).  This 
prediction was proved correct during the 1990s with the discovery of pattern PRRs 
Chapter 1  Introduction     
 28 
(Medzhitov, 2007), which generated an explosion of interest in the field of innate 
immunity.   
 
PPRs can be broadly split into membrane-bound receptors and cytosolic receptors.  The 
most well characterised family of transmembrane PPR to date are the TLRs that sense a 
broad range of PAMPs including bacterial cell wall components, as well as viral and 
bacterial nucleic acids (Ank et al., 2006a; Garantziotis et al., 2008).  The transmembrane 
C-type lectin receptor dectin-1 has been shown to be involved in anti-fungal immunity 
(Robinson et al., 2006; Taylor et al., 2007).  Cytosolic PPRs include the family of 
nucleotide binding oligomerisation domain (NOD)-like receptors (NLRs), and the family 
of retinoic acid-inducible gene I (RIG-I)-like helicases (RLHs).  NLRs are important 
sensors of bacterial components such as peptidoglycan (Fritz et al., 2006), whereas RLHs 
recognise double stranded RNA, which accumulates during the replication of viruses in 
infected cells (Mori et al., 2004).   
 
1.3.1 Toll-like receptors 
Mammalian TLRs are evolutionarily conserved. A year after the drosophila Toll receptor 
was found to confer anti-fungal immunity (Lemaitre et al., 1996), Medzhitov et al 
reported the discovery of a human homologue (Medzhitov et al., 1997).  They showed 
that expression of a constitutively active mutant in the human monocytic cell line THP-I 
cells resulted in the production of inflammatory cytokines such as IL-1 and IL-8.  
Moreover, they showed that the signalling pathway used by drosophila Toll and human 
TLR was evolutionarily conserved, and dependent upon the transcription factor nuclear 
factor kappa-B (NF-κB).  This transcription factor is essential for proper immune 
development and function in humans, and is described in detail in section 1.4.1.  A 
plethora of studies, using a combination of genetic and biochemical approaches, quickly 
confirmed the importance of TLRs in activation of the immune system.  It is now known 
that 10 different TLRs exist in humans (Takeda et al., 2003), and, with the exception of 
TLR10, the cognate ligand for each TLR has been identified and is outlined below and 
shown in figure 1.3. 
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1.3.1.1 TLR4 
TLR4 was the first mammalian TLR to be identified and is the best characterised to date.   
It is activated by lipopolysaccharide (LPS), a component of the cell wall of all gram 
negative bacteria.  Consequently, mice that have mutations in, or are deficient for, TLR4 
are hyporesponsive to LPS (Hoshino et al., 1999; Poltorak et al., 1998; Qureshi et al., 
1999).  Subsequent reports have demonstrated that TLR4 signalling in response to LPS is 
dependent upon the co-receptors CD14 and MD-2 (da Silva Correia et al., 2001; Jiang et 
al., 2000; Nagai et al., 2002).  TLR4 has also been reported to be activated by several 
endogenous molecules that would serve as danger signals such as heat shock proteins 
(Dybdahl et al., 2002; Vabulas et al., 2001; Vabulas et al., 2002), fibronectin (Okamura 
et al., 2001), hyaluronic acid (Termeer et al., 2002), and heparan sulfate (Johnson et al., 
2002).  Interestingly, TLR4 has also been reported to be activated by the fusion proteins 
of the respiratory syncytial virus (Haynes et al., 2001; Kurt-Jones et al., 2000), 
Figure 1.3 Human Toll-like receptors, ligands and adaptors.  See sections 1.3.1 and 
1.3.3 for details.  Figure adapted from Kawai, T. and S. Akira (2007) Trends Mol Med 
13(11): 460-9. 
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suggesting that TLR4 may also protect against certain viral pathogens, in addition to 
bacterial ones.   
 
1.3.1.2 TLR3, 7, 8, and 9 
TLR3, 7, 8 and 9 differ from the other TLRs in that they reside within endosomes and not 
within the plasma membrane.  Furthermore, this subgroup of TLRs recognises nucleic 
acids that are derived from either viral or bacterial DNA or RNA.  For instance, TLR3 is 
activated by double-stranded RNA, which is produced by certain viruses during their 
replication (Alexopoulou et al., 2001).  TLR9 senses unmethylated CpG DNA, which is 
commonly found in bacterial and viral, but rarely within vertebrate genomes (Hemmi et 
al., 2000).  TLR7 and TLR8 are highly homologous and both recognise guanosine- or 
uridine-rich single-stranded RNA (ssRNA) derived from RNA viruses (Heil et al., 2003; 
Lund et al., 2004). 
 
1.3.1.3 TLR1, 2, 6, and 5 
TLR2 is able to recognise a broad variety of microbial products including peptidoglycans 
and lipoteichoic acid from Gram-positive bacteria (Schwandner et al., 1999; Yoshimura 
et al., 1999), glycolipids from Treponema maltophilum (Opitz et al., 2001) and 
components found in the cell walls of yeast (Underhill et al., 1999).  The reason that 
TLR2 is capable of recognising such a diverse array of structures can be partly explained 
by the observation that it forms heterodimers with TLR1 and TLR6 (Ozinsky et al., 
2000).  TLR5, on the other hand, is activated by flagellin which is a principal component 
bacterial flagella (Hayashi et al., 2001). 
 
1.3.2 TLR expression in leukocytes 
TLRs are differentially expressed in both non-immune cell types, particularly epithelial 
cells (reviewed in (Gribar et al., 2008)), and in leukocytes.  Given the crucial role played 
by DCs in shaping the immune response, it is not surprising they possess the full 
repertoire of TLRs, albeit between different subsets.  Using real-time PCR, pDCs have 
been shown to express high levels of TLR7 and TLR9, and low levels of TLR1 and 
TLR6, while additional TLRs were not detected, which is consistent with their role as 
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detectors of viral infection.  Conversely, cDCs do not express TLR9, but express high 
levels of TLR1-5, and modest amounts of TLR6-8.  These expression patterns most likely 
reflect the specialised physiological roles of these distinct DC subsets (Hornung et al., 
2002; Jarrossay et al., 2001; Kadowaki et al., 2001; Krug et al., 2001).  MDDCs show a 
similar TLR expression pattern to cDCs (Jarrossay et al., 2001; Muzio et al., 2000; 
Visintin et al., 2001).  Monocytes themselves, as well as macrophages have been reported 
to express all TLRs except TLR3, although levels of TLR7 and TLR9 were relatively low 
(Hornung et al., 2002; Muzio et al., 2000).  Similarly, granulocytes and T-cells have been 
demonstrated to express all TLRs except TLR3 and TLR6/TLR8 respectively, though at 
varying levels (Caron et al., 2005; Hayashi et al., 2003).  B-cells appear to have a more 
restricted TLR expression pattern, however, relatively large amounts of TLRs1, 2, 6, 7 
and 9 mRNA can be found within these cells (Hornung et al., 2002).  It should be 
highlighted that most of these studies have been performed using mRNA quantification; 
therefore it remains unclear if these data reflect the expression of TLR proteins. 
 
1.3.3 Proximal TLR signalling 
Although far from complete, much progress has been made in understanding the 
signalling cascades utilised by TLRs.  TLRs contain an N-terminal extra-cellular leucine 
rich repeat domain and an intra-cellular domain, which is homologous to the intra-
cellular domain of the IL-1 receptor, and therefore referred to as a Toll/IL-1 receptor 
(TIR) domain.  Five different adapter proteins have been identified that interact with the 
TIR domain through homophilic interactions: myeloid differentiation factor 88 (MyD88); 
Mal (also known as TIR domain containing adapter protein (TIRAP); Toll/IL-1R domain 
containing adapter inducing IFN-β (TRIF); TRIF-related adaptor molecule (TRAM) and 
SAM and ARM-containing protein (SARM).  Studies from mice lacking one or more of 
these adaptors have begun to elucidate the signalling events that result from TLR 
activation.  They show that TLR signalling can be broadly subdivided into the MyD88-
dependent pathway and the MyD88-independent pathway. 
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1.3.3.1 MyD88-dependent pathway 
MyD88 was the first TLR adaptor protein to be identified, and the pathway it regulates is 
the best characterised to date.  Studies from MyD88 deficient mice indicate that MyD88 
is critical for the production of inflammatory cytokines following stimulation of TLRs 1-
9 (Alexopoulou et al., 2001; Hacker et al., 2000; Hayashi et al., 2001; Hemmi et al., 
2002; Hoshino et al., 1999; Schnare et al., 2000; Takeuchi et al., 2000).  Moreover, with 
the exception of TLR3, which had relatively delayed kinetics, stimulation of all TLRs led 
to the rapid activation of NF-κB.  Interestingly, however, in response to ligands to both 
TLR3 and TLR4, but not TLR9, delayed activation of NF-κB was still observed in 
MyD88-deficient cells.  In addition, absence of MyD88 did not inhibit DC maturation, as 
measured by upregulation of MHC class II and co-stimulatory molecules following 
TLR3/TLR4 activation (Alexopoulou et al., 2001; Kaisho et al., 2001).  These 
observations suggested that TLR3 and TLR4 utilise at least one extra signalling pathway 
in addition to MyD88.  Subsequently another adaptor protein, Mal, was identified and 
shown to be essential for TLR4 signalling (Fitzgerald et al., 2001).  Initially, Mal was 
believed to be responsible for the MyD88-independent signal, since its inhibition was 
shown to abolish both inflammatory cytokine production and DC maturation (Horng et 
al., 2001).  However, the generation of mice that lacked both My88 and Mal contradicted 
this finding, and showed that Mal deficient mice have a similar phenotype to MyD88 
deficient mice in response to LPS.  The Mal knock-out mice showed that it was essential 
for TLR4 and TLR2 signalling, but not TLR3, 7 or 9 signal transduction (Yamamoto et 
al., 2002a).  Thus, Mal functions as a bridging protein that links TLR2 and TLR4 to 
MyD88. 
 
1.3.3.2 MyD88-independent pathway 
Further studies identified TRIF as the adaptor protein that was responsible for 
transmitting the MyD88-independent signal from TLR3 and TLR4 (Hoebe et al., 2003; 
Yamamoto et al., 2003; Yamamoto et al., 2002b).  These studies showed that inhibition 
or deletion of TRIF caused impaired interferon- production and NF-κB activation 
following TLR3 or TLR4 stimulation.  In addition to TRIF, TLR4 signalling via the 
MyD88-independent pathway is also dependent on the adaptor TRAM (Rowe et al., 
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2006).  Therefore, TLR4 utilises 4 different adaptor proteins to instigate 2 different 
signalling pathways: the MyD88 pathway requires Mal to act as a bridge; while the 
TRIF-dependent pathway requires TRAM to act as a bridge.  A recent report added 
another layer of complexity to TLR4 signalling.  It showed that TLR4 first induces the 
MyD88-pathway at the plasma membrane, while the TRIF-pathway is only activated 
from early endosomes after endocytosis of the TLR4 complex, although the reasons for 
this elaborate mechanism remain unclear (Kagan et al., 2008).  It worth noting that most 
of findings in the TLR signalling pathways are the results of studies in murine cells, 
especially those derived from knock-out animals. Moreover, recent studies highlighted 
critical differences in the initiation of cytokine responses in human and mouse 
macrophages and MDDCs (Lundberg et al., 2007; Reimer et al., 2008) and provided new 
insights into the complexity of TLR signaling in mouse and human cells. 
 
 
1.4 NF-κB and IRF transcription factors are key regulators of TLR 
gene expression 
The signalling events initiated by TLRs ultimately result in the activation of transcription 
factors that co-ordinate the induction of gene expression programmes.  These gene 
expression programmes include the secretion of cytokines which regulate the behaviour 
of local cells and co-ordinate the subsequent immune response.  2 transcription factor 
families, NF-κB and the interferon regulatory factors (IRFs), are of central importance in 
this process.  
 
1.4.1 NF-κB 
NF-κB was originally discovered as a factor that interacts with the kappa 
immunoglobulin enhancer in pre-B cells (Sen and Baltimore, 1986).  However, the term 
NF-κB now encompasses a family of transcription factors that regulate hundreds of genes 
and impact on diverse cellular functions including immunity, proliferation, apoptosis and, 
in particular, inflammation (Karin and Greten, 2005; Li and Verma, 2002; Perkins and 
Gilmore, 2006).  In fact, such is the importance of NF-κB during inflammation that it 
plays a role in almost every aspect of the response, including its termination (Gadjeva et 
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al., 2004; Lawrence et al., 2001).  It acts in epithelial and tissue-resident haematopoietic 
cells to up-regulate chemokines, inflammatory cytokines and antimicrobial effector 
peptides.  In endothelial cells it promotes the expression of adhesion molecules that are 
necessary for the recruitment of circulating leukocytes and NF-κB also promotes the 
general survival of cells in an inflammatory environment.  Thus in different cell types, as 
well as in response to different stimuli, NF-κB executes distinct gene expression 
programmes.  Consequently, the regulation of NF-κB activity is complex and controlled 
at multiple levels. 
 
1.4.1.1 NF-κB proteins 
The NF-κB module consists of the NF-κB proteins, the inhibitor of NF-κB (IκB) proteins 
and the inhibitor of NF-κB kinase (IKK) complex (figure 1.4).  Altogether there are five 
NF-κB subunits: RelA, RelB, c-Rel, p50 and p52.  They are characterised by the presence 
of a Rel homology domain (RHD) that spans approximately 300 amino acids of the N-
terminus.  The RHD is responsible for DNA binding, dimerisation and interaction with 
the inhibitor of NF-κB (IκB) proteins (Siebenlist et al., 1994).  NF-κB must form homo- 
or hetero-dimers in order to bind DNA and activate transcription, and many of the 
possible combinations of NF-κB dimers have been reported.  A notable exception is 
RelB, which has only been reported to interact with p50, p52 and RelA, and is the only 
subunit incapable of homo-dimerisation (Dobrzanski et al., 1994; Jacque et al., 2005).  
RelA/p50 is the most abundant and therefore most widely studied NF-κB species.  It is 
expressed in most cell types, and is essential for the induction of innate immunity and 
pro-inflammatory cytokine production.  NF-κB complexes containing RelA, RelB or c-
Rel are able to directly activate transcription, since these subunits contain a C-terminal 
trans-activation domain (TAD).  The TAD facilitates interactions with components of the 
basal transcription machinery and additional transcriptional co-factors such as CBP/p300 
(Perkins et al., 1997).  Since p50 and p52 lack the TAD, their respective homo-dimers 
can compete with TAD containing complexes and function as transcriptional repressors 
(Udalova et al., 2000; Zhong et al., 2002).   
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1.4.1.2 NF-κB-DNA binding 
Once liberated from IκBs, NF-κB complexes rapidly translocate from the cytoplasm to 
the nucleus where they bind to promoters and enhancers of target genes.  The consensus 
sequence for the κB site is usually denoted as GGGRNNYYCC (R=purine; 
Y=pyrimidine, N=any nucleotide) (Natoli et al., 2005).  Systematic quantitative studies 
of NF-κB-DNA interactions have demonstrated a wide range of affinities to sequence 
variants (Linnell et al., 2004; Nijnik et al., 2003; Udalova et al., 2002).  Therefore, both 
the number and the strength of the κB sites are likely to impact on the specific patterns of 
gene expression, with weak binding sites sharpening the response.  Despite the highly 
Figure 1.4 Schematic representation of  (A) NF-kB, (B) IkB and (c) IKK 
family members. See sections 1.4.1.1, 1.4.1.3 and 1.4.1.4  for details.  
Copied from Hayden M. S., Ghosh S. Genes Dev. 2004;18:2195-2224 
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degenerate nature of the B site, different NF-κB complexes exhibit only modest 
differences in affinities for a given site (Hoffmann et al., 2003; Udalova et al., 2002).  
However, it was shown that altering a single nucleotide in an NF-κB site may specifically 
alter binding of selected NF-B dimers (p50p50), without affecting the affinity of the 
others (RelAp50) to the site, resulting in elevation of gene expression levels (Udalova et 
al., 2000). Moreover, even when a nucleotide variation does not affect the binding of 
RelARelA and RelAp50 complexes, it may affect their conformation and ability to recruit 
transcriptional co-factor, such as IRF3 (Leung et al., 2004).  Thus, the degeneracy in NF-
κB binding elements may also influence gene expression by altering the balance in 
recruitment of different NF-B dimers or by altering the structure of the bound NF-κB 
complex, influencing the subsequent recruitment of additional co-factors.  Post-
translational modifications, particularly phosphorylation, have also been implicated in the 
regulation of NF-κB trancrriptional activity (reviewed in (Perkins, 2006; Viatour et al., 
2005)), through the differential recruitment of transcriptional co-factors.  In addition, 
some modifications, such as acetylation of lysine 221, have been shown to enhance RelA 
DNA binding (Chen 2002).   
 
1.4.1.3 Inhibitor of NF-κB proteins 
Altogether, there are seven IκB-like proteins that are characterised by the presence of 
multiple ankyrin repeats within their C-terminus (Figure 1.4).  They comprise p100, 
p105, IκB, IκB, IκB, IκB and BCL-3.  p100 and p105 are the precursor proteins of 
p52 and p50 respectively.  They undergo proteolytic cleavage upon stimulation which 
separates the N-terminal RHD domain from the C-terminus containing ankyrin repeats.  
The typical NF-κB inhibitors, IκB, IκB and IκB, were believed to retain NF-κB 
complexes within the cytoplasm (Baeuerle and Baltimore, 1988).  However, more recent 
evidence suggests that this is achieved via a shift in the equilibrium of nuclear-
cytoplasmic shuttling, which occurs even in resting cells (Ghosh and Karin, 2002).  
Numerous studies have demonstrated that the typical IκB proteins have differing 
affinities for distinct NF-κB complexes, and exhibit differential rates of degradation after 
stimulation (Thompson et al., 1995).  These features are likely to contribute to the 
specificity of NF-κB dimer release following stimulation, which will therefore contribute 
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to stimulus-specific gene expression (Hoffmann et al., 2002).  For example, IκB, which 
is the best characterised IκB protein, preferentially associates with the p65/p50 
heterodimer and is rapidly degraded following inflammatory stimuli (Baeuerle and 
Henkel, 1994).  By contrast IκB binds RelA homodimers and RelA/c-Rel heterodimers, 
and is degraded with slower kinetics (Whiteside et al., 1997).  On the other hand, RelB is 
not sequestered by any of the typical IκB proteins and is only associated with p105 
(Solan et al., 2002).  Several reports have shown that the atypical IκB protein BCL-3 can 
interact with the normally repressive p50 and p52 homodimers to positively regulate gene 
expression (Viatour et al., 2003).  However, the mechanism of BCL-3 activation remains 
obscure.  Thus, degradation of the typical IκBs (or p100/p105 processing) is the critical 
step in NF-κB activation, and this event is almost exclusively regulated by the IKK 
complex.   
                      
1.4.1.4 The IKK complex 
The IKK complex consists of 2 serine/threonine kinases, IKK and IKK, and the non-
catalytic but essential scaffold protein NF-κB essential modulator (NEMO; also known as 
IKK) (Figure 1.4).  IKK and IKK share 52% sequence homology and are 
characterised by an N-terminal kinase domain, a C-terminal helix-loop-helix domain and 
a leucine zipper domain.  NEMO appears to be unrelated to IKK/IKK and contains N- 
and C-terminal coiled-coil domains and a C-terminal zinc finger domain.  Despite their 
homology, genetic results clearly demonstrate that IKK and IKK perform distinct roles 
in vivo, and have led to the notion of two distinct NF-κB pathways (Pomerantz and 
Baltimore, 2002). 
 
1.4.1.5 Activation of NF-κB by the canonical pathway 
Studies from knock out animals indicate that IKK and NEMO are essential for 
activation of the canonical NF-κB pathway, while the contribution of IKK is relatively 
minor (Sizemore et al., 2002).  This pathway is triggered by a wide range of 
inflammatory stimuli such as TLR ligands, and is essential for inflammatory cytokine 
production.  IKK undergoes phosphorylation at Ser 177 and Ser 181 (Delhase 1999), in 
a process that is believed to be mainly mediated by TGF-activated kinase 1 (TAK1) 
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(Wang et al., 2001) Chen 2005; Krappmann and Dcheidereit 2005; Chen et al 2006), 
although other candidates have been described such as MEKK3 (Huang et al., 2004; 
Yang et al., 2001), 3-phosphoinositide-dependent protein kinase-1 (Tanaka et al., 2005) 
and angiotensin II (Zhang et al., 2005).  Nevertheless, IKK then phosphorylates specific 
serine residues within the regulatory domains of the typical IκB proteins.  
Phosphorylation creates a binding site for the bTrCP ubiquitin ligases that induce 
polyubiquitination of the IκBs.  Polyubiquitination, in turn, signals for IκB degradation 
by the 26S proteosome (Spencer et al., 1999; Winston et al., 1999), which liberates RelA 
and c-Rel containing complexes.   
 
1.4.1.6 Activation of NF-κB by the non-canonical pathway 
In line with the idea of two distinct NF-κB pathways, most activators of the classical NF-
κB pathway do not activate the non-canonical pathway, which is induced by stimuli such 
as lymphotoxin-, BAFF and CD40 (Xiao et al., 2006).  One exception is TLR4 
stimulation of MDDCs, which leads to the nuclear translocation of all 5 NF-κB subunits, 
and activation of both the canonical and non-canonical pathways (Saccani et al., 2003).  
The non-canonical pathway involves the processing of the p52 precursor 100, and is 
thought to be mediated exclusively by IKK (Claudio 2002; Dejardi 2002).  It has been 
shown that IKK is phosphorylated by NF-κB inducing kinase (NIK) at Ser 176 and Ser 
180 (Ling 1998; Senftleben 2001).  IKKα then phosphorylates p100 at Ser 866 and Ser 
870 (Senftlben 2001; Xiao 2001), which creates a bTrCP docking site similar to the 
canonical pathway Amir 2004; Liang 2006a).  Since p100 is normally associated with 
RelB, p100 processing normally leads to the release of RelB/p52 complexes.    
 
1.4.1.7 Signalling to NF-κB via the MyD88-dependent pathway 
Signalling via both the MyD88-dependent and TRIF-dependent pathways leads to NF-κB 
activation (figure 1.5).  However, as mentioned previously, the kinetics of NF-κB 
activation are quicker via the MyD88-pathway compared to the TRIF-dependent 
pathway.  Following TLR stimulation, MyD88 interacts with members of the IL-1R-
associated kinase (IRAK) family.  This kinase family contains 4 members: IRAK-1; 
IRAK-2; IRAK-4; and IRAK-M.  The standard paradigm holds that IRAK4 is initially  
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                       Figure 1.5 Simplified overview of Myd88 and TRIF-dependent signalling to NF-κB.  
  See sections 1.4.1.7 and 1.4.1.8 for details.   
 
activated by MyD88, and in turn, induces the trans- and auto-phosphorylation of IRAK1 
(Akira and Takeda, 2004).  IRAK-1/-4 then dissociates from MyD88 and binds TNF 
receptor associated factor (TRAF) 6.  TRAF6 is an E3 ubiquitin ligase that catalyses K63 
linked ubiquitination, which is involved in protein interactions, and not proteosomal 
degradation (Chen et al., 2006).  TRAF6 subsequently   activates the IKK complex via 
TAK1, although the mechanism is currently unknown.  It is thought that IRAK-M is a 
negative regulator of TLR signalling since it has been shown to prevent the dissociation 
of IRAK and IRAK-4 from MyD88 and formation of IRAK-TRAF6 complexes 
(Kobayashi et al., 2002).  The role of IRAK-2 is less clear, although it has recently been 
implicated in TRAF6 ubiquitination and NF-κB activation (Keating et al., 2007). 
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1.4.1.8 Signalling to NF-κB via the TRIF-dependent pathway 
Some studies have also implicated TRAF6 in TRIF-dependent signalling to NF-κB 
through TLR3 or TLR4.  In pI:C stimulated 293 cells, TRAF6 is recruited to TLR3 (Jiang 
et al., 2003), and found to specifically interact with TRIF (Jiang et al., 2004; Sato et al., 
2003).  Moreover, over-expression of a dominant-negative version of TRIF, which lacked 
the TRAF6 binding site, inhibited pI:C-induced NF-κB activation in HeLa cells (Jiang et 
al., 2004).  However, IκBα degradation was not inhibited in TRAF6-deficient bone 
marrow-derived macrophages treated with pI:C (Gohda et al., 2004; Hacker et al., 2006), 
suggesting the role of TRAF6 is species or cell-type specific.  In contrast, deletion of 
receptor interacting protein 1 (RIP1) was found to abolish TLR3-mediated NF-κB 
activation in mouse embryonic fibroblasts (MEFs) (Cusson-Hermance et al., 2005; 
Meylan et al., 2004).  Furthermore, phosphorylation of IκB was also found to be 
diminished in LPS-treated MEFs deficient for both MyD88 and RIP1, suggesting that 
RIP1 also mediates TRIF-dependent NF-κB pathway from TLR4 (Cusson-Hermance et 
al., 2005). 
 
1.4.1.9 Termination of the NF-κB response 
Just as NF-κB activity is induced in response to a multitude of stimuli, multiple 
mechanisms have been described that terminate its actions.  One of the best characterised 
mechanisms involves IκBα, which is itself a RelA-dependent gene and therefore rapidly 
resynthesised following its degradation.  Furthermore, the IκBα protein contains a nuclear 
localisation signal, allowing resynthesised protein to enter the nucleus and actively export 
NF-κB to the cytoplasm (Arenzana-Seisdedos et al., 1995; Arenzana-Seisdedos et al., 
1997).  The phosphorylation- and ubiquitin-dependent removal of transcriptionally active 
RelA-containing complexes from the nucleus has also been documented (Lawrence et al., 
2005; Saccani et al., 2004).  Another model of the down-regulation of NF-κB activity 
involves the replacement of distinct NF-κB complexes with differing transcriptional 
activities.  For example, it was shown that during the maturation of human MDDCs, 
rapidly activated RelAp50 complexes were gradually replaced with slowly activated 
p52RelB complexes at specific promoters (Saccani et al., 2003).  Interestingly, at the IL-
12 p40 promoter, dimer exchange correlated with decreased RNA polymerase II 
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occupancy and gene expression, while the opposite was true at the macrophage-derived 
chemokine (MDC) and the EBV-induced molecule 1 ligand chemokine (ECL) promoters,  
Therefore, dimer exchange also highlights how the transcriptional output of an NF-κB-
dependent gene may be subtly fine-tuned following stimulation. 
 
1.4.2 Interferon regulatory factors 
Like NF-κB, members of the IRF family also perform crucial and varied roles in the 
immune system (Tamura et al., 2008).  IRFs were first discovered as factors that interact 
with the IFN-β promoter following virus infection.  The mammalian IRF family is now 
known to contain 9 members (named IRFs1-9).  Knock-out mice have been generated for 
all IRFs, and these studies have clearly demonstrated the diverse roles played by these 
factors.  They are essential for the induction of anti-viral immunity, and play important 
roles in pro-inflammatory cytokine production, haematopoietic differentiation, anti-
bacterial immunity and apoptosis (Honda and Taniguchi, 2006).  In most cases the 
molecular events underlying IRF activation in response to TLR remain incompletely 
understood, but rapid progress has been made in this area recently. 
 
1.4.2.1 IRF structure  
As shown in figure 1.6, each factor contains a highly conserved N-terminal DNA binding 
domain (DBD) of ~120 amino acids that forms a helix-turn-helix motif.  Mutational 
studies using IRF1 and IRF2 showed that 5 conserved tryptophan residues in the DBD 
are essential for DNA binding (Harada et al., 1989). With the exception of IRF1 and 
IRF2, the C-terminal region of IRFs possesses an IRF-association domain (IAD) that is 
important for interactions with other transcriptional co-factors (Higgs and Jefferies, 
2008).  The C-terminus also contains multiple phosphorylation sites that are important in 
mediating interactions with other proteins such as CBP/p300 (Yang et al., 2002).   
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The mechanism of activation is most extensively studied for IRF3.  Studies show that in 
resting cells, IRF3 resides in the cytoplasm.  An activating signal induces its dimerisation 
and subsequent nuclear translocation where it interacts with additional co-factors at the 
promoters of target genes to regulate transcription (Lin et al., 1999).  Furthermore, the 
crystal structure of IRF3 has been elucidated in detail.  It revealed that the IAD and 
flanking auto-inhibitory regions condense to from a hydrophobic core.  It is believed that 
phosphorylation leads to a conformational change in the auto-inhibitory regions and 
causes unmasking of the DBD (Qin et al., 2003).   
 
1.4.2.2 IRF protein function 
IRF proteins seem to have assumed various biological functions during the course of 
evolution, particularly in anti-viral immunity.  As mentioned,  IRF1 was originally 
thought contribute to expression of the IFN- gene (Fujita et al., 1988), however the 
generation of IRF1-deficient mice revealed that it was not essential for IFN- 
Figure 1.6 Schematic representation of IRF family members.  See section 1.4.2.1 for 
details.  Copied from Taniguchi T et al. Annu Rev Immunol. 2001;19:623-55 
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transcription (Reis et al., 1994).  Subsequent studies suggested that IRF3 was the crucial 
factor responsible for IFN- gene induction.  Mice carrying null mutations in the IRF3 
alleles were highly susceptible to EMCV infection, and showed markedly decreased 
expression of IFN- in response to NDV infection in IRF3-deficient MEFs (Sato et al., 
2000).  More recently, however, the characterisation of mice lacking IRF7 has led to 
IRF7 being termed the “master regulator” of type I IFN production.  Following viral 
infection, IFN gene expression is significantly more impaired in MEFs lacking IRF7 
compared to IRF3.  Consequently, IRF7-deficient mice are also more vulnerable to viral 
infection (Honda et al., 2005b).   
 
IRF5 plays an essential role in protection against LPS and CpG-induced lethal shock.  
Consequently, IRF5-deficient animals are characterised by reduced serum levels of pro-
inflammatory cytokines such as TNF, IL-12 and IL6 in these inflammatory models.  
Furthermore, spleen-derived macrophages had reduced expression of TNF, IL12 and IL-6 
in response to treatment with ligands for TLR3, 4, 5, 6 and 9 (Takaoka et al., 2005).   
 
IRFs 4 and 8 and, to a lesser extent, IRFs 1 and 2, play a crucial role in the differentiation 
of immune cell types, particularly DCs.  IRF8-deficient mice had dramatically reduced 
numbers of pDCs and CD8+ cDCs, Langerhans cells and interstitial DCs (Aliberti et al., 
2003; Schiavoni et al., 2004; Tsujimura et al., 2003).  Conversely, IRF2 and IRF4-null 
mice respectively show reduced numbers of CD4+ cDCs (Ichikawa et al., 2004; Suzuki 
et al., 2004).  Moreover, spleens of double knock-out animals only contain DN cDCs and 
are devoid of additional DC subtypes (Tamura et al., 2005).  The loss of IRF1 has a more 
subtle effect on DC development, with a modest increase in pDCs and a reduction in 
CD8+ cDCs being observed (Gabriele et al., 2006).  However, IRF1 is critical for proper 
NK cell (Duncan et al., 1996; Ogasawara et al., 1998; Ohteki et al., 1998), CD8+ T cell 
(Matsuyama et al., 1993) and Th1 cell development (Lohoff et al., 1997; Taki et al., 
1997).  Similar observations were seen in mice lacking IRF2 (Lohoff et al., 2000; 
Matsuyama et al., 1993; Taki et al., 2005).   
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IRF6 deficient mice displayed unexpected phenotypes including abnormal skin, limb and 
cranio-facial developments (Ingraham et al., 2006; Richardson et al., 2006).  Further 
studies are required to understand how these effects are mediated by IRF6.  
 
1.4.2.3 IRF-DNA binding 
IRFs bind to DNA sequences termed interferon-stimulated response elements (ISREs), 
since IRF1 was originally described as a factor that inducibly activated the IFN- gene 
following virus infection (Fujita et al., 1988).  The ISRE consensus sequence is denoted 
as 
A
/GNGAAANNGAAACT (Tamura et al., 2008), although crystal structure analysis of 
IFR1 bound to the IFN-β enhancer revealed the core DNA binding sequence to be GAAA 
(Escalante et al., 1998).   
 
1.4.2.4 Activation of IRFs by viruses 
Although it is becoming increasingly clear that IRFs regulate many components of the 
immune system, it is their contribution to anti-viral immunity that is best characterised 
and understood.  It is believed, that in fibroblasts viral infection induces a two phase 
antiviral response, which is dependent on activation of the interferon receptor in a 
positive feedback loop. Initially virus infection activates IRF3, which can form 
homodimers and induce the IFN-β gene.  IFN-β then activates a set of genes products 
termed interferon stimulated genes (ISGs), including IRF7, and this activation 
subsequently leads to full induction of type I IFNs (Sato et al., 2000). Indeed, the 
induction of interferons in response to most viruses is dramatically reduced in mice 
deficient in IRF7 and, to a lesser extent, IRF3 (Honda et al., 2005b).  The observation 
that IRF7-deficient mice are more vulnerable to viral infection than IRF3-deficient mice 
suggests that IRF7 may form hetero-dimers with IRF3 to initiate the the first wave of 
IFN- induction. Interestingly, residual interferon production is lost in double knock-out 
animals (Tamura et al., 2008).   
 
There is also evidence to suggest that IRF1, 5, 8 and 9 can contribute to specific aspects 
of IFN production.  IRF5 has been shown to form hetero-dimers with IRF7 to regulate 
IFN genes (Barnes et al., 2003), and IRF5-deficient mice were found to be more 
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vulnerable to vesicular stomatitis virus (VSV), herpes simplex virus type 1 (HSV-1) 
(Yanai et al., 2007) and NDV (Paun et al., 2008) infection compared to wild-types.  IRF1 
was found to be essential in the second phase of IFN response by reducing the replication 
of Vaccinia virus (VACV) (Trilling et al., 2009) and Hepatitis C virus (Ciccaglione et al., 
2007; Kanazawa et al., 2004).  The second phase of interferon induction was also 
abolished in mice lacking IRF8 (Tailor et al., 2007).   IRF9 is also critical for an effective 
anti-viral response, as a component of the ISG factor 3 (ISGF3) signalling complex that 
is activated by the interferon receptor, and therefore regulates the transcription of anti-
viral genes (Veals et al., 1993). 
  
1.4.2.5 Signalling to IRFs via the TRIF pathway 
To date it has been shown that 6 different IRF members can be activated by TLR 
stimulation (figure 1.7).  Activation of IRF3 occurs via the TRIF-dependent pathway 
utilised by TLR3 and TLR4, whereas IRFs 1, 4, 5, and 8 are all activated by the MyD88-
dependent pathway.  IRF7 seems to be unique in that both TRIF and MyD88 pathways 
can leads to its activation in a TLR and cell type specific manner.  TRIF-dependent 
signalling from TLR3 and TLR4 is thought to act through TRAF3, which then activates 
the non-canonical IKK proteins IKKε and TBK1 (Hemmi et al., 2004; Oganesyan et al., 
2006; Perry et al., 2004).  However, while activation of the TRIF pathway via TLR3 
results in the activation of both IRF3 and IRF7, TLR4-induced TRIF pathway seems to 
preferentially activate IRF3, although the physiological relevance of this is not clear 
(Tamura et al., 2008). In model cell line studies, both IRF3 and IRF7 are equally 
activated by TLR4-stimulation (Fitzgerald et al., 2003), but IRF7 deficient animals show 
less reduction in IFN-β expression in response to LPS compared to IRF3 deficient 
animals, where it is practically abolished (Honda et al., 2005b; Sakaguchi et al., 2003). 
However, that under certain conditions IRF7 may also participate in TLR4 signalling: 
when IRF7 is upregulated by pretreatment with recombinant IFN-β, LPS induction of 
IFN-β mRNA is observed in DCs from IRF3 deficient animals (Sakaguchi et al., 2003). 
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can  
           Figure 1.7 Simplified overview of Myd88 and TRIF-dependent signalling to IRFs.   
 See section 1.4.2.5 and 1.4.2.6 for details. 
 
 
1.4.2.6 Signalling to IRFs via the MyD88 pathway 
IRF7 also be activated via TLR7 or TLR9, which are mainly expressed on pDCs, and 
exclusively use MyD88 as their adaptor.  Multiple mechanisms of IRF7 activation by 
these receptors have been suggested.  Several studies have shown that IRF7, but not      
IRF3, can interact with MyD88, (Honda et al., 2004; Kawai et al., 2004), as part of a 
larger complex that contains also TRAF6 and IRAK4 (Honda et al., 2004; Kawai et al., 
2004).  Genetic studies have also revealed that IRAK1 and IKKα are essential for the 
expression of IRF7 target genes following TLR7/9 stimulation, and these kinases were 
shown to directly phosphorylate IRF7 in vitro (Hoshino et al., 2006; Uematsu et al., 
2005).  IRF1 has also been shown to form a complex with, and be activated by, MyD88 
following TLR9 stimulation (Negishi et al., 2006).  However, it was unclear if this 
activation was dependent upon additional components, as is the case with IRF7.   
 
Similar to IRF7, it was demonstrated that IRF5 interacts with MyD88 and TRAF6 
following stimulation with TLR9, in addition to TLR4.  As stated previously, IRF4 seems 
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to negatively regulate TLR signalling.  It is up-regulated following TLR stimulation and 
competes with IRF5, but not IRF7, for binding with MyD88 (Negishi et al., 2005).  The 
mechanism of IRF4 activation in response to TLRs remains unclear, although it is 
interesting to note that the majority of IRF4 in resting cells is found in the nucleus 
(Negishi et al., 2005).  Again, the mechanism of IRF8 activation following TLR 
stimulation is unclear, although it is possible that it occurs upstream of NF-κB activation 
since IRF8 null DCs show impaired NF-κB translocation following TLR9 stimulation 
(Tsujimura et al., 2004).  Consistent with this hypothesis, IRF8 has been shown to 
interact with TRAF6 (Zhao et al., 2006). 
                                                                                                                                                      
1.4.3 NF-κB and IRFs can interact to regulate gene expression 
Several lines of evidence suggest that interactions between IRF and NF-κB family 
members are an important mechanism through which stimulus-specific gene expression is 
regulated.  The best characterized example is the IFN-β gene which is highly expressed in 
response to viral infection, and induces an anti-viral state in cells through the up-
regulation of ISGs.  IRF3/IRF7 and RelAp50 have been shown to synergize in activation 
of transcription of the IFN-β gene (which is discussed in detail in section 1.6.1.3) through 
nucleotide sequence-dependent structural changes in the DNA that allow formation of 
complementary DNA conformations for adjacent bound TFs.   
 
Another mechanism of NF-κB and IRF cooperation at the target promoter involves their 
direct physical interaction. As mentioned above (1.3.1.2), IRF3 can be recruited as a 
cofactor to RelA-containing complexes bound to selected κB sites (Leung et al., 2004).  
It was demonstrated that a considerable part of the gene expression signature in cells 
stimulated with LPS is formed by ISGs (Decker et al., 2005; Doyle et al., 2002; 
Toshchakov et al., 2003).  TLR4-mediated ISG expression was dependent upon the 
activities of both IRF3 and NF-κB (Doyle et al., 2002).  Inhibition of either of these 
factors using dominant negative IκBα or dominant negative IRF3 caused a severe 
reduction in the level of selected ISG expression. Of interest, the promoters of some of 
these genes did not contain binding sites for both NF-κB and IRF3, suggesting an indirect 
protein-mediated recruitment. In fact, IRF-3-mediated activation of the ISRE was shown 
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to be promoted by RelA in TLR4-stimulated cells (Wietek et al., 2003).   Moreover, the 
biochemical analysis of protein-protein interactions revealed that RelA and IRF3 can 
interact directly via RelA RHD (Ogawa et al., 2005). Consistent with these findings, it 
was proposed that the disruption of RelA/IRF3 interactions by glucocorticoid receptor 
agonist dexamethasone may be a mechanism behind its inhibitory effect on the 
expression of a subset of genes induced by TLR4 stimulation (Ogawa et al., 2005).   
 
The importance of RelA in inflammatory cytokine production is well documented.  As 
mentioned previously, IRF5-deficient mice also showed impaired expression of several 
inflammatory genes such as TNF and IL-6 in response to various TLR ligands, 
suggesting that both these factors contribute to activation of these genes (Takaoka et al., 
2005).  In fact, data generated within my own lab has shown that RelA and IRF5 can 
physically interact with each other (Dr. David Saliba, personal communication).  IRF5 
deficient cells also showed impaired IL-12 production (Takaoka et al., 2005), a 
phenomenon that has been reported in cells lacking c-Rel (Sanjabi et al., 2000; Wang et 
al., 2008)and IRF3 (Goriely et al., 2006), although it remains unclear whether c-Rel and 
IRF3 or IRF5 interact to regulate IL-12 expression. 
 
 
1.5 Sustained activation of innate immunity can result in auto-immune 
disease 
As discussed above, activation of the immune system under normal physiological 
conditions is tightly regulated.  Multiple feedback mechanisms exist to ensure a prompt 
termination of the response and minimise collateral damage to host cells and tissues.  
However, under certain conditions, sustained or excessive immune activation can lead to 
the development of auto-immune diseases such as rheumatoid arthritis (RA).  RA is 
prevalent, affecting ~1% of the population worldwide, and associated with severe 
morbidity and, in extreme cases, premature mortality.   
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1.5.1 Pathology of RA 
RA is a heterogeneous, chronic, progressive auto-immune disease (Feldmann et al., 
1996a).  The heterogeneity of the disease is emphasized by the revised American 
Rheumatism Association criteria for classification, which requires that 4 out of a possible 
7 symptoms have been present for at least 6 weeks (Arnett et al., 1988).  These can 
include morning stiffness of the joints, swelling of joints or the presence of rheumatoid 
nodules. RA primarily affects the synovial joint, which displays symptoms commonly 
associated with inflammation, as well as progressive destruction of surrounding cartilage 
and bone (Allard et al., 1987) (figure 1.8).  (Cohen et al., 1995; Kasama et al., 1995; 
Katsikis et al., 1994).  In addition, a significant minority of patients can develop 
manifestations in other organs such as pulmonary (Horton, 2004) and cardiovascular 
disease (Goodson, 2002), which contributes to the premature mortality of RA patients.        
                                 
  Figure 1.8 Schematic representation of healthy versus rheumatoid arthritis  
  joint.  The RA joint is characterised by infiltration of cells, mainly macrophages,  
  T-cells and fibroblasts, to the synovial membrane and destruction of cartilage. 
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The normally acellular synovial fluid becomes populated with neutrophils and, to a lesser 
extent macrophages, T lymphocytes and dendritic cells in patients with RA (Feldmann et 
al., 1996a, b).  Furthermore, the synovial membrane markedly increases in size due 
mainly to recruitment of macrophages, fibroblasts and Tlymphocytes (Abrahamsen et 
al., 1975; Klareskog et al., 1981; Van Boxel and Paget, 1975).  A multitude of cytokines 
are expressed in the synovium of RA patients.  Pro-inflammatory cytokines such as 
TNFIL-1 and IL-6 can be detected at both the mRNA and protein levels (Buchan et al., 
1988; Field et al., 1991; Fontana et al., 1982).  Also present in the rheumatoid joint are 
matrix metalloproteinases (MMP), the enzymes which are thought to be the major 
contributor to the destruction of bone and cartilage (Vincenti et al., 1994).  Interestingly, 
anti-inflammatory molecules such as IL-10 are also expressed in the synovial joint of RA 
patients                      
                         
1.5.2 Etiology of RA 
Although the etiology of RA remains undefined, the contribution of genetic risk factors 
has been documented.  In particular, certain alleles encoding the major histocompatibility 
class II complex are believed to account for ~30% of the total genetic risk (Seldin et al., 
1999).  Studies of this locus in the 1980‟s led to the shared epitope hypothesis, whereby 
the DR4 and DR1 subtypes of the DRB1 chain, which is part of the MHC class II 
complex, shared amino acids 70-74 and were most commonly associated with RA 
(Gregersen et al., 1987).  With the advancements of genome-wide screens in the 1990s, 
additional genetic risk factors have been identified, although the association with RA was 
found to be weaker (Cornelis et al., 1998; MacKay et al., 2002; Shiozawa et al., 1998).  
Considering that women are 3-fold more susceptible to RA compared to men, the 
possible role of sex hormones has also been noted, although firm evidence is still lacking 
(Jansson and Holmdahl, 1998).   
 
In addition to genetic risk factors, the high discordance for disease development in 
monozygotic twins has clearly pointed to a role for environmental factors (Bellamy et al., 
1992; Silman et al., 1993), and again, several candidates have been proposed including 
silica dust (Klockars et al., 1987) and smoking (Klareskog et al., 2006; Linn-Rasker et 
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al., 2006).  However, infection is considered by many researchers to be the most 
plausible environmental factor (Carty et al., 2004), with mycobacteria (Bahr et al., 1988; 
Rook et al., 1993), Escherichia coli (Albani et al., 1995), Epstein-Barr virus (Takeda et 
al., 2000) and Parvovirus (Harrison et al., 1998) having all been linked to RA.  If 
infection were to act as a trigger in RA, this would clearly imply a role for TLRs, 
although there is currently no definitive evidence of a link.  However, there is a growing 
body of evidence that endogenous ligands of TLRs may contribute to inflammatory 
cytokine production and therefore perpetuate the inflammatory responses in RA 
(reviewed in (Sacre et al., 2007)).  For example, murine models of RA displayed reduced 
symptoms when lacking TLR4, or when treated with TLR4 antagonists (van den Berg et 
al., 2007).  Furthermore, inhibitors of TLR8 were shown to significantly reduce 
inflammatory cytokine production in ex vivo cultures of synovial membranes derived 
from RA patients (see below) (Sacre et al., 2008) 
 
1.5.3 RA treatment 
It has been demonstrated that mixed cell populations from rheumatoid membrane 
spontaneously produce cytokines even after removal from the joint (Brennan et al., 
1989).  Using this system, which has become a useful model for testing potential 
therapeutic drugs, it was found that blocking TNF 
significantly reduced expression of pro-inflammatory mediators (Feldmann et al., 1994).  
Subsequent clinical trials showed that TNF blockade significantly ameliorated RA 
symptoms and it has since become the most effective treatment against RA (Elliott et al., 
1994; Elliott et al., 1993; Maini et al., 1995; Rankin et al., 1995).  However, 
approximately 30% of patients do not respond to this form of therapy (Feldmann and 
Maini, 2001); thus it is important to investigate whether other cytokines can provide new 
therapeutic targets in RA.   
 
1.6 Class II cytokines exert a broad range of effects on the immune 
system 
Completion of the human genome project just under a decade ago has lead to the rapid 
identification of multiple cytokines.  This is typified by the class II cytokine family, 
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which has more than doubled in size in the past 8 years.  Understanding the biological 
activities of these novel cytokines is important, as it may open up new avenues for 
therapeutic targets for patients with auto-immune diseases such as RA, as some members 
of this family (e.g. IL-10 and IFN-) have already been tested in RA clinical trials 
(Keystone et al., 1998; van Holten et al., 2005). 
 
Cytokine receptors are broadly divided into those with an intrinsic kinase activity in the 
intracellular domain, and those that recruit a tyrosine kinase.  The latter group is further 
sub-divided into class I and class II cytokine receptors, which differ both functionally and 
structurally (Krause and Pestka, 2005).  Generally, class I cytokines, which include IL-
12, GM-CSF and IL-4, are involved in the differentiation or proliferation of immune cells 
or tissues.  Conversely, class II cytokines function to minimize host damage following 
infection or physical insult.  Class I and class II cytokine receptors also have significant 
differences in the positions of conserved cysteine, tryptophan, tyrosine, and 
phenylalanine residues in the fibronectin III domains (Bazan, 1990).   
 
Class II cytokines exert a broad range of effects on the immune system and have been 
implicated in a variety of human diseases.  The ligands consist of type I, II, and III 
interferons (IFNs), interleukin (IL)-10, IL-19, IL-20, IL-22, IL-24, and IL-26 (figure 1.9).  
The genes encoding these proteins are clustered at 4 different loci in the human genome:  
IL-10, IL-19, IL-20, and IL-24 on chromosome 1; type I IFN on chromosome 9; type II 
IFN (IFN- IL-22 and IL-26 on chromosome 12 and type III IFNs on chromosome 19.  
Class II cytokine receptors are transmembrane, heterodimeric protein complexes.  
Receptor signaling from class II cytokines utilizes the JAK-STAT signaling pathway.  
Although these cytokines share only limited sequence homology strongly conserved 
motifs exist.  These motifs account for the structural homology and facilitated the rapid in 
silico discovery of novel family members.  Class II cytokines can be sub-divided into 
interferons and IL-10-related factors, and an overview of these cytokines is given below. 
 
Chapter 1  Introduction     
 53 
       
 
 
1.6.1 Type I IFNs 
Following viral infection, the infected cells secrete factors which inhibit replication of the 
virus.  This observation was first detailed in 1957 by Isaacs and Lindenmann in 
influenza-infected chick embryos, and the secreted factors were termed interferons, due 
to their ability to „interfere‟ with viral replication (Isaacs and Lindenmann, 1957).  More 
than 50 years have passed since that landmark paper, and studies on these biologically 
important factors have pioneered several aspects of biology including mechanisms of 
eukaryotic gene transcription and the realisation that cytokine therapy could be of 
significant clinical benefit (reviewed in (Friedman, 2008; Honda et al., 2005c).   
 
 
1.6.1.1 Type I IFNs and their receptor 
In mammals, type I IFNs consist of multiple IFN-αs (13 in humans), gene(s) encoding 
IFN-β, IFN-, IFN-ε, IFN-κ, IFN- and IFN-ω (Theofilopoulos et al., 2005).   The 
Figure 1.9 Schematic representation of class II cytokine receptors and ligands.  Receptor 
complexes, including the IFN-1 receptor, that utilise the IL-10R2 subunit are shown in red.  Adapted 
from Kotenko and Langer, Int Immunopharmacol. 2004 May;4(5):593-608 
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separation of these type I IFN subgroups is based on sequence homology.  The functions 
of IFN-, IFN-ε, IFN-κ, IFN- and IFN-ω remain ill-defined, in contrast to the 
extensively studied IFN-α and IFN-β.  While most cell types are capable of producing 
type I IFNs in response to viral infection, DCs, particularly pDCs, are the major 
producers (Asselin-Paturel and Trinchieri, 2005).  Part of the reason for this is that IRF7 
is constitutively expressed in large amounts in these cells.  Following stimulation of 
TLR7 or TLR9, which are almost exclusively expressed on pDCs, MyD88 can activate 
IRF7 directly (Honda et al., 2004; Kawai et al., 2004), or indirectly via IRAK1-IRAK4-
IKK(Honda et al., 2004; Hoshino et al., 2006; Uematsu et al., 2005).  Another feature 
of pDCs that allows them to produce high levels of type I IFNs is the location of the 
receptor itself.  In pDCs, TLR9 and its ligand CpG localise for a relatively long time in 
the endosomal compartment (Honda et al., 2005a).  By contrast, in cDCs or 
macrophages, which only produce relatively modest amounts of type I IFNs, CpG is 
rapidly transferred into lysosomal vesicles.  Moreover, it was shown that prolonging the 
retention of CpG in the endosomal compartment of cDCs induced them to mount a robust 
type I IFN response (Honda et al., 2005a). 
 
Type I IFNs signal through a receptor complex consisting of the IFNAR1 and IFNAR2 
subunits, which are ubiquitously expressed.  Activation of the receptor complex results 
predominately in the phosphorylation of STATs 1 and 2, which then dissociate from the 
receptor and form a complex with IRF9.  This complex, known as ISGF3, then 
translocates to the nucleus where it regulates the expression of target ISGs by binding to 
interferon stimulated response elements (ISREs) in their promoters (Stark et al., 1998).   
 
 
1.6.1.2 Biological activities of type I IFNs 
The defining feature of type I IFNs is their ability to inhibit viral replication in infected 
cells.  They do this at multiple levels including inhibition of transcription and translation.  
Two of the best characterised anti-viral systems utilised by type I IFNs are regulated by 
the Mx proteins and the 2‟,5‟-oligoadenylate synthetase (2‟,5‟-OAS) proteins.  MxA 
over-expression has been shown to profoundly inhibit the replication of measles virus and 
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vesicular stomatitis virus in the human monocytic cell line U937 (Schnorr et al., 1993).  
Another study showed that MxA over-expression did not affect viral transcription, but 
did prevent protein synthesis, indicating that viral mRNA transportation or protein 
synthesis itself were inhibited (Pavlovic et al., 1992).   2‟,5‟-OAS proteins, on the other 
hand, activate RNase L, which leads to the rapid degradation of single stranded RNA 
(Carroll et al., 1996; Floyd-Smith et al., 1981). 
 
After their discovery, it quickly became apparent that „interferons‟ could also inhibit 
growth of cell cultures and reduce tumour growth in inoculated mice (Gresser et al., 
1969; Paucker et al., 1962).  However, it is only in more recent years that the full range 
of biological effects exerted by type I IFNs has been appreciated.  It is known that type I 
IFNs can induce DC maturation, as judged by up-regulation of MHC class II and co-
stimulatory molecules such as CD80 and CD86.  They have also been shown to up-
regulate the expression of MHC class I and activate CD8+ T cells against virally infected 
cells (Le Bon et al., 2003; Ogasawara et al., 2002). In addition, type I IFN receptor 
activation has been reported to promote the survival of T-cells (Marrack et al., 1999) and 
influence the secretion of immunoglobulin isotypes (Finkelman et al., 1991).  IFN-α 
treatment of human monocyte-derived macrophages can also up-regulate TLR3, TLR4 
and TLR7 expression, as well as specific TLR signalling molecules, thereby sensitising 
cells to the presence of pathogenic agents (Siren et al., 2005).  It is therefore becoming 
increasingly clear that, in addition to their potent anti-viral activities, type I IFNs exert a 
broad range of effects on both innate and adaptive immune responses. 
Recently IFN- has been shown to have several other immuno-regulatory functions, 
including the regulation of inflammatory genes.  TNF and IL-1 expression can be induced 
in monocytes by co-culturing with membranes of activated T cells. However, treatment 
with IFN- has been shown to inhibit expression of these cytokines, in addition to 
enhancing expression of IL-1 receptor antagonist (IL-1Ra), which is also anti-
inflammatory (Molnarfi et al., 2004).  The mechanism through which this regulation 
occurs is unclear, but one study has reported that it is dependent on PI3K, but not STAT-
1 (Molnarfi et al., 2005).  Moreover, several reports have documented the beneficial 
effects of IFN- in both murine (Treschow et al., 2005; Triantaphyllopoulos et al., 1999; 
Chapter 1  Introduction     
 56 
van Holten et al., 2004) and rhesus monkey CIA models (Tak et al., 1999).  Similar 
observations have been made in small trials in humans (Smeets et al., 2000; Tak et al., 
1999), but a phase II clinical trial reported no significant difference in RA patients treated 
with IFN- or a placebo control (van Holten et al., 2005).   
 
1.6.1.3 Regulation of IFN-β in response to viruses 
Like most cytokines, type I IFNs are regulated at the transcriptional level.  Induction of 
the human IFN-β gene in response to virus infection has been extensively investigated as 
a model of eukaryotic gene regulation for ~20 years.  The proximal IFN-β promoter 
contains a compact set of 4 regulatory elements designated positive regulatory domains 
(PRD) I-IV that spans −102 to −47 (relative to the transcription start site) and is highly 
conserved between human and mouse (Panne, 2008).  Classically, IFN- induction was 
investigated in virally infected fibroblasts.  These early in vitro studies showed that 
PRDII and PRD IV were activated by a RelAp50 heterodimer and ATF2c-Jun 
respectively, while PRDI and PRD III were activated by IRF1, which was the first IRF 
family member to be discovered (Thanos and Maniatis, 1995a, b).  Deletion of the IRF1 
gene revealed that type I IFN production was normal following virus infection, indicating 
that, in vivo, type I IFN expression is not dependent on  IRF1 (Reis et al., 1994).  
Subsequently, two other IRF family members, IRF3 and IRF7, were found to be involved 
in IFN-β production. The enhanceosome assembly was also reported to depend on the 
high mobility group (HMG) I(Y) protein, which induced allosteric changes in the 
promoter that provided a platform for transcription factor recruitment (Falvo et al., 1995).  
Moreover, the authors showed that once formed, the enhanceosome was extremely stable 
in vitro, and argued that stability would permit multiple rounds of transcription and could 
account for the high levels of IFN-β expression observed following virus infection (Yie et 
al., 1999).  In addition, it was shown that enhanceosome formation at the IFN-β promoter 
induces nucleosome remodelling before gene transcription (Agalioti et al., 2000).  
Although the enhanceosome DNA sequence itself is „naked‟, it is flanked by two 
nucleosomes, one of which masks the TATA box.  Enhanceosome formation initially 
induces the recruitment of the GCN5/PCAF histone acetylation transferase complex that 
acetylates the flanking nucleosomes.  This is followed by recruitment of the SWI/SNF 
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complex that remodels, or slides the nucleosomes, thereby unmasking the TATA box and 
allowing the basal transcription machinery to activate transcription.  
 
An atomic model of the Interferon- enhanceosome was reported and showed that the 
aforementioned transcription factors made contacts with almost all nucleotides in the 
enhancer region (Panne et al., 2007).  Interestingly, despite the strong synergy observed 
between RelA/p50, IRF3/7 and ATF2/c-Jun in IFN-β induction, protein-protein contacts 
were minimal, which led the authors to conclude that binding-induced changes in DNA 
conformation and interactions with additional cofactors were the root of cooperative 
occupancy (Panne et al., 2007).  Most recently, an interesting study highlighted the 
possible role played by Alu elements in IFN- induction in virally infected fibroblasts.  
Using circular chromosome conformation capture, it showed that the IFN- enhancer 
specifically interacts with three genetic loci, two of which are on different chromosomes, 
which carry B sites within Alu elements.  Remarkably, transfection of plasmids 
containing intact, but not mutated, B sequence led to enhanced IFN- expression.  The 
authors speculated that NF-B may firstly be recruited to the NF-κB sites in the Alu 
elements, and then transferred to the IFN- enhancer via inter/intrachromosomal 
interactions (Apostolou and Thanos, 2008). 
 
There have been several observations, however, that have caused the enhanceosome 
paradigm of IFN-β transcriptional regulation to be revised.  IRF3 was shown to be 
constitutively expressed, and interact with the PRDI element and IRF3 over-expression 
markedly increased virus-induced IFN-β expression (Sato et al., 1998b).  By contrast, in 
MEFs, IRF7 is only expressed in very low levels, but is itself an ISG and is therefore up-
regulated following type I IFN receptor activation (Marie et al., 1998).  Due to its higher 
levels of expression, IRF3 was considered the main IRF protein involved in IFN-β 
induction.  This conclusion was overturned when mice deficient for these proteins were 
generated.  IFN-β induction was almost abolished in IRF7 deficient MEFs and pDCs in 
response to HSV-1, VSV and EMCV infection.  IRF3 deficient MEFs and pDCs, on the 
other hand, demonstrated only a modest reduction in IFN-β expression compared to wild-
types (Honda et al., 2005b).   
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Another conflicting finding with the enhanceosome model of IFN-β induction came from 
mice that were deficient for RelA and p50.  MEFs from these mice showed only a modest 
decrease, approximately 20%, in IFN-β production following SV infection (Wang et al., 
2007b), suggesting that these factors play only a minor role.  In addition, an elegant study 
from Bosisio et al using fluorescently labelled NF-κB complexes found that they were 
only transiently bound to high affinity binding sites in living cells (Bosisio et al., 2006).  
This observation suggested the high levels of IFN-β gene transcription following viral 
infection is a consequence of transcription factor concentrations in the nucleus following 
stimulation, and not of the stability of the enhanceosome structure.   
 
1.6.1.4 Induction of IFN-α genes following virus infection      
Mice that are deficient for IFN-β, IFN-R1 or IR9 (which forms part of the ISGF3 
complex) show impaired IFN-α induction in response to viral infection (Erlandsson et al., 
1998; Harada et al., 1996).  These observations suggested that IFN-β secretion was a 
prerequisite from maximal induction of IFN-α.  It was also reported that activation of the 
ISGF3 complex leads to up-regulation of IRF7, which then drives expression of the IFN-
α genes, and that ectopic expression of IRF7, but not IRF3, was able to drive expression 
of IFN-α genes (Sato et al., 1998a).  Taken together, these results led to a bi-phasic 
positive feedback model of type I IFN expression whereby virus infection initially 
activates IRF3, which then induces the IFN-β gene.  IFN-β then activates the ISGF3 
complex which up-regulates IRF7 and leads to full induction of type I IFNs (Sato et al., 
2000).  However, subsequent generation of mice deficient for IRF7 showed that IFN-α 
and IFN-β expression in virus infected MEFs was almost completely abolished, while 
IRF3 knockout mice showed a modest reduction (Honda et al., 2005b).  This led the 
authors to conclude that IRF7 is the “master regulator” of type I IFN production in 
response to viral infection, and that low concentrations of IRF7 were sufficient for 
IRF3/IRF7 heterodimer formation and the initial IFN-β production, while subsequent 
production of IFN-α required high concentrations of IRF7 (Honda et al., 2005b).   
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1.6.1.5 Regulation of IFN-β in response to LPS 
As outlined above, genetic studies in mice show that IRF7 is the main factor that 
regulates IFN-β expression in response to viral infection.  However, in response to LPS, 
IRF3, which is activated via the MyD88-independent/TRIF-dependent pathway, is crucial 
for IFN-β activation.  A dominant-negative version of IRF3 was shown to inhibit LPS-
induced IFN-β expression in the murine macrophage cell line RAW 264.7 (Doyle et al., 
2002).  The same study also showed reduced IFN-β expression when IκBα was over-
expressed, implicating the role of NF-κB in LPS-induced IFN-β expression in RAW 
cells.  It has also been shown that IFN-β transcription is markedly diminished in IRF3 
null DCs (Honda et al., 2005c; Sakaguchi et al., 2003).  Moreover, IRF3-deficient mice 
show resistance to endotoxic shock, highlighting its importance in TLR4 signalling.  
Thus, while IRF7 seems to be the critical factor for IFN-β induction in response to viral 
infection, TRIF-activated IRF3 is essential for LPS-induced IFN-β. 
 
1.6.2 Type II IFNs 
Type II IFN, which comprises a single ligand termed IFN-γ, utlises a receptor complex 
distinct from type I IFNs.  Although the IFN-γ was first reported for its anti-viral activity 
(Wheelock, 1965) it is now considered to be an immuno-regulatory cytokine that is 
crucial for the clearance of intracellular pathogens.  IFN-γ is the hallmark cytokine of 
Th1 cells, but also produced by activated NK cells and cytotoxic T cells (Boehm et al., 
1997).  IFN-γ binds to a receptor complex comprising the IFN-γR1 and IFN-γR2 
subunits.  Classically, activation of this receptor complex leads predominately to the 
phosphorylation of STAT1, which then homo-dimerises and translocates to the nucleus.  
There it binds to gamma activate site (GAS) elements containing the sequence 
TTNCNNNAA in the promoters of target genes (Bach et al., 1997).  However, micro-
array analysis in STAT1-null mice revealed a number of genes that were regulated in a 
STAT1-independent manner, suggesting that other signaling pathways contribute to the 
biological effects of IFN-γ (Gil et al., 2001).  IFN-γ can up-regulate MHC class I and II 
complexes and regulate the expression of several cytokines and chemokines including IL-
12 and IP-10.  It can also inhibit the proliferation of Th2 cells (Gajewski and Fitch, 
1988).  IFN-γ is a potent activator of macrophages, and enhances their anti-microbial 
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effector functions such as phagocytosis, and production of reactive oxygen species 
(MacMicking et al., 1997).  Mice lacking IFN-γ or the IFN-γR1 subunit highlight its 
importance in immune functions.  Such mice are more susceptible to infection with the 
intracellular bacteria Mycobacterium bovis and Listeria monocytogenes (Dalton et al., 
1993; Huang et al., 1993). 
 
1.6.3 IL-10  
IL-10 was originally described as a factor secreted from Th2 cells that inhibited 
inflammatory cytokine production, including IFN-γ, from Th1 cells (Fiorentino et al., 
1989).  IL-10 is now considered the most potent anti-inflammatory cytokine, and it exerts 
its effects on, as well as being produced by, most immune cells, although Tregs are a 
major source (Moore et al., 2001).  The IL-10 receptor consists of the ubiquitously 
expressed IL-10R2 subunit, and the IL-10R1 subunit.  IL-10 has been shown to inhibit 
the production of a wide range of inflammatory mediators, including TNF, IL-6 and IL-1 
in monocytes(de Waal Malefyt et al., 1991) and neutrophils (Cassatella et al., 1993).  In 
addition, it also increases the expression of proteins which act to antagonise 
inflammatory mediators, such as soluble TNF receptor (Hart et al., 1996) and IL-1Ra 
(Carl et al., 2004).   
 
Studies in IL-10 transgenic mice highlight the crucial role played by IL-10 in the 
resolution of inflammation.  Mice engineered to constitutively express IL-10 from 
macrophages display a reduced ability to clear bacterial infections and an impaired 
induction of inflammatory cytokines (Lang et al., 2002).  Conversely, when challenged 
with pathogens, IL-10-deficient mice typically die due to an excessive inflammatory 
response (Gazzinelli et al., 1996; Hunter et al., 1997). These findings, together with the 
observation that IL-10 significantly inhibited collagen-induced arthritis (CIA) in mice 
(Walmsley et al., 1996), suggested that IL-10 may be of benefit to RA patients.  
However, a phase II clinical trial found that IL-10 treatment, like IFN-β, only slightly 
attenuated symptoms in humans (Keystone et al., 1998).  Several reports suggest that the 
anti-inflammatory actions of IL-10 are mediated by sustained activation of STAT3 (Riley 
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et al., 1999; Takeda et al., 1999; Williams et al., 2004), although the exact mechanism 
remains elusive. 
 
1.6.4 IL-10 related factors 
1.6.4.1 IL-22 and IL-26 
IL-22 and IL-26 are clustered together, along with IFN-γ, on human chromosome 12.  
Although research into the biology of IL-22 is still in its infancy, the available data 
suggests a pro-inflammatory role.  It was initially shown to be produced by naïve T-cells 
stimulated with CD3 (Xie et al., 2000), while further studies revealed that Th17 cells are 
the major cellular source (Liang et al., 2006).   The IL-22 receptor complex consists of 
the IL-22R1 and the IL10R2 subunits, which are highly expressed on epithelial cells, but 
not leukocytes (Gurney, 2004; Wolk et al., 2004).  It has been reported that IL-22 up-
regulates the expression of inflammatory proteins belonging to the S100 family, MMP-3 
and the chemokine CXCL5 in keratinocytes (Boniface et al., 2005).  It has also been 
shown to act as a pro-inflammatory mediator in a lung infection model (Whittington et 
al., 2004) and in a model of septic shock (Weber et al., 2007).  Furthermore, IL-22 has 
been implicated in the pathogenesis of both psoriasis (Zheng et al., 2007) and RA, where 
it was shown to promote inflammatory response in synovial tissues (Ikeuchi et al., 2005).   
 
There is still a paucity of data regarding IL-26.  Initially, IL-26 mRNA was reported to be 
detected in unstimulated PBMCs from healthy donors, and up-regulated in T-cells 
infected with herpesvirus saimiri (HVS) (Knappe et al., 2000).  Subsequent reports 
showed that NK cells, naïve T cells and Th17 cells respectively stimulated with IL-2/IL-
12, anti-CD3 monoclonal antibody and IL-23 upregulated IL-26 (Wilson et al., 2007; 
Wolk et al., 2002).  More recently, IL-26 protein was shown to be expressed in 
infiltrating Th17 cells in biopsies from patients with active Crohn‟s disease (Dambacher 
et al., 2008).  The IL-26 receptor complex consists of IL-20R1 and IL-10R2 chains 
(Sheikh et al., 2004).  It is highly expressed on intestinal epithelial cells and stimulation 
results in production of several inflammatory cytokines including TNF and IL-8 
(Dambacher et al., 2008).   
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1.6.4.2 IL-19, IL-20 and IL-24 
IL-19, IL-20 and IL-24 are clustered together with IL-10 on human chromosome 1.  
These cytokines are strongly up-regulated in LPS-treated, and to a lesser extent, anti-CD3 
monoclonal antibody treated PBMCs, and in IL-1β treated keratinocytes (Kunz et al., 
2006). However, it was shown that stimulated NK-cells or B-cells do not produce IL-19 
or IL-20 (Gallagher et al., 2000; Wolk et al., 2002).  There are also several reports 
documenting the specific expression of IL-19 and IL-20 in the skin of psoriasis patients 
(Li et al., 2005; Otkjaer et al., 2005; Romer et al., 2003; Wei et al., 2005) and in diseased 
skin of atopic dermatitis patients (Kunz et al., 2006), In line with the potential role of 
these cytokines in skin diseases, their receptors are highly expressed in skin, as well as 
respiratory and reproductive organs, although their exact contribution to disease remains 
unclear.  (Kunz et al., 2006). 
 
1.6.5 IFN-λs 
IFN-λ1, 2 and 3 (also known as IL29, IL-28A and IL-28B respectively; and type III IFNs 
collectively) were first reported in 2003 by two groups independently.  At the amino acid 
level, IFN-λ2 and IFN-λ3 display homology of approximately 96%, suggesting a recent 
gene duplication event, while IFN-λ1 is 81% homologous to IFN-λ2/3.  It should be 
noted that IFN-λ1, which is the main IFN- produced in human cells, is not expressed in 
mice due to the insertion of a stop codon within the gene. Instead IFN-λ2/3 take on the 
major role in mouse cells.  Interestingly, the IFN-λs have features that are common to 
both interferons and IL-10 related factors, which partly accounts for the dual 
nomenclature.  Like IL-10 related factors, the genes encoding type III IFNs contain 
multiple exons (5 for IFN-λ1, 6 for IFN-λ2/3), whereas type I IFNs are intronless.  
Furthermore, the IFN-λR consists of the IL-10R2 subunit, which is shared by IL-10, IL-
22 and IL-26, in addition to the unique IFN-λR1 subunit (also known as IL-28R1 
subunit).  In contrast, the subunits that make up the type I IFN receptor complex are not 
utilized by any other cytokines.  However, despite the use of a distinct receptor complex, 
the IFN-λR activates similar signaling pathways to that of the type I IFN receptor.  It has 
been shown that IFN-λR activation results in the phosphorylation of STATs 1, 2, 3, 4 and 
5, and, furthermore, the formation of the ISGF3 complex (Dumoutier et al., 2004; 
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Kotenko et al., 2003).  Consequently, several of the biological functions regulated by the 
IFN-λs are also regulated by type I IFNs.   
 
1.6.5.1 Biological functions of IFN-λs 
By definition, the IFN-λs must possess anti-viral activity, and the majority of early 
studies on these novel cytokines assessed this function. The deficient induction of IFN- 
λs by rhinovirus in asthmatic primary bronchial epithelial cells and alveolar macrophages 
correlated highly with severity of rhinovirus-induced asthma exacerbation and virus load 
in experimentally infected human volunteers.  This suggested that, similar to IFN- 
(Wark et al., 2005), IFN-s may contribute to prevention of rhinovirus-induced asthma 
(Contoli et al., 2006). In the original publications Kotenko et al demonstrated that IFN-λ1 
exhibited anti-viral activity against VSV in 3 different human cell lines, HeLa, HT29 and 
A549 cells, and that this activity was comparable to IFN-α (Kotenko et al., 2003).  
Similarly, Sheppard et al showed that when pre-treated with IFN-λs, the human 
hepatocellular carcinoma cell line HepG2 was protected against the viral-induced 
cytopathogenic effect of EMCV infection (Sheppard et al., 2003).  In this system, the 
anti-viral effects of IFN-λ1 were stronger than IFN-λ2, but weaker than IFN-α.  This 
trend was replicated in several subsequent studies that examined a broader range of cell 
types and viruses.  Osterlund et al showed that viral protein expression in influenza A 
infected human MDDCs was reduced when the cells were pre-treated with IFN-λ1, but 
this reduction was less pronounced when compared to IFN-α or IFN-β pre-treated cells 
(Osterlund et al., 2005).  This finding was confirmed and extended by a comprehensive 
comparison of the anti-viral activities of IFN-λ1, IFN-λ2, IFN-α and IFN-β in 23 
different human cell lines encompassing a range of different cell types (Meager et al., 
2005).  The different cell lines were infected with EMCV and then analysed by 
cytopathic effect reduction anti-viral assay.  While almost all the cell lines were highly 
sensitive to treatment with IFN-β or IFN-α2b, approximately two-thirds of the cell lines 
were relatively insensitive to IFN-λ1, which was itself between 2-10 fold more potent 
than IFN-λ2.  There was not a clear correlation between mRNA levels of the IFN-
λR1/IL10R2 subunits and cell responsiveness in the cell lines tested.  However, the most 
responsive cell line, LN319 (a glioblastoma), did contain the greatest amount of receptor 
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expression (Meager et al., 2005).  Taken together, in vitro data suggest the anti-viral 
activity of type III IFNs seems be weaker and more selective compared to type I IFNs, 
and that the activity of IFN-λ1 is more potent then IFN-λ2. 
 
The subsequent generation of mice lacking the IFN-λR1 subunit allowed a more thorough 
dissection of the contribution of the IFN-λ system to viral infection in vivo.  The 
susceptibility of these mice to a range of RNA and DNA viruses was similar compared to 
wild-type mice, while type I IFN receptor-deficient mice displayed severely impaired 
viral clearance (Ank et al., 2008; Mordstein et al., 2008).  However, some interesting 
observations were made in these reports that point to specific contributions for the IFN-λs 
against viral infections.  For example, in a genital herpes model, pre-treatment with TLR3 
or TLR9 agonists effectively provides resistance to pathogenic symptoms in wild-type 
mice.  However, this effect was lost in IFN-λR1-null mice and, furthermore, treatment 
with recombinant IFN-λ2 was able to protect both wild-type and type I IFN receptor null 
mice in this system (Mordstein et al., 2008).  Similarly, mice unresponsive to type I and 
type III IFNs were hypersensitive to influenza infection, and IFN-λ2 treatment efficiently 
protected IFN-R1 null mice from influenza-infection lethality.  However, the authors 
report that IFN-λ2 was unable to protect against hepatotropic viral infection, and that type 
I and type III IFN receptor-deficient mice were as susceptible as type I IFN-deficient 
mice to hepatotropic viruses (Ank et al., 2008).  An interesting study from Ank et al 
showed that IFN-λ2 does not protect HepG2 cells from HSV-2 infection, but IFN-λ2 
administration effectively protects against in vivo HSV-2 infection, strongly suggesting 
that IFN-λ2 can modulate other components of the immune system (Ank et al., 2006a).   
 
Indeed, as with type I IFNs, there is growing evidence that the IFN-λs are highly 
pleiotropic.  For example, it has also been demonstrated that the IFN-λs induce anti-
proliferative effects on neuroendocrine tumor cells and intestinal epithelial cells (Brand et 
al., 2005; Dumoutier et al., 2004; Zitzmann et al., 2006).  In addition, several studies 
from the Gallagher group have focused on the potential immuno-regulatory functions of 
IFN-λ1.  They found that low levels of IL-6, IL-8 and IL-10 were secreted in IFN-1 
treated human monocytes and macrophages, while TNF and IL-1 were unaffected (Jordan 
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et al., 2007a).  Furthermore, IFN-λ1 was shown to induce the mRNA expression of the 
chemokines monokine induced by IFN-γ (MIG/CXCL9), IFN-γ inducible protein-10 (IP-
10/CXCL10) and IFN-γ inducible T-cell alpha chemo-attractant (I-TAC/CXCL11) in 
PBMCs (Pekarek et al., 2007).  In addition, it was reported that naïve T-cells stimulated 
in the presence of IFN-λ1 expressed reduced levels of the Th2 cytokine IL-13, while IL-
4, IL-5 and the Th1 cytokine IFN-γ were largely unaffected (Jordan et al., 2007b; 
Srinivas et al., 2008).  Another group showed that IFN-λR1 mRNA expression is up-
regulated during DC differentiation from monocytes and that IFN-λ1-treated MDDCs 
express high levels of CCR7 and were able to migrate to the lymph nodes of SCID/Bg 
mice (Mennechet and Uze, 2006).  Moreover, MHC class I and MHC class II molecules 
were up-regulated in IFN-λ1 treated MDDCs to comparable levels as seen with IFN-β 
treatment.  However, in contrast to IFN-β, co-stimulatory molecule (CD80/CD86) 
expression was unaffected.  Interestingly, the authors further reported that IFN-λ1 treated 
MDDCs were also able to induce the proliferation of Tregs, suggesting a potential 
immuno-suppressive role for IFN-λ1 (Mennechet and Uze, 2006).  Considering these 
reports on the immuno-modulatory functions of IFN-λs, it would be of interest to assess 
the potential role of this cytokine family in auto-immune diseases.   
 
1.6.5.2 IFN-λR expression is cell specific 
The specific and cell type-restricted biological effects of type III IFNs suggests that the 
IFN-λR is not, unlike the type I IFN receptor, ubiquitously expressed.  Although, there 
have been some conflicting reports on this subject, it is now widely believed that the IFN-
λR is mainly expressed on epithelial cells and pDCs.  Initially IFN-λR1 mRNA was 
shown to be expressed in most human tissues, albeit to different levels.  Moderate to high 
expression was observed in the lung, skin, stomach, intestine, heart, kidney, pancreas, 
thyroid, skeletal muscle and testis, while expression was almost absent from the bone 
marrow, brain, spinal chord and uterus (Kotenko et al., 2003; Sheppard et al., 2003).  
This work was extended by Sommereyns et al who used immuno-histochemistry to show 
that expression of the IFN-λR1 subunit was restricted to epithelial kidney cells.  By 
contrast, the type I IFN receptor was present on the epithelial cells, in addition to 
endothelial cells and the surrounding adipose tissue.  Similarly, in the brain they showed 
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that IFN-λ2 responsive cells were restricted to the rare epithelial cells of the meninges, 
while both epithelial and endothelial cells were responsive to IFN-α (Sommereyns et al., 
2008).  Another investigation assessed which haematopoietic cells were responsive to 
IFN-λ2 by measuring 2 ISGs: OAS-1 and IRF7.  It was found that only pDCs 
significantly up-regulated these genes in response to IFN-λ2 treatment, whereas splenic 
cDCs, T-cells, B-cells and peritoneal macrophages were only responsive to IFN-α.  
Furthermore they also showed that keratinocytes and vaginal epithelial cells, but not 
fibroblasts were IFN-λ2 responsive (Ank et al., 2008).   
 
1.6.5.3 IFN-λs are induced by viral infection and specific TLR activation 
The original publications that described the IFN-λs showed that their mRNA expression 
could be induced in various human cells lines (HeLa cells, HuH7 hepatoma cells and HT-
29 cells) that had been infected with different viruses (sindbis virus, dengue virus or 
VSV) (Kotenko et al., 2003), and in peripheral blood mononuclear cells that had been 
infected with EMCV or stimulated with pI:C (Sheppard et al., 2003).  Subsequent 
investigations showed that type III IFNs could be induced by most viruses tested 
including rhinoviruses (Contoli et al., 2006), human respiratory syncytial virus (Spann et 
al., 2004), herpes simplex virus (Melchjorsen et al., 2006), Newcastle disease virus 
(Onoguchi et al., 2007), human cytomegalovirus, (Brand et al., 2005), influenza A virus 
and Sendai virus (Osterlund et al., 2005).  While most cell types seem capable of up-
regulating IFN-λs in response to viral infection, DCs, and particularly pDCs, are believed 
to be the major producers (Ank et al., 2006b; Coccia et al., 2004).  In addition, the IFN-
λs have also been shown to be induced by activation of TLRs 3, 4, 7, and 9 (Coccia et al., 
2004; Yang et al., 2005).  Furthermore, it was demonstrated that following LPS or pI:C 
stimulation in MDDCs IFN-λ1 and IFN-β mRNA were co-induced with similar kinetics, 
whereas IFN-α was not induced at all.  This observation led the authors to speculate that 
IFN-β and the IFN-λs are regulated by a common mechanism. 
 
1.6.5.4 Regulation of type III IFNs   
There are several additional lines of evidence to suggest that the expression of type I and 
type III IFNs may be regulated by similar signaling pathways.  For example, PBMCs 
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from patients with IRAK4 deficiency showed impaired type I and type III IFN induction 
after stimulation with TLR7, 8 and 9 agonists, while LPS and pI:C treatment resulted in 
normal expression (Yang et al., 2005).  MEFs deficient for IRF3 or TBK1 both show 
severely impaired IFN-λ2 induction following infection with NDV, while transient 
transfection with a constitutively active from of IRF3 lead to significantly increased 
levels of IFN-λ1 and IFN-λ2 in human 293T cells (Onoguchi et al., 2007).  Bio-
informatic analysis of the IFN-λ1 promoter revealed putative NF-κB and IRF binding 
sites in the proximal IFN-λ1 promoter region, which, when mutated, inhibited IFN-λ1 
gene reporter assays (Onoguchi et al., 2007).  In addition, Osterlund et al showed in vitro 
binding of IRF1, IRF3 and IRF7, as well as RelA, p50 and RelB to predicted sites within 
the proximal IFN-λ1 promoter (Osterlund et al., 2007).  However, two observations have 
led to the hypothesis that type I and type III IFNs may have qualitative or at least 
quantitative differences in their regulation.  First of all, it was noted that following viral 
infection in the central nervous system with 2 different viruses, mouse IFN-λ2/3 
expression was minimal while IFN-α/ expression was robust (Sommereyns et al., 2008).  
It was also reported that human monocyte derived macrophages stimulated with LPS 
resulted in IFN-β, but not IFN-λ1 induction (Wolk et al., 2008).  Although these 
differences may be due to species of cell type specific differences, it remains to be 
determined to what extent the regulation of type I and type III IFN genes overlap. 
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1.7 Aims 
Cytokines expression is an essential part of a healthy immune response, but excessive or 
sustained cytokine production can contribute to the development of auto-immune 
diseases such as rheumatoid arthritis.  The past decade has seen the rapid discovery of 
cytokines, particularly within the class II cytokine family.  A better understanding of their 
biological functions and how the expression of these cytokines is regulated will increase 
our knowledge of the immune system, and may lead to novel therapeutic targets to treat 
auto-immune disease.  As outlined above, many of these novel IL-10 related class II 
cytokines have already been linked with a variety of inflammatory diseases including 
rheumatoid arthritis, psoriasis and Crohn‟s disease.  In contrast, studies on the IFN-λs 
have largely focused on how their anti-viral activities compare to type I IFNs.  There is 
only limited data regarding additional immuno-regulatory functions of the IFN-λs, and 
particularly if they play a role in inflammatory disease.  Therefore this thesis set out to 
investigate the hypothesis that:  IFN-1 will act as an anti-inflammatory cytokine 
(similar to IL-10) to limit the level of pro-inflammatory gene expression 
 
 
The specific aims of this project were: 
 
1) To characterise the expression of IFN-λ1 and IFN-λR1 in models of acute (human 
myeloid cells stimulated with TLR ligands) and chronic (human RA and collagen 
induced arthritis in mice) inflammation. 
 
2) To investigate the functional role of IFN-λ1 in acute and chronic inflammation. 
 
3) To examine the molecular mechanisms of IFN-λ1 gene expression in acute 
inflammation.    
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2.1 Materials 
Unless otherwise stated, all general laboratory reagents were purchased from Sigma, 
Dorset, UK. 
 
2.1.1 Human cell lines 
Cell line Description       
A549s Human lung carcinoma cell line   
TLR3-293s Human embryonic kidney (HEK)-293 cells that stably express toll-like receptor 3 
TLR4-293s Human embryonic kidney (HEK)-293 cells that stably express toll-like receptor 4, 
CD14 and MD2 
 
 
2.1.2 Taqman primer probes  
All Taqman primer probes were purchased from applied biosystems. 
Gene  Species   Cat. #  
PO  human    4310879E 
IFN-λ1  human    Hs00601677_g1 
IFN-λR1  human    Hs00417120_m1 
IFN-β  human    Custom order, IFN-Β_CDS-ANY 
TNF  human    Hs00174128_m1 
IL-10  human    Hs00174086_m1 
IFN-λ2  mouse    Mm00663660_g1 
IFN-λR1  mouse    Mm00558035_m1 
IFN-β  mouse    Mm00439546_s1 
IFN-g  mouse    Mm00801778_m1 
IL-1β  mouse    Mm99999061_mH 
TNF  mouse    Mm00443258_m1 
IL-10  mouse    Mm00439616_m1 
HPRT  mouse    Mm00446968_m1 
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2.1.3 Antibodies 
 
2.1.3.1 ELISA antibodies  
Antigen Type  Final concentration  Source (Cat. #) 
 
TNF capture  4g/ml    BD Biosciences 
        (551220 & 
 detection  0.5g/ml   554511) 
 
IL-6 capture  1g/ml    BD Biosciences 
        (554543 & 
 detection  0.5g/ml   554546) 
  
 
IL-8 capture  2g/ml    BD Biosciences 
        (554716 &  
 detection  0.5g/ml   554718) 
 
 
IP-10 capture  4g/ml    BD Biosciences 
        (555046 & 
 detection  0.5g/ml   555048) 
 
  
IFN-1 capture  1g/ml    R&D systems 
        (DY1598) 
 detection  0.4g/ml 
 
2.1.3.2 Western blot antibodies 
Antigen Isotype  Source (Cat. #)  Dilution  
 
Stat1  Rabbit   Cell Signaling (9172)  1:2000 
P-Stat1 (Ser727)  Rabbit   Cell Signaling (9177s)  1:2000 
STAT3  Rabbit   Cell Signaling (9132)  1:2000 
P-Stat3 (Tyr705)  Rabbit   Cell Signaling (9131S)  1:2000 
HA  Mouse   Covance (MMS-101P)  1:5000 
RelA  Rabbit   Santa Cruz (sc-372)  1:5000 
RelB  Rabbit                           Santa Cruz (sc-226)                 1 :5000 
c-rel  Rabbit                        Santa Cruz (sc-71)                     1 :5000 
p50                             Rabbit                           Santa Cruz (sc-114)                1 :5000 
p52                             Rabbit                          Santa Cruz (sc-298)                  1:5000 
IRF3  Rabbit   Santa Cruz (sc-9082)  1:4000    
IRF5  Goat   Abcam (ab2932)   1:1000  
IRF7  Rabbit    Santa Cruz (sc-9083)  1:4000 
Chapter 2  Materials and methods    
 72 
Actin                            Mouse                            Sigma  (A5441)   1:5000 
Tubulin                               Mouse                              Sigma (T-9026)   1:3000 
Anti-mouse IgG  Sheep   Amersham (NA9310V)  1:5000  
HRP conjugate 
Anti-rabbit IgG  Donkey   Amersham (NA9340V)  1:5000 
HRP conjugate 
 
2.1.3.3 Chromatin immuno-precipitation antibodies  
Antigen  Species  Source (Cat. #)  
RNA polymerase II Rabbit   Santa Cruz sc-899x 
RelA (NFκB p65 (C-20)) Rabbit   Santa Cruz sc-372x 
 
 
2.1.4 siRNA oligonucleotides      
All siRNA oligonucleotides were ON-TARGETplus™ siRNA Reagents and purchased 
from Dharmacon, Surrey, UK.  
mRNA target    cat. # 
RelA     003533 
RelB     004767 
c-rel     004768 
p50     003520 
p52     003918 
IRF3     006875  
Non-targeting Pool   D-001810-10-20 
 
 
2.1.5 Primers 
All primers were purchased from Eurofins MWG Operon, London, UK. 
 
2.1.5.1 Primer sequences for generation of IRF expression constructs 
wt = wild-type; DN = dominant negative; C = C-terminal HA tag; N = N-terminal HA tag 
Construct primer (for/rev) Sequence 
 
wt IRF3-C for   AATGAGCTCATGGGAACCCCAAAGCCACGGAT 
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  rev   AATGAATTCTTAAGCATAATCAGGAACATCAT  
     AAGGATAGCTCTCCCCAGGGCCCTG 
 
wt IRF3-N for    AATGAGCTCATGTATCCTTATGATGTTCCTGA  
     TTATGCTGGAACCCCAAAGCCACGGAT 
  rev   AATGAATTCTTATCAGCTCTCCCCAGGGCCC 
 
DN IRF3-C for   AATGAGCTCATGGATACCCAGGAAGACATTCTGG 
  rev   AATGAATTCTTAAGCATAATCAGGAACATCAT  
     AAGGATAGCTCTCCCCAGGGCCCTG 
 
DN IRF3-N for   AATGAGCTCATGTATCCTTATGATGTTCCTGA  
     TTATGCTGATACCCAGGAAGACATTCTGG  
  rev   AATGAATTCTTATCAGCTCTCCCCAGGGCC 
 
wt IRF5-C for   AATGAATTCATGAACCAGTCCATCCCAGTGGCT 
  rev   AATGTCGACTTAAGCATAATCAGGAACATCAT  
     AAGG ATATTGCATGCCACCTGGGTGCA  
 
wt IRF5-N for   AATGAATTCATGTATCCTTATGATGTTCCTGA  
     TTATGCTAACCAGTCCATCCCAGTGGCT 
  rev   AATGTCGACTTATTGCATGCCACCTGGGTGCA 
 
DN IRF5-C for   AATGAATTCATGTTTGGTGCAGAGAGGAGGAGG 
  rev   AATGTCGAC TTAAGCATAATCAGGAACATCAT  
     AAGGATATTGCATGCCACCTGGGTGCA 
 
DN IRF5-N for   AATGAATTCATGTATCCTTATGATGTTCCTGA  
     TTATGCTTTTGGTGCAGGAGAGGAGGAGG  
  rev   AATGTCGACTTATTGCATGCCACCTGGGTGCA 
 
wt IRF7-C for   AATAGATCTATGCCAGTCCCCGAGCGCCCTGC 
  rev   AATGTCGACTTAAGCATAATCAGGAACATCAT  
     AAGGATACTGCTCCAGCTCCATAAGGAAGC  
 
wt IRF7-N for   AATAGATCTATGTATCCTTATGATGTTCCTGA  
     TTATGCTCCAGTCCCCGAGCGCCCTGC 
Chapter 2  Materials and methods    
 74 
  rev   AATGTCGACTTACTGCTCCAGCTCCATAAGGA  
     AGC 
 
 
DN IRF7-C for   AATAGATCTATGCAGGCAGAGCCGTACCTGTCAC 
  rev   AATGTCGACTTAAGCATAATCAGGAACATCAT 
     AAGGATACTGCTCCAGCTCCATAAGGAAGC 
 
DN IRF7-N for   AATAGATCTATGTATCCTTATGATGTTCCTGA  
     TTATGCTCAGGCAGAGCCGTACCTGTCAC 
  rev   AATGTCGACTTACTGCTCCAGCTCCATAAGGA  
     AGC 
 
2.1.5.2 Primer sequences for generation of IFN-1 luciferase gene reporter constructs 
Primer name   Sequence (5’-3’) 
IFN-λ1 -1106   AATGGTACCCGCATCACCAGCTATCTGAT 
IFN-λ1 -1901   AATGGTACCATAGAGAGATATAGACTAGATA 
IFN-λ1 -3209   AATGGTACCCCCTAATTTGACCCACCCTAAT 
IFN-λ1 -5068   AATGGTACCCCATAGTTTAGGTGACCTGAAAG 
IFN-λ1 reverse   AATAGAGCTCAGCGGCATGGCTCTGCTTT 
 
2.1.5.3 Primer sequences for EMSA assays 
Putative B site are shown in bold on the forward primer 
Site Primer (for/rev) Sequence 
 
B1 for   agctCAAAGTGGAAATTCTCATTTCC 
 rev   agctGGAAATGAGAATTTCCACTTTG 
 
κB2 for   agctCCGTCAGGGACTCCCTGAGGCC 
 rev   agctGGCCTCAGGGAGTCCCTGACGG 
 
κB3 for   agctTCTTCTGGAAACACCCCAGAGT 
 rev   agctACTCTGGGGTGTTTCCAGAAGA 
 
κB4  for   agctAACAACGGGTCTTCCTTACTCA 
 rev   agctTGAGTAAGGAAGACCCGTTGTT 
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κB5 for   agctAGAGATGGGGTTTCACCATGTT 
 rev   agctAACATGGTGAAACCCCATCTCT 
 
κB6 for   agctATAGGAGGGGATTTATTAGGGG 
 rev   agctCCCCTAATAAATCCCCTCCTAT 
 
 
2.1.5.4 Primer sequences for chromatin immuno-precipitation  
Primer  Gene of interest Sequence (5’-3’)            
         
A_for   IFN-λ1   AGGAGGGGATTTATTAGGGGAATTGGCTCA 
A_rev  IFN-λ1   TCTCCAGCTTGCAGATGGCCTGT 
 
B_for  IFN-λ1   GTTCCACAACAGGCCATCTGCAAGC 
B_rev  IFN-λ1    AGTCCTGAGGCTTTTATTCTGGAACTGAGC 
 
C_for  IFN-λ1   ACCCCATTTCTGCCTCTATCCCACTGT 
C_rev  IFN-λ1    TGTTCTGTCTCTCTGGAGAACCCTGACT 
 
D_for  IFN-λ1   CAGCTCACTGCAGCCTCCGCCT 
D_rev  IFN-λ1   ATCAGCCAGGCGTGGTGGCACA 
 
E_for  IFN-λ1   TGGCCAGGCTGGTCTCGAACTCC 
E_rev  IFN-λ1   TGTGCAGCTGGGCATGGTGGCT 
 
F_for  IFN-λ1   AGGCGTGAGCCACCATGCCCAG 
F_rev  IFN-λ1   GGGACACCCTGCACCTGCCCTT 
 
G_for  IFN-λ1   CTTGGCCAGGAGCAGTGGCTCA 
G_rev  IFN-λ1   TGCCCAGGCCAGTCTTGAACTCCT 
 
H_for  IFN-λ1   GCCCACCACATTGGGTAACAACGG 
H_rev  IFN-λ1   TCTGGGTATGACTCTGGGGTGTTTCCA 
 
I_for  IFN-λ1   CTAGCACTTTGCGAGGCTGAAGCAGGA 
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I_rev  IFN-λ1   GGGTCTCACTATGTTGCCCAGGCCAGT 
 
J_for  IFN-λ1   GGGAGGCCAAGGCAGGCAGATCA 
J_rev  IFN-λ1   GTGCATGCCATCACGCCTGGCTA 
 
K_for  IFN-λ1   CAGGAGTTCGAAGCCAGCGTGACCA 
K_rev  IFN_λ1    GCGATTCTCCTGCCTCAGCCTCCT 
 
L_for  IFN-λ1   TCCAGCCTGGGCAACAAGAGCA 
L_rev  IFN-λ1   ACTCCAGCCTGGGTGATGGAGTGA 
 
M_for  IFN-λ1   GCCCCGCCCACTCATGCCTCTT 
M_rev  IFN-λ1   ATCGCAACTGCTTCCCCAGCGG 
 
N_for  IFN-λ1   GCCAGTTGGCTGAAAGCTGCCCA 
N_rev  IFN-λ1   GGCAGGGCCAAGTGAGCTGGGA 
 
O_for  IFN-λ1   AGACCACAGGCGCATGCCACCA 
O_rev  IFN-λ1   ACTCCCTGGGCAGCTTTCAGCCA 
 
prom_for IFN-β   TGAAAGGGAGAAGTGAAAGTGGG 
prom_rev IFN-β   AAGGCTTCGAAAGGTTGCAGTTA 
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2.2 Buffers and solutions 
 
2.2.1 Isolation of synoviocytes derived from inflamed membranes of rheumatoid 
arthritis patients 
Washing buffer: PBS  
 0.1% BSA  
 
Cell isolation buffer: PBS (without Ca
2+
 or Mg
2+
) 
 0.1% BSA 
 2 mM EDTA 
 
FACS buffer: PBS (without Ca
2+ 
or Mg
2+
) 
 1% FCS 
 0.02% sodium azide 
 
Fixing buffer: PBS (without Ca
2+
 or Mg
2+
) 
 0.5% paraformaldehyde 
 0.02% sodium azide 
 
 
2.2.2 Western blotting 
Whole cell lysis  20 mM Tris pH8 
buffer for cell lines:   300 mM NaCl  
 0.1% NP-40  
 10% glycerol 
  
 
Whole cell lysis buffer for  20 mM Tris pH8 
primary human myeloid cells: 150 mM NaCl   
 1% NP-40  
 10% glycerol  
  
  
Cytoplasmic lysis buffer:   10 mM HEPES, pH 7.9  
 10 mM KCl  
 0.1 mM EDTA  
 0.1 mM EGTA 
 
 
 
Nuclear lysis buffer: 20 mM HEPES, pH 7.9 
 400 mM NaCl 
 1 mM EDTA 
 1 mM EGTA 
 
4X loading buffer:                             200 mM Tris-HCl pH 6.8 
                                                           8% SDS 
                                                           40% Glycerol 
                                                           4% Mercapto Ethanol 
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                                                            50 mM EDTA 
                                                            0.08% Bromophenol Blue 
 
Transfer buffer: 25 mM Tris-base 
 192 mM glycine 
 20% methanol 
 
Blocking buffer: PBS 
 5% dried milk powder 
 0.5% tween 
 
Washing buffer: PBS 
 0.5% tween 
 
 
2.2.3 EMSA 
Buffer A:                                            10 mM Hepes, pH 7.9 
                                                          10 mM  KCl  
                                                            0.1 mM EDTA 
                                                            0.1 mM EGTA 
 
Buffer B:                                           20 mM Hepes, pH 7.9 
                                                           0.4 M NaCl 
                                                         1 mM EDTA 
                                                          1 mM EGTA 
 
2 x Binding buffer:                            20 mM Hepes, pH 7.9 
                                                         2   mM  EDTA 
                                                        2   mM EGTA 
                                                         25% glycerol 
                                                         0.125-0.250 mg/ml dI-dC 
 
 
2.2.4 Chromatin immuno-precipitation 
Cytoplasmic lysis buffer: 50 mM Tris, pH 8.0    
 2 mM EDTA, pH 8.0  
 0.1% NP40   
 10% Glycerol   
 
Nuclear lysis buffer: 50 mM Tris pH, 8.0  
 5 mM EDTA   
 1 % SDS   
 
Dilution buffer (DB): 50mM Tris, pH 8.0   
 5mM EDTA    
 200mM NaCl    
 0.5 % NP40   
 
Washing Buffer (WB):  20mM Tris, pH 8.0   
 2mM EDTA   
 0.1 % SDS   
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 1 % NP40   
 500 mM NaCl    
 
Extraction Buffer (EB):  1X TE  
 2 % SDS 
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2.3 Methods          
 
2.3.1 Cell culture  
All cell cultures were maintained at 37°C in 5% CO2 and 95% humidity. 
 
2.3.1.1 Maintenance of cell lines  
Cell lines used in this thesis are listed in table 2.1.1.  All cell lines were maintained in 
DMEM (4.5 g/L glucose, L-Glutamine and Sodium Pyruvate) supplemented with 10% 
FCS and 1% penicillin/streptomycin.  In addition, TLR3-293 cells were supplemented 
with 10g/ml of blasticidin and TLR4-293 cells were supplemented with 10g/ml and 
50g/ml of Blasticidin and HygroGoldTM (Invivogen) respectively.  Cells were passaged 
upon reaching a confluency of approximately 70-80%.  The culture media was aspirated 
and cells were washed once with PBS before addition of trypsin/EDTA for 5-10 minutes 
at 37°C after which they were resuspended in a suitable volume and diluted 1:6. 
 
All cell lines were regularly screened for mycoplasma infection while they remained in 
long term culture.  The screening test was kindly performed by Mrs P Amjadi. 
 
2.1.3.2 Cryopreservation of cells 
Cell lines subjected to cryopreservation were first collected and then resuspended in a 
mixture of 90% FCS and 10% DMSO at a concentration of 10
7
 cells/ml.  They were then 
transferred in to cryovials in 1ml aliquots and placed at -70°C in an insulated container to 
ensure slow freezing.  The cryovials were subsequently transferred into a liquid nitrogen 
tank for long term storage.  Upon re-culture, cryovials were placed in a waterbath at 37°C 
until the contents were thawed after which cells were quickly washed to remove the 
DMSO and resuspended in the appropriate culture media. 
 
2.3.2 Isolation and differentiation of primary human myeloid cells 
2.3.2.1 Isolation of human peripheral blood mononuclear cells    
Peripheral blood mononuclear cells (PBMCs) were isolated by density centrifugation of 
platelet-pheresis residues from healthy donors that were purchased from North London 
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Blood Transfusion Service (Colindale, UK).  Heparinised residues were diluted with 1:1 
with HBSS and layered over an equal volume of Ficoll-Hypaque lymphoprep
TM
 in sterile 
50ml tubes.  Centrifugation was performed at 1000 RCF for 20 minutes at room 
temperature.  The interface layer was collected and washed twice by centrifugation for 10 
min at 900 RCF.    
 
2.3.2.2 Isolation of human monocytes 
Enriched populations of monocytes were obtained by centrifugation at 2,500 r.p.m. in a 
Beckman JE6 elutriator (Beckman Coulter).  Elutriation is a process that separates a 
heterogeneous cellular population based on size.  Cells are loaded into a specialised 
chamber and subjected to a centrifugal field, which is counter-balanced by pumping 
media (RPMI in 1% FCS and 1% penicillin/streptomycin) through the chamber at a 
constant rate.  As the flow rate gradually increases cells of increasing size are ejected 
from the chamber and collected.  Monocytes are typically ejected when the flow rate is 
increased to 18-22ml/minute and their purity is determined by analysis of cell size and 
granularity using flow-cytometry.  Only fractions containing more than 80% monocytes 
were used in experiments. 
  
2.3.2.3 In vitro differentiation of human monocytes into dendritic cells  
Upon collection of monocyte-enriched fractions cells were counted and resuspended in 
RPMI supplemented with 10% FCS 1% penicillin/streptomycin at a concentration of 10
6
 
cells/ml.  GM-CSF and IL-4 (Peprotech, UK) were added at a final concentration of 
50ng/ml and 10ng/ml respectively.  10ml of cell suspension was seeded per 10ml tissue 
culture dish.  5-7 days later non-adherent cells were harvested, resuspended in fresh 
culture media to a concentration of 10
6
 cells/ml and seeded appropriately.  
 
2.3.2.4 In vitro differentiation of human monocytes into macrophages  
Upon collection of monocyte-enriched fractions cells were counted and resuspended in 
RPMI supplemented with 10% FCS 1% penicillin/streptomycin at a concentration of 10
6
 
cells/ml.  Macrophages were generated by either addition of M-CSF or GM-CSF 
(Peprotech, UK) at a final concentration of 100ng/ml or 50ng/ml respectively.  10ml of 
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cell suspension was seeded per 10ml tissue culture dish.  4-6 days later adherent cells 
were harvested by scraping, resuspended in fresh culture media to a concentration of 10
6
 
cell/ml and seeded appropriately.   
 
2.3.3 Isolation of synoviocytes derived from inflamed membranes of rheumatoid 
arthritis patients  
Synovial tissue was obtained from rheumatoid arthritis patients undergoing joint 
replacement surgery at Charring Cross Hospital, Ravens Court Park Hospital, or the 
Central Middlesex Hospital, London UK.  Ethical approval for the use of this tissue was 
granted to the Kennedy Institute of Rheumatology (RREC 1752), by the Riverside 
Research Ethics Committee, Chelsea and Westminster Hospital, London UK.  Inflamed 
synovial membranes derived from rheumatoid arthritis patients contain several cell types, 
or synoviocytes, of which macrophages, lymphocytes and fibroblasts are the most 
abundant.  The synoviocytes are held together by a mesh of extra-cellular matrix.  The 
membranes are typically removed from knee, wrist or elbow joint by surgery, and 
subsequently excess fat is removed using scissors.  Membranes are then subjected to 
enzymatic digestion using collagenase, which degrades the matrix and remaining fat.  
Synoviocytes were then stored in liquid nitrogen until required.  The procedure was 
kindly carried out by Ms Rene Best and Ms Lauren Schewitz (Kennedy Institute of 
Rheumatology).  The mixed synoviocyte population was separated into cell-type specific 
enriched fractions using anti-body conjugates that recognise cell-type specific trans-
membrane proteins.  Real-time PCR analysis was then performed to ascertain the 
individual contribution of each cell type to cytokine expression ex vivo.  In addition, 
purified synoviocytes were also cultured ex vivo in the presence or absence of biological 
agents, and supernatants were harvested for ELISA analysis. A list of all the buffers and 
their composition used during the synoviocyte isolation procedure can be found in section 
2.2.1. 
 
2.3.3.1 Macrophage isolation  
Macrophages were isolated using the Dynabeads® CD14 cell isolation kit (Invitrogen, 
US.  40l of CD14+ Dynabeads were washed with 1ml washing buffer and resuspended 
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in 40l of washing buffer then placed on ice.  The synoviocytes were pelleted and 
resuspended in 0.5ml of cell isolation buffer.  100l was transferred into a fresh 1.5ml 
eppendorf tube for RNA extraction (sample 1: “mixed synoviocytes”).  In addition 20l 
of the mixed synoviocyte population was transferred into a FACS tube for FACS 
analysis.  40l of the washed CD14+ Dynabeads were then transferred to the remaining 
380l of the mixed synoviocytes (3.8x106 cells) and placed on a rotator for 25 minutes.  
The tubes were then placed onto the magnet for 2 min and the supernatants 
(predominantly containing lymphocytes and fibroblasts) were transferred into a new 1.5 
ml eppendorf tube.  The beads were then washed twice in cell isolation buffer and lysed 
in 350l of RLT lysis buffer.  Cells lysates were transferred into a fresh tube and stored 
at -80
o
C until RNA extraction was performed (sample 2: “macrophages”). 
 
2.3.3.2 Lymphocyte and fibroblast isolation  
Lymphocytes were subsequently isolated from the fibroblasts using the Dynal Monocyte 
Negative Isolation Kit (DyMNIK).  50l of DyMNIK beads were washed with 1ml 
washing buffer and resuspended in 50l of washing buffer then placed on ice.  20l of 
420l of the lymphocyte and fibroblast cell mix was transferred into a FACS tube for 
FACS analysis and placed on ice.  20l of DyMNIK blocking reagent and 20l of 
DyMNIK antibody mix were added to the remaining cells for 20 min.  The cells were 
then pelleted and resuspended in 450l of cell isolation buffer.  The 50l of washed 
DyMNIK beads were added to the sample and incubated on a rotator for 15 minutes.  The 
tubes were then placed onto a magnet for 2 minutes and the supernatant (predominantly 
containing fibroblasts) was transferred into a new 1.5 ml eppendorf tube.  40l of the 
fibroblast enriched population was then transferred into a FACS tube for FACS analysis 
and placed on ice.  The remaining 460l of the fibroblast enriched population was 
pelleted and resuspended in 350l of RLT lysis buffer and stored at -80oC (sample 3: 
“fibroblasts”).  The DyMNIK beads (attached to predominantly lymphocytes) were 
washed twice in 0.5ml of cell isolation buffer and then resuspended in 350l of RLT lysis 
buffer.  Cells lysates were transferred into a fresh tube and stored at -80
o
C until RNA 
extraction was performed (sample 4: “lymphocytes”).   
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2.3.3.3 FACS analysis of isolated cellular populations 
The cells collected for FACS analyses were washed twice with 1ml of ice cold PBS and 
subsequently resuspended in 100l of FACS.  The samples were then incubated with 2l 
of anti-CD14/CD45 antibody mix for 30 minutes in the dark at 4
o
C.  The cells were 
washed twice with 0.5ml of ice cold FACS buffer prior to resuspension in 100l of fixing 
buffer.  The samples were then analysed by flow cytometery on a BD FACS Canto II 
machine.  
 
2.3.4 Analysis of collagen induced arthritis in IFN-R1 knock-out mice 
2.3.4 Induction of CIA 
Male and female 10-14 week old mice were selected to be immunized with 200mg/ml of 
chicken type II collagen dissolved in complete freund‟s adjuvant.  This procedure was 
kindly carried out by Ms Katrina Blazkova and Dr. Saba Alzabin at the Kennedy Institute 
of Rheumatology.  
 
2.3.4.2 Clinical score 
The development of arthritis was assessed daily for the duration of the experiment.  Each 
paw was assessed individually to provide a record of each individual arthritic paw from 
which the number of arthritic paws, as well as an average clinical score could be 
deducted.  Clinical score was kindly recorded by Ms Katrina Blazkova at the Kennedy 
Institute of Rheumatology.  
 
The criteria by which the severity of clinical score was graded are defined as follows: 
0 = normal 
1= slight swelling 
2 = pronounced swelling 
3 = pronounced swelling and light joint rigidity 
4 = ankylosis  
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2.3.4.3 RNA extraction from paws 
Whole arthritic paws were placed in 1ml of RLT buffer containing 2M DTT and 
homogenised in a precellys 24-Dual using 3 cycles of for 30 seconds at 6500 R.P.M. 
(with a pause of 10 seconds between cycles).  350ml of homogenate was then dissolved 
1:2 in fresh RLT buffer and passed through a QIAshredder by centrifugation for two 
minutes at 13000 R.P.M.  The debris was then pelleted and the supernatant transferred to 
a fresh tube.  RNA was purified using a QiaAmp RNA Blood mini kit (Qiagen, GmbH, 
Germany) as per manufacturer‟s instructions.  RNA was eluted in 30l of water and 
analysed by real-time PCR. 
 
 
2.3.5 Quantitative real-time PCR  
Real-time PCR allows the quantification of mRNA levels within distinct populations of 
cells.  All gene expression analyses carried out in this study used TaqMan primer probes 
to amplify mRNA which had previously been reverse-transcribed to generate cDNA.  A 
list of all primer probes used is found in section 2.1.2     
 
2.3.5.1 RNA extraction and quantification  
Total RNA was extracted from cells using a QiaAmp RNA Blood mini kit (Qiagen, 
GmbH, Germany) as per manufacturer‟s instructions.  Typically cells were eluted in 40l 
of sterile, RNAase free water.  RNA concentration was quantified using a nanodrop 1000 
(Thermo Scientific, Wilmington, Delaware USA).     
 
2.3.5.2 cDNA synthesis 
cDNA was synthesised from total RNA using SuperScript® III Reverse Transcriptase 
(Invitrogen, USA) and 18-mer oligo dTs (Eurofins MWG Operon, London, UK).  cDNA 
synthesis reactions contained 500ng-2g of total RNA in a final volume of 20l.  
Following synthesis samples were diluted 1:4 in sterile water and stored at -20°C until 
required.  
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2.3.5.3 Quantitative real-time PCR 2 standard curve method 
Real-time PCR 2-standard curve method requires cDNAs of both the gene of interest and 
a housekeeping gene to generate a standard curve.  Human cDNA clones of IFN-1, IFN-
R1, IFN- and IL-10 were kindly provided by Dr S Kotenko (New Jersey Medical 
School, USA) and a human TNF cDNA clone was kindly provided by Mrs N Ito 
(Kennedy Institute of Rheumatology, UK).  A human PO cDNA clone was generated as 
described in section 2.3.8.3.   
The cDNA clones were serially diluted 1:25 to generate standard curves that covered a 
range of Cts that reflected the heterogeneity of gene expression within the samples.  A 
representative IFN-1 standard curve is shown in figure 2.1.  The top value for each 
standard curve was arbitrarily chosen but the values of the each consecutive point on the 
standard curve reflected the dilution factor i.e. 1:25.  The Ct values of both the gene of 
interest and the house-keeping gene were then converted into concentrations according to 
their respective standard curve.  Finally, mRNA levels were normalised by dividing the 
calculated value of the gene of interest by the calculated concentration of the house-
keeping gene within each sample.   
 
 
Figure 2.1.  A representative IFN-1 standard curve.   A standard curve was generated by serial 1:25 
dilutions of a plasmid encoding IFN-1.  The top standard had a concentration of approximately 5ng/ml.  
Blue lines at the bottom of indicate non-template controls. 
 
Real-time PCR reactions were performed in a Corbett Rotor-gene 6000 machine (Corbett 
Research Ltd, Cambridgeshire, UK) and analysed using Corbett Rotogene 6000 software.  
TaqMan® PreAmp Master Mix (Applied Biosystems) and Custom TaqMan® Gene 
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Expression Assays were (Applied Biosystems) used as per the manufacturers 
instructions.  Reactions were carried out in 20l volumes.  Thermocycling conditions 
were as follows:  
 
10 min at 95ºC 
45 cycles: 
10s at 95ºC  
35s at 60ºC   
 
 
2.3.6 ELISA 
ELISA allows the quantification of proteins that have been secreted into the supernatant 
by cultured cells.  Antibodies were used to specifically capture the protein of interest 
from culture supernatants.  Biotin-antibody conjugates were subsequently incubated with 
the immuno-complexes before that addition of streptavidin-HRP.  Finally HRP substrate 
was added to the samples which induce a colour change that can be quantified.  Running 
a standard curve of known protein concentrations in parallel to the samples enabled 
absolute concentrations of secreted proteins to be inferred.  All ELISA antibodies used in 
this thesis are listed in table 2.1.3.1. 
 
Capture antibodies were diluted in PBS and applied to 96-well plates overnight at 4ºC to 
adhere.  The PBS was then removed and plates were blocked with PBS containing 2% 
BSA for 1h at room temperature.  In between all subsequent steps, plates were washed 3 
times with PBS containing 0.05% tween.  A 7-point standard curve was generated by 1:2 
serial dilutions of the protein of interest in PBS containing 0.5% BSA, with the top 
concentration ranging from 4-10ng/ml.  The sensitivity thresholds for all ELISA assays 
were 10-50pg/ml.  After removing the blocking solution from the plates, standards and 
samples of interest were placed on top of the capture antibody and incubated for 2h at 
room temperature.  The biotinylated detection antibody was diluted in PBS containing 
0.05% BSA and then applied to the plates for 1h at room temperature after washing.  This 
procedure was repeated except streptavidin-HRP was incubated with the immuno-
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complexes instead of the biotinylated detection antibody.  Finally, the plates were 
washed, TMB Microwell Peroxidase Substrate (KPL, Inc, Maryland, USA) was added to 
the appropriate wells and the enzymatic reaction was terminated by addition of 1M 
H2SO4.  Absorbance was read at 450nm by a spectrophotometric ELISA plate reader 
(Labsystems Multiscan Biochromic) and analysed using Ascent Labsystems software.  
All samples were analysed in triplicate in a volume of 50l. 
 
2.3.7 Western blotting  
Western blotting allows for the identification and semi-quantification of specific proteins 
and specific post-translational modifications of proteins e.g. phosphorylation.  Following 
lysis of cellular membranes total protein concentration was determined and equal 
amounts were resolved by SDS-PAGE.  Resolved proteins were then transferred onto a 
membrane prior to immuno-blotting with antibodies specific for the protein of interest.  
All antibodies used for western blotting in the study are listed in table 2.1.3.2.  A list of 
all the buffers and their composition used in western blotting experiments can be found in 
section 2.2.2.2. 
    
2.3.7.1 Preparation of whole cell protein extracts  
Cells were harvested, transferred to 1.5ml eppendorf tubes and washed once with ice cold 
PBS.  Cells were then resuspended in 50-100ml of the appropriate lysis buffer containing 
protease inhibitors (Protease Inhibitor Cocktail Tablets, Roche, catalogue number 
04693124001) and phosphatase inhibitors (sodium fluoride, 2.5mM; sodium 
pyrophosphate, 1mM; sodium orthovanadate, 1mM) and the tubes were placed on ice for 
approximately 20 minutes.    Cellular debris was then pelleted by centrifugation and the 
lysate was transferred into new tubes and stored at -80ºC until required.  
 
2.3.7.2 Preparation of nuclear and cytoplasmic protein extracts  
Cells were washed once with PBS and resuspended at 5x10
6
 in ice-cold cytoplasmic lysis 
buffer containing protease inhibitors for 15 min on ice.  66 l of 10% NP-10 was added 
to 1 ml of cell suspension, and the cells were lysed by vortexing for 10s. Cell nuclei were 
pelleted by centrifugation at 1000 RCF at 4
o
C for 5 mins. The cytoplasmic protein 
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extracts were collected and the nuclear pellets were washed once in ice-cold cytoplasmic 
lysis buffer.  The nuclei proteins were extracted from the pellet by adding 100 l of 
nuclear lysis buffer followed by 60 mins incubation on ice with intermittent vortexing.  
The extracts were then centrifuged at 16,000 RCF for 2 mins to pellet nuclear debris and 
supernatants were transferred to new eppendorf tubes.    
   
2.3.7.3 Protein quantification: BCA assay 
Protein concentrations were determined using BCA Protein Assay Reagent (Thermo 
Scientific, Wilmington, Delaware USA) as per the manufacturer‟s instructions.  Briefly, a 
6-point standard curve was generated by 1:2 serial dilutions of BSA in water, with the top 
standard at a concentration of 2g/ml.  BCA reagent A and B were mixed at a ration of 
50:1 and 200l was dispensed into an appropriate number of wells in a 96-well plate.  2l 
of sample and 10l of standard was added per well.  Additionally, 2l of lysis buffer only 
served as a blank.  The plate was incubated for 1h at 37ºC, after which the absorbance 
was read at 574nm on a Multiskan Bichromatic
TM 
plate reader.  Protein concentrations 
were calculated according to the standard curve using Ascent 2.4.2 Labsystems software.  
All samples were analysed in duplicate. 
 
2.3.7.4 SDS-PAGE 
10-15g of total protein and an appropriate volume of 4X loading buffer were heated to 
95°C for 10 min.  The denatured proteins were then separated at 150-200 volts on a pre-
cast NuPAGE® Novex 4-12% Bis-Tris or 10% Bis-Tris gels as appropriate (Invitrogen) 
that were immersed in NuPAGE® MOPS SDS Running Buffer (Invitrogen) running 
buffer.  A Full-Range Rainbow Molecular Weight Marker (GE Healthcare) was run in 
parallel so that the molecular weight of visualised proteins could be estimated. 
 
2.3.7.5 Protein transfer 
Following SDS-PAGE, resolved proteins were transferred to a polyvinylidene difluoride 
(PVDF) membrane.  PVDF membranes were cut to a suitable size, hydrated in methanol 
and then equilibrated in transfer buffer.  The PVDF membrane was placed on top of the 
gel containing resolved proteins, then sandwiched between 4 pieces of transfer-buffer 
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soaked filter paper.  The assembly was then placed in a transfer cassette in between two 
transfer soaked sponges and inserted into a transfer tank filled with pre-cooled transfer 
buffer.  A constant voltage of 30V was applied for 2h at room temperature. 
 
2.3.7.6 Immuno-blotting and protein detection 
After protein transfer membranes were incubated in blocking buffer and placed on a 
shaker at 4ºC overnight.  In between all subsequent steps membranes were subjected to 
3x 15 minute washes with washing buffer.  Primary and HRP-conjugated secondary 
antibodies were diluted in washing buffer and sequentially incubated with the membranes 
for 1h at room temperature with gentle agitation.  Immuno-complexes were detected 
using the chemiluminescent substrate solution ECL (GE Healthcare), visualised using 
Hyperfilm MP (Amersham Pharmacia Biotech, UK) and developed using a AGFA Cruis-
60 automatic film processor.  When multiple protein detections were required on the 
same membrane antibodies were stripped from the membrane using ReBlot Plus Strong 
Antibody Stripping Solution (Chemicon) as per the manufacturer‟s instructions. 
 
2.3.8 Cloning and generation of genetic constructs 
2.3.8.1 Generation of wild-type and dominant-negative IRF-3, 5 and 7 constructs  
The strategy for generation of wild-type (wt) and dominant negative (DN) IRF-3, 5, and 7 
constructs is shown in figure 2.2.  Briefly, cDNA clones of wild-type (wt) IRF-3, 5 and 7 
were kindly provided by Dr. K. Fitzgerald (University of Massachusetts, USA). These 
plasmids served as a template to generate wt and DN cDNAs by PCR.  Primers were 
designed (see table 2.2) so that DN IRF constructs lacked a DNA binding domain, and 
each construct had a HA tag at either the N- or C-terminus of the respective cDNA.  IRF 
fragments were then purified and cloned into pENTR4.3F.  wt and DN IRFs were then 
recombined into pAD/PL DEST for delivery into human myeloid cells.   
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Figure 2.2  Cloning strategy employed for generation of HA-tagged wt and dn IRF-3, IRF-5, and 
IRF-7 adeno-viral constructs.  (A) Desired sequences were generated by PCR, after which IRF-3; IRF-5; 
IRF-7 were respectively digested with SacI/EcoRI; EcoRI/SalI; BglII/SalI.  (B) Fragments were ligated 
with vector pENTR4.3F, after it had been subjected to the same combinations of restriction digests.  (C) 
IRF/pENTR constructs were subsequently recombined into the adeno-viral derived vector pAD/PL DEST.        
 
2.3.8.2 Generation of human IFN-1 gene reporter constructs 
The strategy for generation of IFN-1 gene reporter constructs is shown in Figure 2.2.  
Briefly, IFN-1 promoter of lengths of approximately 1kB and 5kB were obtained by 
PCR (see table 2.1 for primer sequences) of genomic DNA (kindly provided by Dr. D. 
Moyes, KIR), and cloned into Topo TA vector.  Positive clones were identified by 
sequencing and sub-cloned into the pGL3 Basic vector using SacI/KpnI.  For delivery 
into human myeloid cells, IFN-1 reporter constructs were transferred into an adenoviral 
vector backbone.  Therefore, IFN-promoter/luciferase cDNA was excised with 
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KpnI/BamHI and sub-cloned into pENTR 4.1, which had been modified to contain CMV-
driven GPF.  Finally, IFN-1 promoter/luciferase was recombined into pAD/PL DEST.        
 
Figure 2.3  Cloning strategy employed for generation of IFN- gene promoter constructs.  IFN-1 
promoter lengths were generated by PCR of genomic DNA and subsequently cloned into a TOPO TA 
vector (A).  Positive clones were selected and sub-cloned into pGL3 Basic vector with KpnI/SacI (B).  
Before IFN-1 promoters/luciferase gene cDNA were sub-cloned into pENTR 4.1 (C), this vector was 
modified to contain CMV-driven GFP.  The modification was achieved by digesting CMV/GFP from 
vector p201 (D) with XbaI (which was subsequently blunt ended) and NotI, and digesting pENTR4.1 with 
EcoRI (which was subsequently blunt ended) and NotI.  The desired fragments were then purified and 
ligated.  IFN-λ1 promoters/luciferase cDNA was then sub-cloned into modified pENTR4.1 using 
KpnI/BamH I (E).  
 
Modified  pENTR4.1 
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2.3.8.3 Generation of PO cDNA clone  
Total RNA was extracted from moMPHs, and 1g of total RNA was used to synthesise 
cDNA.  PO cDNA was amplified by PCR using the following primers: F: 5‟TGCCCA 
GGGAAGACAGGGCG and R: 5‟- ATATGGGATTTGGTCTCTTTGACTAA.  PCR fragments were 
then cloned into TA TOPO vector (Invitrogen). 
 
2.3.8.4 PCR    
PCR reactions were performed in a DYAD Peltier Thermal Cycler, in 50l volumes.  
Proofreeading Taq polymerase and dNTPs were obtained from Roche and primers were 
obtained from MWG Bbiotech.  50ng of template DNA was used per reaction.  PCR 
reactions were resolved by electrophoresis in 1% agarose 1xTAE gel.  Addition of either 
ethidium bromide or SYBR green allowed visualisation under UV light.  Hyperladder IV 
(Bioline) was used to determine the molecular weight of DNA fragments.  All PCR 
reactions used touch-up PCR under the following thermal cycling conditions:  95C for 
10 min; 4 cycles of 95C for 30s, 52C for 1 min, 68C for 3 min; 4 cycles of 95C  for 
30s, 57C for 1 min, 68C for 3 min; 4 cycles of 95C  for 30s, 57C for 1 min, 68C for 
3 min; 4 cycles of 95C  for 30s, 62C for 1 min, 68C for 3 min; 18 cycles of 95C for 
30s and 68C for 3 min; 10 min at 68C; 15 min at 4C.  For amplification of the IFN- 
5KB promoter the extension time at 68C was carried out for 5 min instead of 3 min.  
        
2.3.8.5 Restriction digests  
Restriction digests were performed using New England Biolabs (NEB) or Roche 
enzymes and buffers as per manufacturer‟s guidelines.  Typically, restriction digests were 
performed in 20-50l reactions for 1-2h in a water bath set to 37C    
        
2.3.8.6 Dephosphorylation of digested vectors  
To reduce the likelihood of digested vector selfligation, 1l of Antarctic phosphatase 
(New England Biolabs) was added to vector DNA digests for 30 minutes.  This enzyme is 
compatible with all NEB restriction digest enzyme buffers.   
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2.3.8.7 Blunt-Ending of 5` and 3` Overhangs 
Sticky DNA ends were blunt-ended using Klenow enzyme (New England Biolabs).   1l 
of Klenow and 0.5l 10mM dNTP mix were added at the end of the digest reaction and 
the mixture was allowed to proceed at room temperature for 15min.                        
 
2.3.8.8 DNA purification  
PCR or restriction digest reaction mixtures were resolved on a standard 1% agarose 
1xTAE gel containing SYBR Green II.  Desired DNA fragments were excised and 
purified using a Qiagen gel extraction kit according to manufacturer‟s instructions.   
 
2.3.8.9 DNA ligation   
Purified DNA was quantified by resolution on an agarose 1xTAE gel.  Ligations 
contained an insert:vector ratio of 3:1, where 50ng of vector was used per ligation.  The 
mass of insert used was calculated by the formula: 
 
mass of insert = mass of vector X length of insert 
                                     length of vector 
 
Ligation reactions were performed in 10l volumes using 1l of T4 ligase and buffer 
respectively, with an appropriate volume of distilled water.  Reactions were carried out 
overnight at room temperature.  Vector only ligations were performed in parallel to 
indicate the efficiency of selfligation.  
       
2.3.8.10 Transformation of chemically competent cells  
Chemically competent DH5-or TOP10 cells (Invitrogen) were transformed with 
ligation products as per manufacturer‟s guidelines.  Cells were grown on LB agar plates 
containing the appropriate antibiotic.          
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2.3.8.11 Amplification and isolation of plasmids  
5ml cultures of LB Broth were inoculated with individual bacterial colonies and grown 
overnight at 37ºC in a shaker (Innovar 44) set to 200 revolutions per minute (R.P.M.).  
Plasmids were harvested using Qiagen Mini-Prep Kit as per manufacturer‟s instructions.    
     
2.3.8.12 Identification of positive clones   
Plasmids were subsequently subjected to restriction digest to identify positive clones.  
Sequencing of putative positive clones was performed by MWG Biotech. 
     
2.3.9 Transfection and adenoviral infection of cell cultures 
Delivery of nucleic acids into cell cultures is an important tool in functional studies.  In 
this study siRNA oligonucleotides were delivered into cell lines and primary human 
myeloid cells in order to knock down specific proteins.  All siRNA oligonucleotides used 
in this study are listed in section 2.1.4.  Expression constructs and luciferase gene 
reporter constructs were delivered into cell lines by transfection.  Plasmids are 
inefficiently transfected into primary human myeloid cells therefore the aforementioned 
constructs were delivered into these cells using adenoviridae.   
 
2.3.9.1 Transfection of siRNA oligonucleotides into cell lines 
siRNA knockdown in cell lines was performed using Lipofectamine™ RNAiMAX 
Transfection Reagent (Invitrogen) as per the manufacturer‟s instructions.  Briefly, cells 
were seeded in 96-well plates in 100 l penicillin/streptomycin free media.  The 
following day the desired concentration of siRNA oligonucleotide was mixed with 
optimum to a final concentration of 10l.  Then 0.2l of RNAiMAX was added to 10l 
of optimum in a separate tube.  These two mixtures were incubated for 5 minutes, then 
mixed together and incubated for a further 20 minutes at room temperature.  The 20l 
mixture was then added to the culture media and incubated at 37ºC overnight.  The 
following day the supernatants were aspirated and replaced with standard media.  72 
hours post-transfection the desired experimental conditions were applied.   
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2.3.9.2 Transfection of siRNA oligonucleotides into MDDCs 
siRNA knockdown in MDDCs was performed using DharmaFECT® Transfection 
Reagent I as per the manufacturer‟s instructions.  Briefly, the desired concentration of 
siRNA oligonucleotide was incubated with 115l of optimum and incubated for 20 
minutes at room temperature.  Meanwhile, 4x10
5
 MDDCs were resuspended in 250l of 
penicillin/streptomycin free and FCS free media.  The siRNA oligonucleotide mixture 
was then mixed with the cells and incubated at 37ºC for 2 hours.  The supernatant was 
subsequently aspirated and replaced with standard media.  72 hours post-transfection the 
desired experimental conditions were applied. 
 
2.3.9.3 Transfection of plasmids into cell lines  
Transfections of genetic constructs into cell lines were performed using Lipofectamine™ 
2000 Transfection Reagent (Invitrogen) as per the manufacturer‟s instructions.  Briefly, 
cells were seeded appropriately and the following day the desired concentration of the 
plasmid was added to 100 l Optimem.  Then 4 l of pre-warmed Lipofectamine was 
added to 200 l pre-warmed Optimem.  These two mixtures were incubated for 5 
minutes, then mixed together and incubated for a further 30 minutes at room temperature.  
The media was then aspirated from the cells and replaced with the mixture containing the 
plasmid.  The cells were incubated at 37ºC for 2 hours after which the supernatant was 
replaced with standard media.  48 hours post transfection the desired experimental 
conditions were applied. 
 
2.3.9.4 Adenoviral infection of primary human myeloid cells 
Adenoviral infections of primary human myeloid cells were performed in 96-well plates 
in triplicate.  Cells were seeded appropriately and the following evening standard media 
was replaced with serum free RPMI containing the desired number of viral particles in a 
final volume of 50l.  The plates were centrifuged at 600 RCF for 30 minutes then placed 
at 37ºC overnight.  The following day the supernatants were aspirated and replaced with 
100l of standard media and the cell were allowed to recover for 2 days before the 
application of experimental conditions. 
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2.3.10 Luciferase gene reporter assays 
Luciferase gene reporter assays allow the transcriptional activity of specific DNA 
sequences to be assessed in cell cultures.  This technique utilises the firefly luciferase 
gene: a bioluminescent enzyme that catalyses the conversion of luciferin into oxyluciferin 
and light.  The DNA sequence of interest was cloned directly upstream of the luciferase 
gene and the resulting genetic construct was transfected into the cell line of choice.  The 
cells were then subjected to the desired experimental conditions and then the 
transcriptional activity of the respective DNA sequence was inferred by measuring 
photon release after the addition of luciferin to the cell lysate.  In experiments with cell 
lines, cells were co-transfected with a plasmid encoding Renilla luciferase, which was 
under the control of the thymidine kinase promoter.  This promoter was not responsive to 
the experimental conditions, therefore measuring Renilla activity was used to normalise 
for transfection efficiencies, cytotoxic effects and differences in cell number.  In 
experiments with primary human myeloid cells, luciferase activity were normalised by 
presenting data as fold induction and by measuring GFP intensity. 
 
Luciferase assays were performed in triplicate in 96-well plates using Dual-Glo™ 
Luciferase Assay System reagent (Promega).  After transfection of cell lines (section 
2.3.9.3) or infection of primary human myeloid cells (see section 2.3.9.4) cells were 
stimulated as indicated in the results text.  Supernatants were then removed and 25l of 
PBS and The Dual-Glo™ Luciferase Reagent was added to each well respectively.  Cells 
were placed on a shaker for 20 minutes after which lysates were transferred into 
luminometer plates and luciferase activity was measured using a Wallac Victor 
platereader (Edenglen limited).  25l of Dual-Glo™ Stop & Glo® Reagent was then 
added to each well and after 10 minutes Renilla activity was measured.  Data were 
normalised by dividing luciferase activity values by renilla activity values.   
 
2.3.11 EMSA 
This technique is one of the methods to study DNA-protein interactions. Free DNA and 
DNA bound to protein will exhibit different electrophoretic properties which allows them 
to be separated on a native acrylamide gel. DNA-protein complexes will migrate through 
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the gel slower than free DNA. The assay also allows identification of DNA-protein 
complexes by employing specific antibodies, since DNA-protein-antibody complexes 
migrate at a slower rate compared to DNA-protein complexes.  Primers used in EMSA 
analysis are listed in section 2.1.5.3.  Buffers used in EMSA analysis are listed in section 
2.2.3. 
 
2.3.11.1 DNA probe design and labelling 
The most common probe for an EMSA is a radiolabelled short oligonucleotide duplex. It 
consists of two complementary oligonucleotides comprising the binding site of interest, 
flanked by short sequences. The duplex is end-labelled with 
32
P to the highest specific 
activity by either T4 polynucleotide kinase (blunt end duplexes) or Klenow (5‟ 
overhanging duplexes).  
 
The two complementary oligonucleotides were dissolved in TE to a final concentration of 
15 pmole/l (15 M). 10l of each oligonucleotide is mixed to 10l of 10X buffer H 
(Boehringer) and 70l of water in a 1.5 ml tube. The mixture was then layered with 50l 
of mineral oil. Primers were annealed by placing tubes in a beaker with ~1L of boiling 
water for 5 minutes and then allowed to cool down to room temperature overnight.  2l 
of the annealed duplex (6 pmoles of ends) were mixed with 2l of 32P-dCTP (6 pmoles), 
1lof “-dNTP” mixture (3 mM each of dATP, dGTP, dTTP), 2l of 10x Klenow enzyme 
buffer, 12l of water and 1l of klenow enzyme. The mixture was incubated at room 
temperature for 30-45 minutes and the radiolabelled oligoduplex was purified through 
Chroma spin TE-10 spin colums (Takara). The level of incorporation was estimated by 
monitoring the radioactivity left in the column and the radioactivity recovered in the 
flowthrough.  The probe was diluted down to ~20000 CPM/l. 
 
2.3.11.2 Nuclear protein extract preparation 
5 x 10
6
 cells were harvested and washed twice with ice-cold PBS and subsequently 
resuspended in ice-cold buffer A containing protease inhibitors (Protease Inhibitor 
Cocktail Tablets, Roche, catalogue number 04693124001) and phosphatase inhibitors 
(sodium fluoride, 2.5mM; sodium pyrophosphate, 1mM; sodium orthovanadate, 1mM)  
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and 1 mM DTT.. Cells were incubated in ice for 15 minutes before 66l of NP-40 was 
added. The cell pellet was recovered following centrifugation at 12,000 rpm for 30 
seconds and resuspended in 500l of buffer B containing protease inhibitors and 1 mM 
DTT. The mixture was centrifuged for 30 seconds at 16,000 RCF and the volume of the 
nuclear pellet was estimated by subtracting its weight to the one of an empty Eppendorf 
tube.  The nuclear pellet was resuspended to 3 volumes of buffer B and incubated on ice 
for 30-60 minutes with intermittent vortexing. The supernatant containing the nuclear 
proteins was recovered following centrifugation. Protein concentration was measured via 
the BCA assay which normally results in 1-2 mg/ml. The extract was aliquoted and 
stored at -70C and never used more than two times.  
 
2.3.11.3 Binding reaction and gel run 
2l of nuclear extract were mixed with 2l of radiolabelled probe and 4l of 2x binding 
buffer and subsequently incubated at room temperature for 10-15 minutes. When 
antibodies were intended to be used for complex identification then the binding buffer, 
the nuclear extract and the antibodies were mixed together and incubated for 5-10 
minutes before adding the labelled probe. The reaction was further extended for another 
10 minutes.  Each reaction was separated on a 5 % acrylamide gel (0.5 x TBE) at 200 V 
for 2 hours at 4 C. the gel was then dried and exposed it to autoradiography.  
 
2.3.12 Chromatin immuno-precipitation 
Chromatin immuno-precipitation is a technique that allows the analysis of interactions 
between endogenous transcription factors and endogenous promoters in cell cultures.  
Cells were subjected to the desired experimental conditions then fixed by adding 
formaldehyde which cross-links any protein-DNA interactions.  Nuclear extracts were 
subsequently sonicated to shear the DNA, after which the transcription factor of interest, 
and any interacting DNA fragments, was immuno-precipitated with specific antibodies.  
Antibodies used in ChIP are listed in section 2.1.3.3.  After rigorous washing, immuno-
complexes were eluted, cross-linked interactions reversed and DNA fragments are 
purified.  The immuno-precipitated DNA fragments were then examined by real-time 
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PCR.  Primers used in ChIP analysis are listed in section 2.1.5.4.  A list of all the buffers 
and their composition used in ChIP experiments can be found in section 2.2.4. 
 
2.3.12.1 Preparation of nuclear extracts 
6-7x10
6 
cells were seeded in 10cm tissue culture dishes and stimulated the following day 
as desired.  Cells were collected into 14ml falcon tubes and treated with 1% 
formaldehyde (final concentration) for 5 minutes at room temperature.  Cells were then 
quenched by addition of 125 mM Tris (final concentration) pH 7.5, rinsed with ice cold 
PBS and placed on ice.  3 washes were performed with ice cold PBS to remove the 
formaldehyde.  When handling adherent cells, formaldehyde was added directly into the 
tissues culture dishes for 10 minutes, followed by quenching and washing, before 
harvesting cells by scraping.  Cells were then pelleted by centrifugation at 1000 r.c.f. at 4 
ºC, resuspended in 900l of cytoplasmic lysis buffer containing protease inhibitors 
(Protease Inhibitor Cocktail Tablets, Roche, catalogue number 04693124001) and 
phosphatase inhibitors (sodium fluoride, 2.5mM; sodium pyrophosphate, 1mM; sodium 
orthovanadate, 1mM) and placed on ice for 5 minutes.  Cell lysates were then transferred 
into 1.5ml eppendorf tubes and spun in a micro- centrifuge for 5 minutes at 4ºC to pellet 
the nuclei.  The supernatant was aspirated and the pellet was resuspended in 600l 
nuclear lysis buffer and stored at -80ºC until required. 
 
2.3.12.2 Sonication 
Nuclear extracts were sonicated using a Bioruptor
TM
 (Diagenode).  Each sample was 
subjected to 6x 12 second pulses at 20% amplitude.  To ensure that the DNA was sheared 
to a suitable size i.e. 500-1000 base pairs, a 40-50l aliquot was removed from each 
sample and analysed by electrophoresis.  First the cross-linking was reversed by placing 
the aliquots at 65ºC overnight, followed by a standard phenol chloroform extraction and 
ethanol precipitation.  The samples were resuspended in 30l of water, and 10l was 
loaded into a 1% agarose TAE gel and run at 100V until the samples were sufficiently 
resolved to ascertain the DNA fragment size. 
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2.3.12.3 Immuno-precipitation 
All immuno-precipitation steps were carried out at 4ºC on a rotator.  120l of nuclear 
extract was used per immuno-precipitation.  The sample was first diluted 10 times with 
dilution buffer to reduce the concentration of SDS, and then pre-cleared with 80 Protein 
A Sepharose™ bead slurry (GE Healthcare) for 2h.  All sepharose beads used during 
ChIP experiments had previously been saturated with sonicated salmon sperm 
(Invitrogen) to reduce any non-specific binding to the beads.  The sepharose beads were 
then pelleted by centrifugation and the supernatants transferred to fresh tubes.  2g of the 
desired antibody was added to each sample, and incubated overnight.  Immuno-
complexes were then collected with 30l of protein A sepharose beads for 30 minutes, 
and subsequently washed 3 times with wash buffer, followed by 3 washes with T.E.  An 
aliquot of unbound sample was retained for normalisation purposes (the unbound 
material shall be referred to as the “input”).  The beads were then resuspended in 125l 
of extraction buffer for 20 minutes, after which they were pelleted and the supernatant 
was transferred to a fresh tube. 
 
2.3.12.4 DNA purification 
Immuno-precipitated complexes and “input” fractions were heated to 65ºC overnight to 
reverse the cross-linked protein-DNA interactions.  The DNA fragments were then 
purified using the QIAquick PCR Purification Kit as per the manufacturer‟s instructions.  
Immuno-precipitated DNA and “input” DNA were eluted in 200l and 300l 
respectively and stored at -20ºC until required. 
 
2.3.12.5 Real-time PCR analysis 
Analyses of DNA fragments were performed in a Corbett Rotor-gene 6000 machine 
(Corbett Research Ltd, Cambridgeshire, UK) and analysed using Corbett Rotogene 6000 
software.  All reactions used SYBR®Premix Ex Taq™ master mix (Takara Bio USA), 
8l of DNA and a final primer concentration of 0.1M.  A list of primers used in ChIP 
experiments can be found in section 2.1.5.4.  The following thermal cycling conditions 
were used: 
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30 seconds at 95ºC  
40 cycles of:  
10 seconds at 95ºC 
25 seconds at 60ºC 
 
2.3.13 MTT cytotoxic assay 
The 3-{4,5,-Dimethylthiazol-2yl}-2,5-diphenyltetrazolium bromide cell viability assay is 
based on the principle that tetrazolium salts are reduced to water-insoluble formazan 
crystals in metabolically active cells as a function of redox potential of mitochondria.  
The orerall activity of mitochondrial dehydrogenases is directly correlated with the 
number of viable cells.  Thus, this assay can be used to measure factor-induced 
cytotoxicity or non-specific cell death in a population of cells, since treatment with a 
cytotoxic factor will reduce the rate formazan crstal formation. 
 
Following the end of the experimental conditions, supernatants were removed and 
replaced with fresh culture medium containing 5g/ml MTT and cultured at 37˚C for 4h.  
Cells were then lysed by addition of one volume of 10.15M hydrochloric acid containing 
10% (w/v) SDS and placed at 37˚C overnight.  Absorbance was read at 620nm on a 
Multiskan Biochromatic plate reader using Ascent 2.4.2 software to measure the levels of 
viable cells. 
 
2.3.14 Purification of recombinant proteins  
Recombinant purified proteins (IRF3, RelA and p50) were used to assess the affinity of 
transcription factor binding to putative regulatory elements in EMSA assays.  Protein 
purification was kindly performed by Dr. Alessandra Lanfrancotti (Kennedy Institute of 
Rheumatology).  Briefly, HEK-293 cells were seeded in 10 T-175 flasks.  When the cells 
reached a confluency of 80% the media was removed and replaced with 10ml of serum-
free DMEM containing the appropriate HA-tagged expression adeno-viral construct at an 
MOI of six.  Two hours later 10ml of DMEM containing 4% FCS and 2% P/S was added 
to the flasks and the cells were cultered overnight.  The following day the cells were 
pelleted, wash twice with PBS and lysed with lyis buffer (50mM Tris pH 7.5; 150mM 
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NaCl; 0.1% IGEPAL) containing protease inhibitors (Protease Inhibitor Cocktail Tablets, 
Roche, catalogue number 04693124001) and phosphatase inhibitors (sodium fluoride, 
2.5mM; sodium pyrophosphate, 1mM; sodium orthovanadate, 1mM).  Lysates were then 
sonicated using a Bioruptor
TM
 (Diagenode).  Each sample was subjected to 3x30 second 
pulses at 30% amplitude.  HA-tagged proteins were then purified using an anti-HA 
affinity matrix (Roche, catalogue number 11815016001) as per the manufacturer‟s 
instructions.  Purified proteins were then desalted and concentrated using Vivaspin 
columns (sartorius-stedim, catalogue number vs0131) as per the manufacturer‟s 
instructions. 
 
2.3.15Bio-informatic analysis 
Genomic sequences were obtained using the publically available UCSC Genome Browser 
website (http://genome.ucsc.edu/) and the Ensembl website 
(http://www.ensembl.org/index.html).  Predicted transcription factor binding sites were 
obtained using the JASPAR Database (http://jaspar.cgb.ki.se/). 
 
2.3.16 Statistical analyses 
Quantitative data are presented as mean ± standard deviation or standard error as 
indicated.  All statistical analyses were performed using GraphPad Prism 5.0 software.  
Experiments containing only two measurments were analysed using a T-test.  
Experiments containing three or more measurments were analysed using one-way 
ANOVA.   
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Chapter 3: 
 
Does IFN-λ1 have a role in inflammation? 
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3.1 Introduction 
Inflammation is usually a transient physiological process that contributes to the clearance 
of infectious agents and tissue damage.  But a variety of diseases, for example 
rheumatoid arthritis, can develop if this process becomes deregulated.  Myeloid cells, 
such as macrophages and dendritic cells, are central to an inflammatory response as they 
are major producers of inflammatory mediators, including the classical cytokines TNF 
and IL-6.  The last decade has seen rapid discovery of novel cytokines, particularly in the 
class II cytokine family.  Members of this family exert a broad range of effects on the 
immune system, and understanding what role these recently identified cytokines play in 
inflammation may lead to more effective therapeutic targets in disease.  The IFN-s are 
novel are class II cytokines, which have mainly been studied for their anti-viral and 
activities.  Therefore, this chapter set out to investigate the role of IFN-λs during 
inflammation.  To do this, expression of IFN-1 and the IFN- receptor were 
characterised in human cells in two different inflammatory settings: 
  
1. LPS stimulated human myeloid cells derived from healthy donors 
 
2. Synovial tissue derived from rheumatoid arthritis patients 
 
The first system is a model of acute inflammation, while the second system represents 
chronic inflammation.  This chapter shows that IFN-λ1 mRNA is expressed in both 
systems, but only LPS activated monocyte-derived dendritic cells produce detectable 
amounts of IFN-λ1 protein.  In addition, it was found that the IFN-λ receptor was not 
highly expressed in either system, and therefore its activation would be unable to 
modulate inflammatory cytokine production. Alternative means to understand the role of 
the IFN-s in inflammation are discussed.  
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3.2 Characterising the role of IFN- in acute inflammation 
At the start on this investigation, it had been reported that IFN-λ1 could be induced in 
monocyte-derived dendritic cells (MDDCs) in response to specific toll-like receptor 
(TLR) ligands, including lipopolysacchride (LPS) (Coccia et al., 2004).  LPS is a 
component of the cell wall of gram negative bacteria that stimulates a receptor complex 
consisting of TLR4 and CD14, and is commonly used to model an acute inflammatory 
response.  However, it was unknown if other human myeloid cells were capable of 
expressing IFN-λ1 in response to LPS.  Therefore I analysed IFN-λ1 mRNA and protein 
induction in MDDCs, M-CSF macrophages, GM-CSF macrophages and monocytes.  A 
schematic illustration of how these cell types were derived is shown in figure 3.1. 
 
  
Figure 3.1 Schematic illustration of generation of cell types used to model acute inflammation.  
Monocytes were purified from healthy donors by elutriation and differentiated ex vivo into „M-CSF‟ 
macrophages, „GM-CSF macrophages and DCs.  The reagents used and the length of time required for 
differentiation are indicated in the diagram. 
 
3.2.1 Human myeloid cells differentially express IFN-1 in response to LPS  
Observations from initial experiments indicated that IFN-λ1 mRNA was often not 
detected in untreated myeloid cells from most donors.  Therefore, it was not possible to 
accurately measure the induction of IFN-λ1 using real-time PCR delta-delta Ct method of 
analysis, since this method required a basal level of mRNA in untreated cells to be used 
as a calibrator.  For this reason the less commonly used 2-standard curve method of 
Chapter 3  Results    
 107 
analysis was adopted, and is described in detail in section 2.3.5.3.  mRNA levels were 
normalised against the large ribosomal protein RPLPO (PO).  It was found that following 
4h of LPS treatment, IFN-λ1 mRNA was induced to varying degrees in all 4 human 
myeloid cell types (figure 3.2A).  On average, the strongest induction was observed in 
MDDCs (approximately 6 logs), while the responses of M-CSF-macrophages and GM-
CSF-macrophages were similar (approximately 5 logs).  Monocytes, on the other hand, 
showed only a modest increase in IFN-1 mRNA expression after LPS treatment 
(approximately 1 log).   
 
                  
Figure 3.2 LPS activates the IFN-1 gene in primary human myeloid cells.  5x105 cells were plated in a 
24-well plate and the next day were either left untreated or treated with 100ng/ml of LPS for (A) 4 hours or 
(B) 24h. (A) mRNA was harvested and IFN-1 mRNA levels were analysed by real-time PCR 2-standard 
curve method.  White triangles indicate IFN-1 mRNA was undetected; white dots indicate IFN-1 mRNA 
in untreated cells; black dots indicate IFN-1 mRNA in LPS-treated cells.  (B) Supernatants were collected 
and IFN-1 protein concentration was determined by ELISA.  Data are presented as mean +/- S.E.M. of 4 
independent experiments, each performed in triplicate.  
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Cells from the same healthy donors were also stimulated with LPS for 24h and culture 
supernatants were analysed for IFN-λ1 protein by ELISA (figure 3.2B).  On average, 
MDDCs produced more than 2ng/ml of IFN-λ1 protein after stimulation.  Surprisingly, 
and despite the strong induction seen at the level of mRNA, no IFN-λ1 protein was 
detected from the culture supernatants of M-CSF-macrophages or GM-CSF-
macrophages.  It should be noted, however, that the lower limit of detection of the assay 
was approximately 100pg/ml.  Consistent with the relatively low levels of mRNA, no 
IFN-λ1 protein was detected in the supernatants of LPS treated monocytes.  Thus, while 
the human IFN-λ1 gene is strongly inducible by LPS in both monocyte-derived 
macrophages and MDDCs, only MDDCs produce detectable amounts of secreted IFN-λ1 
protein. 
 
3.2.2 MDDCs and M-CSF macrophages express low levels of IFN-R1  
The question of whether IFN-λ1 can modulate or contribute to an acute inflammatory 
response in human M-CSF macrophages or MDDCs was subsequently investigated.  To 
begin with, these cells were examined for expression of the IFN-λ receptor.  This receptor 
is a hetero-dimeric protein complex consisting of the IFN-λR1 subunit and the IL-10R2 
subunit.  Since the IL-10R2 is ubiquitously expressed, expression of the IFN-λR1 subunit 
dictates which cells are responsive to IFN-λ1 (Commins et al., 2008).  Due to the lack of 
commercially available antibodies that recognised the IFN-λR1 subunit, IFN-λR1 mRNA 
levels were quantified using real-time PCR (figure 3.3A).  As a positive control, receptor 
levels were also measured in the lung carcinoma A549 epithelial cell line, since they have 
been shown to be highly responsive to IFN-λ1 in an anti-viral assay (Meager et al., 
2005).  Out of 4 different donors, the levels of IFN-λR1 mRNA observed in MDDCs and 
M-CSF macrophages were similar and ~100-fold lower than found in A549 cells.  These 
relatively low levels of IFN-λR1 mRNA found in M-CSF macrophages and MDDCs led 
me to hypothesise that in these cell types IFN-λ receptor activation would result in 
minimal signal transduction.  
 
To test this hypothesis M-CSF macrophages and MDDCs were analysed for STAT 
activation following treatment with recombinant IFN-λ1 (kindly provided by Dr. S. 
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Kotenko, New Jersey Medical School).  IFN-λ1 receptor activation has been shown to 
result in the phosphorylation of multiple STAT proteins, including STAT1 and STAT3 
(Kotenko et al., 2003).  As a positive control, cells were also treated with either IFN-α or 
IL-10, which are known to activate STAT1 and STAT3 in these cells.   
                  
Figure 3.3 M-CSF macrophages and MDDCs do not express high levels of functional IFN-receptor.  
(A) IFN-R1 mRNA expression was analysed using real-time PCR 2-standard curve method in M-CSF 
macrophages and MDDCs from four different donors and A549 cells.  (B) 5x105 cells were seeded in a 24-
well plate and the following day either left untreated or treated with IFN-1, IL-10 or IFN- at a 
concentration of 100ng/ml for the indicated lengths of time.  Cells were then harvested and analysed by 
western blotting using antibodies against the indicated proteins.  Arrow indicates correct molecular weight 
of STAT1.  Data are representative of two independent experiments. 
 
As expected, treatment with IFN-α led to a substantial increase in the levels of phospho-
STAT1 (p-STAT1) and a more modest increase in the levels of phospho-STAT3 (p-
STAT3).  Similarly, both p-STAT1 and p-STAT3 were readily detected in IL-10 treated 
cells.  By contrast, the presence of p-STAT1 or p-STAT3 was not observed in IFN-λ1 
treated cells.  Similar results were obtained in MDDCs (data not shown).  To ensure that 
the gifted IFN-λ1 protein was functional, the same experiment was performed in A549 
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cells (figure 3.3B).  Again, high levels of p-STAT and p-STAT3 were observed in IFN-α 
treated cells.  p-STAT1 and p-STAT3 could also be detected in IFN-λ1 treated A549s, 
confirming that the IFN-λ1 protein was functional.  It should be noted however, that the 
bands were weaker compared with IFN-α stimulated cells.  Expression of the IL-10 
receptor is largely confined to leukocytes, therefore p-STAT1 or p-STAT3 was not 
observed in IL-10 treated A549s.  Overall these data demonstrate that the IFN- receptor 
is not highly expressed on M-CSF macrophages or MDDCs, resulting in no IFN-1-
induced signalling in these cells.   
 
3.2.3 IFN-λ1 does not modulate LPS-induced pro-inflammatory cytokine expression 
in MDDCs or M-CSF macrophages 
Since human MDDCs and M-CSF macrophages expressed relatively low levels of the 
IFN-λ receptor and did not confer IFN-1-induced signalling, it seemed unlikely that 
IFN-λ1 would modulate inflammatory cytokine production from these cells.  To confirm 
this, M-CSF macrophages and were either pre-treated with IFN-λ1 overnight, then 
stimulated with LPS for 24h, or co-stimulated with IFN-λ1 and LPS for 24h, and the 
inflammatory cytokines TNF and IL-6 were assessed by ELISA (figure 3.4).  To 
normalise between donors the data are expressed TNF and IL-6 levels as a percentage of 
control cells.  In the three donors analysed, TNF and IL-6 levels ranged between 1-
8ng/ml and 500pg/ml-4ng/ml respectively.  As controls, cells were treated with either IL-
10 or IFN-α.  In all three donors analysed IL-10 profoundly, and concentration 
dependently, inhibited LPS-induced TNF and IL-6 production.  Furthermore, greater 
inhibition was seen when cells were pre-treated with IL-10, rather than co-stimulated 
with IL-10 and LPS.  Conversely, IFN-α substantially augmented LPS-induced TNF 
production, and again this effect was more pronounced when cells were pre-treated rather 
than co-treated with IFN-α.  There was also a trend for IFN-α to increase LPS-induced 
IL-6 production, although this effect was less pronounced compared to TNF.  On the 
other hand, IFN-λ1 treatment did not modulate LPS-induced TNF or IL-6 expression 
levels in M-CSF macrophages.  Similar results were observed for LPS-induced IL-8 
production (data not shown).      
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Figure 3.4 IFN-1 does not modulate LPS-induced TNF or IL-6 production in M-CSF macrophages. 
105 cells were seeded in a 96-well plate and the following day either pre-treated (overnight) or co-treated 
with IFN-1 (A & B) , IL-10 (C & D) or IFN- (E & F) and stimulated with 10ng/ml of LPS for either 4h 
or 24h.  Supernatants were collected and TNF (A, C & E) or IL-6 (B, D & F) protein concentrations were 
determined by ELISA. The concentrations of IFN-1, IL-10 or IFN- are indicated in the figure legends 
(ng/ml).  Data are normalised to control cells = 100% and presented as mean +/- S.E.M. of three 
independent experiments, each performed in triplicate. 
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Figure 3.5 IFN-1 does not modulate LPS-induced TNF or IL-6 production in MDDCs. 105 cells were 
seeded in a 96-well plate and the following day either pre-treated (overnight) or co-treated with IFN-1 (A 
& B) , IL-10 (C & D) or IFN- (E & F) and stimulated with 10ng/ml of LPS for either 4h or 24h.  
Supernatants were collected and TNF (A, C & E) or IL-6 (B, D & F) protein concentrations were 
determined by ELISA. The concentrations of IFN-1, IL-10 or IFN- are indicated in the figure legends 
(ng/ml).  A, C & E data are normalised to control cells = 100% and presented as mean +/- S.E.M. of three 
independent experiments, each performed in triplicate.  B, D & F Data are presented as mean IL-6 
concentration +/- S.D. of a representative experiment out of two independent experiments, each performed 
in triplicate. 
 
IFN-λ1 was also unable to modulate LPS-induced TNF and IL-6 production in MDDCs, 
whereas IL-10 and IFN- exerted a similar trend in MDDCs as seen in M-CSF 
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macrophages (figure 3.5).  The levels of TNF and IL-6 measured in the supernatants of 
LPS-treated MDDCs ranged between 6,000-12,000ng/ml and 5,000-30,000ng/ml 
respectively. 
 
3.2.4 IFN-λ1 does not modulate inflammatory cytokine production in A549 cells  
The ability of IFN-λ1 to modulate inflammatory cytokine expression in A549 cells was 
subsequently analysed, since they seemed to express relatively high levels of functional 
IFN-λ receptor and conferred IFN-1-induced signalling.  Other reports have shown that 
inflammatory cytokines such as IL-6 and IL-8 were strongly induced by IL-1 at 
relatively low concentrations (1 ng/ml) in A549 cells, whereas LPS had no effect even at 
high concentrations (1g/ml) (Boost et al., 2008; Coulter et al., 1999; Veranth et al., 
2008).  This study confirmed that IL-1, but not LPS, was able to induce IL-6 protein in 
A549 cells (figure 3.6A).  In parallel, cells were also stimulated with TNF and IL-1 to 
assess if these cytokines were capable of inducing IL-6 production.  It was found that 
stimulation with TNF was just as potent as IL-1, whereas IL-1 was about 30% less 
effective at inducing IL-6 (figure 3.6A).  Subsequently, cells were treated overnight with 
IFN-λ1 and levels of IL-1β-induced and TNF-induced IL-6 were examined.  To be 
consistent with the previous experiments, the effect of IFN-α pre-treatment was also 
investigated in this cell system; however IL-10 was not used since its receptor is not 
expressed in these cells.  Compared to control cells, IFN-λ1 pre-treatment had minimal 
effect on IL-6 production that was induced by either TNF or IL-1 respectively (figure 
3.6B).  IFN-α also had minimal effect on IL-6 production.  Similarly, both IFN-λ1 and 
IFN-α had negligible effect on IL-8 production (figure 3.6C).  As a positive control, the 
same supernatants were also analysed for IP-10 expression since it is a known interferon-
stimulated gene (figure3.6D).  Treatment with IFN-1, IFN-, TNF or IL-1 alone 
resulted in minimal induction of IP-10, similar to control cells.  However, when IFN-λ1 
was used in combination with TNF or IL-1, strong induction of IP-10 was observed 
(~1.7ng and 1ng/ml respectively).  Interestingly, the level of induction was greater than 
observed with IFN-α pre-treatment (~1ng/ml and 0.4ng/ml respectively).  Therefore both 
IFN-λ1 and IFN-α did not modulate inflammatory cytokine production in A549 cells, but 
were able to act synergistically with TNF and IL-1to upregulate IP-10.         
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Figure 3.6 Effect of IFN-1 receptor activation on inflammatory cytokine protein production in A549 
cells.  (A) 2x105 cells were seeded in a 24-well plate and the following day left untreated or treated with IL-
1 (1ng/ml); IL-1 (1ng/ml); TNF (10ng/ml); or LPS (10ng/ml) for 8h.  Supernatants were then collected 
and IL-6 concentrations were determined by ELISA.  (B), (C) & (D) 2x105 cells were seeded in a 24-well 
plate and the following day left untreated or treated with IFN-λ1 or IFN-α overnight.  The following 
morning cells were either left untreated or treated with TNF or IL-1β for 8h.  Supernatants were collected 
and (B) IL-6, (C) IL-8 and (D) IP-10 concentrations were determined by ELISA.  Data are presented as 
mean +/- S.D. of a representative experiment out of two independent experiments, each performed in 
triplicate. 
 
3.2.5 IFN-λ1 and IFN-α regulate similar target genes in A549 cells 
Microarray analysis has indicated that IFN-λ1 and IFN-α induce almost identical gene 
expression programs in the hepatoma cell line HepG2 (Doyle et al., 2006).  All the genes 
that were highly induced were known interferon stimulated genes (ISGs) that encode 
proteins involved in antiviral responses.  I was therefore interested to investigate whether 
IFN-λ1 and IFN-regulated similar genes in A549 cells (figure 3.7).  It was observed 
that treatment with both IFN-λ1 and IFN-α led to a substantial increase of 2OAS, Mx1 
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and IRF7 mRNA levels.  The level of gene induction seen with IFN-was greater than 
with IFN-λ1, consistent with the higher levels of STAT phosphorylation in IFN-α 
compared to IFN-λ1 treated cells.  The RNA editing enzyme ADAR1 was not induced by 
either IFN.  In addition to ISGs, I also examined the expression of IFN-λ1, to assess 
whether it was upregulated following IFN treatment.  Interestingly, both IFN-λ1 and IP-
10 were upregulated in response to IFN-α, but not IFN-λ1, suggesting there may be some 
differences in their gene expression programs in A549 cells.   
 
          
Figure 3.7 IFN-1 and IFN- regulate similar target genes in A549 cells.  2x105 Cells were seeded in a 
24-well plate and the following day were either left untreated or treated with the indicated concentrations of 
IFN-λ1 or IFN-α for 4h.  mRNA was then harvested and the expression levels of the indicated genes were 
assessed using real-time PCR Ct method.  Data are presented are mean +/- S.D. of a representative 
experiment out of two independent experiments, each performed in triplicate.   
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I also investigated whether IFN-λ1 or IFN-α could synergise with TNF to induce the 
aforementioned genes in A549 cells (figure 3.8).   
         
Figure 3.8 TNF is able to synergise with IFN-λ1 and IFN-α to activate interferon stimulated genes 
and the IFN-λ1 gene  in A549 cells.  2x105 Cells were seeded in a 24-well plate and the following day 
were either left untreated or treated with the indicated concentrations of IFN-λ1 or IFN-α for 4h, or treated 
overnight with IFN-λ1 or IFN-α then stimulated with TNF (10ng/ml) for 4h.  mRNA was then harvested 
and the expression levels of the indicated genes were assessed using real-time PCR Ct method.  Data are 
presented are mean +/- S.D. of a representative experiment out of two independent experiments, each 
performed in triplicate.   
 
With the exception of IP-10 (~1,500-fold increase), TNF treatment alone was unable to 
induce any of these genes to any great extent.  Again, the levels of induction of ADAR1 
were minimal when cells were stimulated with TNF or IFN-λ1/IFN-α.  However, strong 
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synergism was observed with the 2OAS, Mx1 IRF7 and IP-10 genes.  Interestingly the 
IFN-λ1 gene was also strongly activated when cells were treated with both TNF and IFN-
λ1/IFN-α (fold increase of ~200 or ~1500 respectively).  Therefore, IFN-λ1, similar to 
IFN-α, is able to synergistically induce several ISGs, and IFN-λ1 itself, in A549 cells.   
 
 
3.3 Expression of IFN- in synovial tissue derived from rheumatoid 
arthritis patients 
 
3.3.1 Characterisation of IFN-λ1 expression in synovial tissue derived from 
rheumatoid arthritis patients 
Rheumatoid arthritis is a chronic inflammatory disease characterised by swelling of 
synovial membranes, due to infiltration of several cell types and proliferation of 
synoviocytes.  The dissociated membranes spontaneously secrete multiple cytokines, 
even following removal from the diseased joint, making then a useful model to study the 
pathogenesis of the disease.  To assess if IFN-λ1 could have a role in rheumatoid 
arthritis, its expression was analysed in dissociated synovial membranes derived from 
rheumatoid arthritis patients (figure 3.9A).  The levels of IL-10 and TNF were also 
assessed as positive controls, since they are known to be expressed in RA synoviocytes.  
All 6 patient samples examined expressed IFN-λ1 mRNA.  However, the average levels 
of IFN-λ1 mRNA were significantly lower than, IL-10 and TNF (mean difference ~2 logs 
and 3 logs respectively), but comparable to IFN-.      
 
In parallel, the same samples were cultured ex vivo for 48h.   There were 2 reasons for 
doing this.  Firstly, to compare how the levels of IFN-λ1 mRNA might change after 
removal from the inflamed joints of RA patients.  Secondly, examine the levels of IFN-λ1 
protein in the culture supernatants.  However, no significant differences were observed in 
IFN-λ1 mRNA expression between samples that had been cultured ex vivo for either 0h 
or 48h (figure 3.9B).  On the other hand, 48h of ex vivo culture led to a significant 
reduction in the levels of IL-10.  While the levels of TNF also decreased after culture the 
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difference was not significant.  In addition, IFN-λ1 protein was not detected in any of the 
culture supernatants that were examined by ELISA (figure 3.9C), whereas TNF protein 
was measured in most samples (fig 3.9D).  Thus IFN-λ1 is not highly expressed in RA 
synoviocytes.   
 
      
Figure 3.9 Low levels of IFN-1 are spontaneously expressed in rheumatoid synoviocytes.  
Synoviocytes were isolated from synovial tissue of rheumatoid arthritis patients cultured ex vivo for either 
0h or 48h.  (A) & (B) mRNA was harvested and cytokine levels were measured using real-time PCR 2-
standard curve method. (C) and (D) Supernatants were collected and (C) IFN-1 or (D) TNF protein 
concentrations were determined by ELISA.  Data are presented as mean +/- S.D. of triplicate measurments. 
(A) One star indicates p value<0.05; 1-way ANOVA.  (B) One star indicates p value<0.05; students T-test.  
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3.3.2 Separation of cell types found within synovial tissue 
The most abundant cell types within the synovial tissue are macrophages, T-lymphocytes 
and fibroblasts.  It is known that upon infection with viruses, macrophages produce larger 
quantities of IFN-λ1 compared to fibroblasts.  Therefore, it was hypothesised that, in the 
synovial tissue, macrophages would produce more IFN-λ1 than T-lymphocytes and 
fibroblasts, since high levels of IFN-λ1 expression were observed in LPS-stimulated 
macrophages from healthy donors (figure 3.1A).  In order to test this hypothesis, IFN-λ1 
mRNA was quantified after these cell types had been separated.  Again, synoviocytes 
were cultured ex vivo for either 0h or 48h before being subjected to the separation 
process.  Synoviocyte separation was achieved using antibody/magnetic bead conjugates 
that recognise cell-type specific trans-membrane proteins.  First, synovial macrophages 
were positively selected using anti-CD14
+
 antibodies, and then synovial T-lymphocytes 
were isolated using an antibody mixture, which resulted in the negative selection of 
synovial fibroblasts.  The synoviocyte separation procedure is illustrated in figure 3.10.   
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Figure 3.10 Overview of synoviocyte separation procedure.  Synovial membranes were extracted from 
rheumatoid arthritis patients and subject to mechanical and enzymatic digestion.  „Macrophage‟, „T-
lymphocyte‟ and „fibroblast‟ enriched populations were subsequently isolated using antibody/magnetic 
bead conjugates.  See section 2.3.3 for methodological details.  
 
At each stage in the synoviocyte isolation procedure, a sample was collected and 
subsequently analysed by FACS analysis to confirm the purity of each population.  Cells 
were stained for CD14
+
 and CD45
+
, which are markers of macrophages and leukocytes 
respectively.  A representative dot plot from patient BU039 is shown (fig 3.11).  In this 
patient, three populations of cells were initially observed; CD14
+
/CD45
+
, CD14
-
/CD45
+
 
and CD14
-
/CD45
- 
(Figure 3.11A), which corresponded to macrophages, T-lymphocytes 
and fibroblasts respectively.  Following the positive selection of synovial macrophages, 
the percentage of CD14
+
 cells was reduced from 31% to 2.5% (fig 3.11B).  The 
subsequent positive selection of synovial T-lymphocytes caused the population of CD14
-
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/CD45
+
 cells to be reduced from approximately 40% to 12%, leaving a population of 
synovial fibroblasts that was 75% pure (fig 3.11C).   
 
                       
Figure 3.11 Assessment of synoviocyte isolation efficiency. Representative FACS dot plots confirming 
isolation procedure of cell types from rheumatoid joint of patient BU039. X axis = CD45; Y axis = CD14.  
(A) Mixed cell population containing macrophages (CD45+;CD14+); lymphocytes (CD45-; CD14+) and 
fibroblasts (CD45-; CD14-); (B) Following positive selection of macrophages the number of CD14+ positive 
cells is reduced; (C)  Following the positive selection of lymphocytes the number of CD45+ cells is 
reduced. 
 
A summary of the purity of synoviocyte separation for the other patient samples is shown 
(figure 3.12).  Thus, the synoviocyte isolation procedure resulted in 3 distinct populations 
of cells: „macrophage enriched‟ synoviocytes; „T-lymphocyte enriched‟ synoviocytes and 
„fibroblast enriched‟ synoviocytes.   
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Figure 3.12 Summary of purity of synoviocyte populations following cell isolation procedure.   
 
3.3.3 IFN-λ1 expression in distinct synoviocyte populations  
Of the 3 distinct synoviocyte populations, the T-lymphocyte population was discarded 
due to insufficient yields of RNA.  Therefore, IFN-λ1 levels were only measured in the 
macrophage and fibroblast enriched populations.  However, no significant differences in 
IFN-λ1 expression were detected between the „macrophage enriched‟ or „fibroblast 
enriched‟ populations of synoviocytes (figure 3.13).  This was true for samples that had 
been cultured ex vivo for either 0h or 48h.  Again, as a positive control, the levels of IL-
10 and TNF were assessed in these samples.  However, at both time points, the levels of 
TNF were found to be significantly greater in the „macrophage enriched‟ synoviocyte 
population, which is in agreement with a previous report (Chu et al., 1991).  Similarly, 
IL-10 levels were significantly higher in the „macrophage enriched‟ population.  From 
these data, it is difficult to draw any firm conclusions especially because synovial tissue 
from only 6 patients was analysed.  However, it can be said that in all 6 patients, the 
levels of IFN-λ1 mRNA were considerably lower than both TNF and IL-10, and that its 
expression was similar in macrophage and fibroblast enriched populations.  Moreover, no 
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IFN-λ1 was detected in the supernatants of ex vivo synoviocyte cultures, although it may 
have been present in concentration lower than 100pg/ml.   
 
                          
Figure 3.13 Expression of (A) IFN-1, (B) TNF and (C) IL-10 in distinct populations of synoviocytes.  
Synoviocytes were isolated from synovial tissue of rheumatoid arthritis patients and cultured ex vivo for 
either 0h or 48h.  Synoviocytes were then separated into distinct populations and mRNA levels were 
assessed by real-time PCR 2-standard curve method.  mix = synoviocyte mixture; mph = „macrophage 
enriched‟ population; fibro = „fibroblast enriched‟ population.  One star indicates p value<0.05; students T-
test. 
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3.3.4 Characterisation of IFN-R1 expression in synovial tissue derived from 
rheumatoid arthritis patients 
Although the analysis of synovial membranes can provide useful insight to the underlying 
mechanisms of rheumatoid arthritis, they do not encompass the whole disease.  
Therefore, it could not be precluded the additional cell types not found within synovial 
membranes, for example those present in the synovial fluid, might produce IFN-λ1 in 
large quantities.  For this reason, the ability of IFN-λ1 to act upon synovial membranes 
was subsequently investigated.  To begin with, the cDNA samples generated during the 
synoviocytes separation procedure were assessed by real-time PCR for the expression of 
IFN-λR1 subunit (figure 3.14A).  Again, there were no significant differences in the 
levels of IFN-λR1 between the „macrophage enriched‟ and „fibroblast enriched‟ 
populations.  Furthermore, the levels of IFN-λR1 observed in the synoviocyte 
populations were similar to that in M-CSF macrophages and MDDCs. 
 
As STAT phosphorylation was not seen in M-CSF macrophages and MDDCs following 
treatment with recombinant IFN-λ1, it seemed that synovial membranes would behave 
similarly.  To confirm this, synoviocytes from three different patients were treated with 
IFN-λ1 and STAT1 phosphorylation was examined by western blotting (figure 3.14B).  
IL-10 and IFN- were again used as positive controls.  It was apparent that, compared to 
untreated A549 cells, considerable levels of constitutive STAT1 phosphorylation were 
seen in untreated synoviocytes.  IFN-α treated synoviocytes consistently showed a 
modest increase in the levels of p-STAT1, although this signal was weaker compared to 
IFN- treated A549s.  Interestingly, treatment with with IFN-1 and IL-10 respecively 
led to a slight inhibition in p-STAT1 levels compared to control synoviocytes, although 
the underlying mechanism was unclear.   
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Figure 3.14 IFN-λR1 expression in RA synoviocytes is similar to that in myeloid cells.  (A) RA 
synoviocytes were cultured for 0h or 48h then separated into distinct cellular populations.  mRNA was then 
harvested and IFN-λR1 mRNA were assessed by real-time PCR 2-standard curve method.  (B) 5x105 
Synoviocytes were seeded in a 24-well plate and either left untreated or treated with IFN-1, IFN- or IL-
10 at the indicated concentrations (ng/ml) for 15 minutes.  Cells were then analysed by western blotting 
using antibodies against the indicated proteins.  Data are representative of three independent experiments.   
 
 
3.3.5 Effect of IFN-λ1 treatment on spontaneous cytokine expression from inflamed 
synoviocyte cultures 
Finally, I investigated if IFN-λ1 was able to modulate spontaneous inflammatory 
cytokine production in RA synoviocytes (figure 3.15).  Therefore synoviocyte cultures 
from three different patients were either left untreated, or treated with 10 or 100 ng/ml of 
recombinant IFN-λ1.  24h later supernatants were collected and the levels of TNF, IL-6 
and IL-8 were determined by ELISA.  Again IL-10 and IFN- were used as controls.      
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Figure 3.15 IFN-1 does not modulate spontaneous cytokine production from cultured synovial 
membranes derived from rheumatoid arthritis patients.  Synoviocytes were purified from synovial 
membranes from three rheumatoid arthritis patients.  5x105 cells were seeded in a 24-well plate and either 
left untreated, or treated with IFN-λ1, IFN-α, IL-10 or LPS at the indicated concentrations.  24h later, 
supernatants were collected and (A) TNF, (B), IL-6, (C) IL-8 and (D) IP-10 protein concentrations were 
determined by ELISA.  (A), (B) and (C) Data were normalised to untreated cells = 100% and are as mean 
+/- S.E.M. of three independent experiments, each performed in triplicate.  (D) Data are presented as mean 
IP-10 concentration +/- S.E.M. of 3 independent experiments, each performed in triplicate.  One star 
indicates p value<0.05; three stars indicates p value<0.005; 1-way ANOVA. 
 
In untreated cells the levels of TNF in the culture supernatant ranged from 45-53 pg/ml; 
IL-6 33-95ng/ml; IL-8 23-96 ng/ml.  IL-10 was found to significantly inhibit the 
production of all three cytokines examined, which is consistent with a previously 
published report (Morita et al., 2001).  It should be noted that this decrease in cytokine 
production was not due to cytotoxic effects, as judged by MTT assay (data not shown).  
Interestingly, IFN- had differential effects on TNF, IL-6 and IL-8 production.  IL-8 was 
significantly and concentration dependently inhibited.  There was a trend for TNF levels 
to increase, although the difference was not significant.  The effects of IFN-α on IL-6 
expression were minimal compared to control cells.  By contrast, the levels of TNF, IL-6 
and IL-8 measured in IFN-λ1 treated cells were almost identical compared to control 
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cells.  The same supernatants were also analysed for IP-10 levels.  IP-10 was not detected 
in the supernatants of any samples except those treated with IFN-α, which showed a 
concentration dependent increase in IP-10 production.  Therefore, IFN-λ1 was unable to 
modulate spontaneous production of inflammatory cytokines or IP-10 in cultured RA 
synoviocytes. 
      
 
3.4 Characterisation of collagen induced arthritis in IFN-λR1 knock out 
mice   
From these data, it is difficult to draw any firm conclusions regarding the role of IFN-λ1 
in rheumatoid arthritis, partly because synovial tissue from only six patients was 
analysed.  However, the low levels of IFN-λ1 and IFN-λR1 seen in synovial membranes 
do not support the hypothesis that IFN-λ1 plays a strong role in synovial degradation.  At 
the same time, it is not possible to be certain that IFN-λ1 does not have a role in 
rheumatoid arthritis, since analysing only synovial membranes is not sufficient to capture 
the whole range of mechanisms underlying the disease.  For example, the membranes are 
only removed from patients with very severe and established arthritis, therefore, it is not 
possible to assess if IFN-λ1 would have a role in the early stages of disease development.  
Also, it is possible that the site of IFN-λ activity is not in the joint but in the lymph nodes.  
Therefore, in order to explore the role of the IFN-λs in arthritis in greater depth, 
investigations were moved from the described ex vivo cell system into an in vivo system 
using IFN-λR1 knock-out mice.    
 
3.4.1 Female IFN-λR1 knock-out mice develop severe arthritic symptoms in collagen 
induced arthritis 
Collagen induced arthritis (CIA) is a commonly used model of human RA.  Subcutaneous 
injection of chicken type II collagen into mice results in the induction of symptoms 
associated with human RA including swelling of paws, recruitment of macrophages and 
T-cells to synovial membranes and release of inflammatory mediators and progressive 
destruction of bone and cartilage.  CIA was induced in wild-type and IFN-λR1 knock-out 
mice to understand if the IFN-λs play a role in the induction of arthritis (figure 3.16).   
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Figure 3.16 Female, but not male, IFN-λR1 knock-out mice develop significantly higher clinical score 
compared to wild-type mice in collagen induced arthritis.  Wild-type or IFN-λR1 knock-out mice, 10-
14 weeks old, were immunised with 200mg/ml of chicken type II collagen in complete freunds adjuvant  
(A) & (B) clinical score and (C) & (D) number of arthritic paws were monitored daily.  Data are presented 
as mean +/- S.E.M. of 3 female wt; 4 female KO; 8 wt male; and 9 KO male mice.  One star indicates p 
value<0.05; two stars indicate p value<0.01; 2-way ANOVA.  wt = wild-type mice; KO = IFN-λR1 knock-
out mice. 
 
 
These experiments were performed by Ms Katrina Blazkova and Dr. Saba Alzabin at the 
Kennedy Institute of Rheumatology.  Following the onset of arthritic symptoms, the 
number of affected paws and clinical score was recorded daily.  In wild-type mice it was 
observed that males developed a more severe disease phenotype compared to females, 
which is consistant with previous publications (Holmdahl et al., 1986b).  Although the 
reasons for the sex differences in mice in the development of CIA are unclear, both sex 
hormones (Holmdahl et al., 1986a) and the influence of genes located on the X-
chromosome have been implicated (Jansson and Holmdahl, 1993).  Interestingly, female 
IFN-λR1 receptor knock-out mice had a significantly higher clinical score compared to 
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wild-type mice (figure 3.16A).  Furthermore, wild-type females only developed swelling 
in a maximum of one paw, 2-3 paws were affected in IFN-λR1 knock-out mice.  
Therefore, the difference in clinical score in females was mainly due to the number of 
paws that were affected, and not the extent of swelling in individual paws (figure 3.16C).  
On the other hand, a reverse trend was observed between male wild-type and male IFN-
λR1 knock-out mice in both clinical score (figure 3.16B) or number of affected paws 
(figure 3.16D), although the differences were not significant.  However, these data are 
from one experiment and will therefore have to be validated. 
 
3.4.2 Levels of cytokine expression are similar in the paws of wild-type and IFN-λR1 
knock-out mice 
Arthritic paws from the experiment described above were analysed histologically.  As 
expected, compared to control paws substantial of inflammatory infiltrates were observed 
in the paws of arthritic mice.  However, only negligible differences were observed in 
inflammatory infiltrates between wild-type and IFN-λR1 knock-out mice (data not 
shown).   
 
In instances where more than one paw showed arthritic symptoms, total mRNA was 
harvested and the levels of TNF, IL-10, IL-1 and IFN- were analysed by real-time 
PCR (figure 3.17).  It is also worth noting that the levels of TNF, IL-1and IFN-β found 
in arthritic paws were similar to those observed in non-arthritic paws, while the levels of 
IL-10 were ~30-fold higher in arthritic paws.  However, minimal differences were 
observed in the expression of these cytokines between wild-type and IFN-λR1 knock-out 
mice.  There was arguably a trend for higher expression of TNF in IFN-λR knock-out 
mice compared to wild-types (~2-fold).  However, due to the small sample size (i.e. 4 
wild-type paws and 3 IFN-λR1 knock-out paws were analysed) it is difficult to draw firm 
conclusions. Therefore this experiment will have to be repeated with more samples.  It 
would also be more informative in future experiments to analyse cytokine expression 
from distinct cell types and at different stages of the disease.  
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Figure 3.17 Cytokine expression is similar in arthritic paws of wild-type and IFN-λR1 knock-out 
mice with collagen induced arthritis.  mRNA was harvested from whole arthritic paws.   As controls 
mRNA was also harvested from non-immunised mice.  mRNA levels of the indicated cytokines were 
assessed using real-time PCR ct method in triplicate.  Data are normalised to cytokine expression levels 
of non-immunised mice.  wt = wild-type; -/- = IFN-λR1 knock-out 
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3.5 Discussion 
The IFN-s are a novel family of class II cytokines that have features common to both 
type I IFNs and IL-10 related factors.  In terms of gene structure the IFN-λs are more 
similar to IL-10 related factors, which posses multiple exons.  Moreover, the IFN-λ 
receptor comprises the IL-10R2 subunit, which is also shared by the IL-10, IL-22 and IL-
26 receptors, in addition to the unique IFN-λR1 subunit.  By contrast, both receptor 
subunits utilised by the type I IFN receptor are unique.  However, at the amino acid level 
the IFN-λs are more closely related to type I IFNs.  Moreover, they activate similar 
signalling pathways and consequently possess similar biological activities such as anti-
viral activities.  However, it was unclear whether IFN-λs had a role in inflammation of 
inflammatory disease.  Therefore in this chapter I set out to characterise the expression of 
IFN-λ1 and the IFN-λ receptor during both acute and chronic inflammation, and to 
dissect the potential role played by IFN-λ1 during an inflammatory response. 
 
LPS is a potent stimulator of the innate immune system and commonly used to evoke an 
acute inflammatory response.  At the onset of this investigation it had been shown that 
IFN-λ1 mRNA is strongly induced in MDDCs in response to LPS stimulation (Coccia et 
al., 2004).  I also found, in all four donors examined, that IFN-λ1 mRNA was strongly 
induced by LPS.  In addition, I also examined LPS-mediated IFN-λ1 expression in M-
CSF macrophages, GM-CSF macrophages and monocytes, since these cell types are also 
potent inducers of inflammation.  I observed a strong induction of IFN-λ1 mRNA in both 
M-CSF macrophages and GM-CSF macrophages and only a modest induction in 
monocytes.  A study by Wolk et al reported similar levels of induction of IFN-λ1 in 
MDDCs and monocytes in response to LPS (Wolk et al., 2008).  However, it also 
showed, in contrast with this study, that IFN-λ1 was not expressed in M-CSF 
macrophages.  The reason for this discrepancy is not clear.  However, it should be noted 
that Wolk et al used 6h of LPS treatment (compared to 4h in this investigation), at which 
time IFN-λ1 mRNA levels may have begun to decline.  In addition, the protocols for M-
CSF macrophage generation were slightly different in the two studies, as Wolk et al 
cultured monocytes in the presence of M-CSF for six days (compared with four days in 
this investigation).  Moreover, work from my lab has indicated that M-CSF macrophages 
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are considerably less responsive to LPS six days post-differentiation compared to four 
days post-differentiation.  This investigation also showed that IFN-λ1 protein was readily 
detected in the supernatants of LPS-treated MDDCs, but not other myeloid cells, which is 
consistent with Wolk et al (Wolk et al., 2008).   
 
A major difference between the type I and type III IFN systems seems to be the pattern of 
receptor expression.  In contrast to the almost ubiquitously expressed type I IFN receptor, 
the IFN-λ receptor seems to be expressed in a more cell-type specific manner.  It should 
be stressed that investigations of IFN-λ receptor expression have been hindered by the 
absence of a commercially available antibody that recognises the IFN-λR1 subunit.  
Therefore, IFN-λ receptor cellular expression has been inferred from analysing IFN-λR1 
mRNA levels, analysis of target genes or ability to induce an anti-viral state in infected 
cells.  Studies in human cell lines have consistently shown that endothelial and fibroblast 
cells are unresponsive to IFN-λ1, as measured by anti-viral assays and induction of target 
interferon stimulated genes (Kotenko et al., 2003; Lasfar et al., 2006; Meager et al., 
2005; Zhou et al., 2007).  However several studies have identified human epithelial cells 
as a cellular target of the IFN-λs (Ank et al., 2008; Doyle et al., 2006; Meager et al., 
2005; Sommereyns et al., 2008).  In the mouse, the IFN-λ receptor shows a similar 
expression pattern, with epithelial cells and tissues being highly responsive to type III 
IFNs in contrast to fibroblasts (Ank et al., 2008; Jordan et al., 2007a; Sommereyns et al., 
2008).  Therefore it appears the IFN-λs may have evolved a more specialised role in the 
anti-viral defence system by boosting immunity in epithelial structures, which are the 
most common route of entry for viral infection.   
 
It has become clear, however, that in addition to their anti-viral functions type I IFNs also 
regulate other aspects of the immune system.  However, it was unclear whether the IFN-
λs also possess additional functions.  Therefore, I characterised the expression of the 
IFN-λ receptor in MDDCs or M-CSF macrophages, to determine if IFN-λ1 might 
modulate function of these cells during inflammation.  In the absence of an antibody that 
recognises the IFN-λR1 subunit, I analysed components of the IFN-λ1 signal transduction 
pathway.  I was unable to detect phosphorylation of STAT1 or STAT3 in IFN-λ1-treated 
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MDDCs or M-CSF macrophages.  By contrast, STAT1 and to a lesser extent, STAT3 
phosphorylation were easily detected in the epithelial cell line A549 cells, which have 
been shown to be highly responsive to IFN-λ1 in an anti-viral assay (Meager et al., 
2005).  In addition A549 cells were found to express substantially higher levels (~100-
fold) of IFN-λR1 mRNA compared to M-CSF macrophages and MDDCs.  Taken 
together, these results suggest the IFN-λ receptor is not highly expressed on MDDC or 
M-CSF macrophages.  I also found that IFN-λ1 was unable to modulate LPS-induced 
expression of TNF, IL-6 or IL-8 in MDDCs or M-CSF macrophages.  As expected, IL-10 
substantially inhibited production of these cytokines which has been previously reported 
(Fiorentino et al., 1991).  Interestingly, IFN-α treatment was found to augment LPS-
induced cytokine production in MDDCs and M-CSF macrophages.  The mechanism of 
this augmentation is unclear, but it has been reported that IFN- (which uses the same 
receptor as IFN-) enhanced the production of LPS-induced TNF and IL-1in human 
monocytes (Molnarfi et al., 2004). 
 
However, other studies have suggested that M-CSF macrophages and MDDCs may 
express low levels of IFN-λ receptor.  Jordan et al reported that human M-CSF 
macrophages, in addition to monocytes, specifically upregulate IL-6, IL-8 and IL-10 
following treatment with IFN-λ1 (Jordan et al., 2007a).  Although it should be noted that 
the concentrations of IFN-λ1 used in their study (1g/ml) were considerably higher than 
in this investigation (10ng/ml).  Furthermore one report has documented that MDDCs 
upregulate the IFN-λR1 mRNA (~10-fold) during their differentiation from monocytes 
(Mennechet and Uze, 2006).  The same report also showed that IFN-λ1 treated MDDCs 
acquire a partially mature phenotype and can specifically induce the proliferation of 
Tregs.  However, this work has not yet been validated by other groups, and at least one 
lab has been unable to reproduce these results (Dr. S. Kotenko, New Jersey Medical 
School, personal communication).   Therefore, it is possible that the IFN-λ1 receptor is 
present on M-CSF macrophages and MDDCs at very low levels in humans.  Of interest, 
one study has also examined the induction of the interferon stimulated genes IRF7 and 
OAS1 in a range of murine leukocytes following treatment with IFN-λ2 or IFN-α (Ank et 
al., 2008).  It found that both genes were significantly upregulated in splenic cDCs, 
Chapter 3  Results    
 134 
pDCs, peritoneal macrophages, T-cells and B-cells stimulated with IFN-.  By contrast, 
IFN-λ2 (100ng/ml) treatment only caused an induction of IRF7 and OAS1 in pDCs, 
suggesting only pDCs expressed high levels of the IFN-λ receptor in the mouse. 
 
RA is a chronic inflammatory disease characterised by swelling of synovial joints and 
recruitment of several cell types, or synoviocytes, to synovial membranes.  Synoviocytes 
express high levels of cytokines which contribute to the pathogenesis of RA (Feldmann et 
al., 1996a).  Even after removal from the joint, synoviocytes spontaneously produce 
cytokines making them a useful model system to study the disease.  Therefore, to 
understand if IFN-λ1 plays a role in RA I analysed the expression of IFN-λ1 and IFN-
λR1 in synovial membranes.  However, IFN-λ1 mRNA levels were expressed at 
significantly lower levels than TNF or IL-10.  In line with this result IFN-λ1 protein was 
not detected in supernatants of cultured synoviocytes, whereas TNF was detected in most 
samples.  The most abundant cell types in synovial membranes are macrophages T-cells 
and fibroblasts.  Since M-CSF macrophages from healthy donors are capable of 
producing large quantities of IFN-λ1, it was hypothesised that synovial macrophages 
would express more IFN-λ1 compared to T-cells or fibroblasts.   However, similar levels 
of IFN-λ1 mRNA were observed between the „macrophage enriched‟ and „fibroblast 
enriched‟ synoviocyte populations.  In contrast, synovial macrophages expressed 
significantly higher levels of TNF and IL-10.  Furthermore, the levels of IFN-λR1 seen in 
distinct synovial populations were comparable to those found in M-CSF macrophages 
and MDDCs from healthy donors, and substantially lower than in A549 cells.   
 
In addition I was unable to detect upregulation of STAT1 phosphorylation in RA 
synoviocytes following treatment with IFN-λ1.  Therefore it was not surprising that IFN-
λ1 was unable to modulate the spontaneous expression of inflammatory cytokines from 
RA synoviocytes cultures.  Overall the low expression levels of IFN-λ1and the IFN-λR1 
subunit in RA synoviocytes suggest that IFN-λ1 plays a minimal role in the late stages of 
RA.  However, it can not be precluded that IFN-λ1 does not play a role in the 
development of RA.   
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Thus, the goal of trying to understand the role played by the IFN-λ1 in inflammation and 
inflammatory disease in this chapter was hindered by the use of cell system that do not 
express high levels of the IFN-λ receptor.  Therefore, to allow a more thorough dissection 
of the role of the IFN-λs in inflammation, investigations were moved into a mouse 
system using IFN-λR1 knock-out mice, which were obtained towards the end of this 
project (July, 2008).  Initial experiments of collagen induced arthritis (CIA) indicated that 
female IFN-λR1 knock-out mice developed more severe arthritic symptoms compared to 
wild-types, whereas minimal differences were observed in males.  This is an interesting 
observation, considering that RA is more prevalent amongst females than males.  
However, this experiment has only been performed once and therefore must be repeated.  
In addition I also examined the expression of cytokines in inflamed paws of arthritic 
mice.  However, expression levels of TNF, IL-1β IL-10 and IFN-β were similar between 
wild-type arthritic, IFN-λR1 knock-out and naïve mice.  Further studies are required to 
fully understand the contribution of the IFN-λs to CIA. 
 
It is worth noting that during the immunisation of mice with type II collagen ulcerations 
developed at the site of injection, which was the base of the tail.  These ulcerations 
quickly healed in wild-type mice (within a day), however in most IFN-λR1 knock-out 
worsened and persisted for several days.  One explanation for this is that IFN-λs exhibit 
some anti-inflammatory activities upon keratinocytes.  It would therefore be of interest to 
assess IFN-λR1 knock-out mice in other model of inflammation in addition to CIA, 
particularly those that involve epithelial cells since they express high levels of IFN-λ 
receptor.  For example, psoriasis is a chronic inflammatory skin disorder that results 
excessive growth of keratinocytes.  Multiple mouse models of psoriasis exist that are the 
result of spontaneous mutations or genetic engineering, and capture many aspects of the 
human disease (Gudjonsson et al., 2007).  It would be intriguing to cross these mice with 
the IFN-λR1 knock-out mice and assess the progression of psoriatic symptoms.  It may 
also be fruitful to examine models of irritable bowel syndrome (IBS) using IFN-λ1 
knock-out mice, as this disease mainly affects epithelial cells of the intestine, which again 
express high levels of IFN-λR receptor. 
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Interestingly, other novel class II cytokines that share the IL-10R2 subunit have been 
shown to act mainly on epithelial cells and have been linked with inflammatory diseases.  
For example, transgenic mice that over-express IL-22 have been shown to develop 
psoriasis-like skin alterations (Wolk et al., 2009).  Moreover, IL-22 neutralising 
antibodies were found to prevent disease development in a T-cell dependent murine 
model of psoriasis (Ma et al., 2008).  In addition, upregulation of IL-26 was reported in 
patients with active Crohn‟s disease and IL-26 stimulation of intestinal epithelial cells 
resulted in the production of inflammatory cytokines (Dambacher et al., 2008).  Also 
mice deficient for the IL-20R2 subunit, which is utilised by IL-19, IL-20 and IL-24, were 
shown to be protected against psoriatic-like symptoms induced by IL-23 administration 
(Chan et al., 2006).  Therefore, it seems that most novel class II cytokines play a role in 
inflammation-associated disorders involving epithelial cells. 
 
Finally, I found that IFN-λ1 and IFN-α induced similar target interferon stimulated genes 
in A549 cells.  Similar results were obtained in HepG2 cells (Doyle et al., 2006).  
Interestingly, most of these target genes synergistically activated by co-treatment of IFN-
λ1/IFN-α with TNF, although the underlying mechanism was unclear.  However, a recent 
study showed that c-rel-deficient MEFs had reduced levels of ISG expression following 
treatment with IFN- (Wei et al., 2008).  Therefore, it would be interesting to modulate 
to the expression levels of individual NF-B subunits in A549 cells, either by siRNA 
knock-down or by over-expression, and assess the impact on IFN-1/IFN- target gene 
expression to further dissect the role of NF-B in ISG expression. 
 
I also found that IFN-λ1 mRNA was weakly induced by IFN-α (~10-fold), but not by 
IFN-λ1.  However, when used in combination with TNF, both IFN-λ1 and IFN-α were 
able to induce IFN-λ1 mRNA by more than 200-fold.  Although there is only limited data 
in the literature regarding IFN-λ1 regulation, this observation suggests that both NF-κB 
and STAT/IRF pathways are required for maximal induction of IFN-1. 
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Chapter 4: 
 
Key role of RelA and IRF3 in IFN-1 induction 
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4.1 Introduction 
In the previous chapter, I sought to understand the role played by IFN-λ1 during 
inflammation.  During this line of investigation, a strong, robust induction of IFN-λ1 in 
response to LPS was observed in MDDCs, although the molecular mechanisms 
underlying this induction were unclear.  However, a report investigating the expression of 
type I and type III interferons in response to different stimuli suggested that the 
regulation of IFN-λ1 and IFN-β may be similar (Coccia et al., 2004).  It found that 
infection with influenza virus was able to induce all interferon sub-types examined, 
whereas only IFN-λ1 and IFN-β were induced in response to TLR4 activation (Coccia et 
al., 2004).  Furthermore, their induction in response to TLR4 activation occurred with 
highly similar kinetics.  Therefore, I set out to test the hypothesis that the induction of 
IFN-λ1 and IFN-β is regulated by a common mechanism in MDDCs in response to LPS. 
 
Of all eukaryotic genes, the mechanism of IFN-β induction is one of the best understood, 
and has been extensively studied in human fibroblasts in response to viral infection.  This 
model states that transcriptional activation is dependent upon the formation of a multi-
protein complex at the proximal promoter of IFN-β.  This complex consists of proteins 
from several transcription factor families, of which NF-κB and IRFs are thought to be the 
most important.  Moreover, the same transcription factors are shown to be activated 
downstream of TLR4 signalling.  Therefore, in this chapter the role NF-κB and IRF 
proteins were systematically investigated in LPS-induced IFN-λ1 induction in MDDCs.  
This was done using 2 complementary approaches: 
  
1. By inhibiting specific NF-κB and IRF proteins using siRNA 
 
2. By over-expressing of specific NF-κB and IRF proteins 
 
Ultimately, this chapter shows that RelA and IRF3 are critical transcription factors 
mediating the LPS-induced IFN-λ1 in MDDCs. 
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4.2 Characterisation of MDDC as a system to investigate LPS-induced 
IFN-λ1 expression 
 
4.2.1 IFN-λ1 and IFN-β are expressed with similar kinetics 
I first confirmed that IFN-λ1 and IFN-β genes had a similar kinetics of induction in 
response to TLR4 stimulation.  To do this, MDDCs from five healthy donors were 
stimulated with 100ng/ml of LPS for different lengths of time and then mRNA levels 
were quantified using real-time PCR.  A representative donor is shown in figure 1.1A and 
1.1B. In line with the report from Coccia and co-workers, IFN-λ1 and IFN-β consistently 
showed a similar kinetics of expression, with mRNA levels peaking between 1h and 4h 
after stimulation (Coccia et al., 2004).  It is worth noting that peak IFN-β levels were 
always observed 1h post-stimulation.  While peak IFN-λ1 mRNA levels were also 
observed 1h post-stimulation in some donors, most donors showed peak levels 4h after 
LPS treatment.  8h post-stimulation the levels of expression of both genes had begun to 
decrease, and by 24h they had usually returned to basal levels.  The magnitude of IFN-λ1 
and IFN-β gene expression could vary between donors, although peak fold-induction 
typically ranged from 10
4
 to 10
6
.   
 
During these experiments cell supernatants from the same samples were collected, and 
the levels of secreted IFN-λ1 protein were measured by ELISA.  A representative donor 
is shown in figure 1.1C.   IFN-λ1 protein was never detected in untreated MDDCs, 
however at both 8h and 24h post-LPS the concentration of IFN-λ1 in the supernatants 
was usually between 1.5-3 ng/ml.  Approximately 300pg/ml of IFN-λ1 was detected 
following 4h of LPS treatment in most donors.  IFN-λ1 protein expression from a 
representative donor is shown in figure 1.1C.  Thus, in human MDDCs, TLR4 
stimulation causes a rapid, robust and transient induction of IFN-λ1 and IFN-β mRNA.  
Furthermore, IFN-λ1 protein was readily detected in cell supernatants both 8h and 24h 
after LPS treatment.     
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Figure 4.1 Kinetics of LPS-induced IFN-1 induction in human MDDCs. 5x105 MDDCs were seeded 
in a 24-well plate and the following day stimulated with 100ng/ml of LPS the indicated lengths of time.  
(A) and (B) mRNA was harvested and the levels of (A) IFN-1 and (B) IFN- were measured by real-time 
PCR 2-standard curve method.  Data are presented as mean +/- S.D. of a representative experiment out of 
five independent experiments, each performed in triplicate.  (C) Supernatants were collected and IFN-1 
protein levels were assessed by ELISA. Data are presented as mean +/- S.D. of a representative experiment 
out of five independent experiments, each performed in triplicate.  
 
 
4.2.2 IFN-λ1 mRNA induction in MDDCs is transcriptionally regulated  
The rapid induction of IFN-λ1 mRNA in MDDCs suggested that it may be regulated at 
the level of transcription.  To test this idea, I blocked mRNA transcription using 
actinomycin D, and then measured IFN-λ1 induction following LPS treatment (figure 
4.2A).   As a control, cells were also treated with DMSO only, since this was the solvent 
in which the actinomycin D was disolved.  Following LPS treatment, IFN-λ1 mRNA 
levels were ~2-fold greater in DMSO treated cells compared to untreated cells.  However, 
after treatment with actinomycin D, IFN-λ1 induction was inhibited more than 100-fold.   
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To further investigate the nature of IFN-λ1 gene expression in response to LPS, I 
assessed the recruitment of RNA polymerase II using chromatin immuno-precipitation 
(ChIP) (figure 4.2B).  MDDCs from 2 different healthy donors were either left untreated, 
or treated with LPS for 1h or 4h.  Two different primer sets were used which amplified 
the IFN-λ1 promoter region and the second intron of the IFN-λ1 gene respectively.  As a 
positive control RNA polymerase II recruitment was also analysed at the IFN- 
promoter.  On average, a 2-fold increase in RNA polymerase II binding was observed 
after 4h of LPS treatment at both the IFN-λ1 promoter and intra-genic region.  Although 
less pronounced, a small increase of ~1.5-fold was detected after 1h of LPS treatment.  
These levels of RNA polymerase II enrichment were modest and non-significant, but 
they are comparable to those observed at the IFN-β promoter.  RNA polymerase II 
recruitment at the IFN-β promoter increased ~3-fold after 1h of LPS treatment, and had 
almost returned to basal levels after 4h.  Therefore, the kinetics of RNA polymerase II 
recruitment to the IFN-λ1 and IFN-β promoters complements the kinetics of mRNA 
expression, in that peak levels of IFN-λ1 are slightly delayed compared to IFN-β.   
 
I also inhibited protein translation in MDDCs by treating the cells with cyclohexamide, 
prior to measuring the induction of IFN-λ1 mRNA in response to LPS (figure 4.2C).  
Again, DMSO treatment alone had only minimal effect on the cells.  After 1h of LPS 
treatment, the levels of IFN-λ1 induction were similar in cyclohexamide treated cells 
compared to controls, suggesting that IFN-λ1 is a primary response gene.  In other words, 
all the transcription factors and signalling molecules necessary for its induction were 
already present within resting MDDCs and do not need to be synthesised.  Interestingly, 
however, cyclohexamide pre-treatment resulted in increased levels of IFN-λ1 mRNA 
production compared to control cells 4h after LPS trratment.  This result suggested that 
protein synthesis might be required to deactivate the IFN-λ1 gene following TLR4 
activation.   
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Figure 4.2 IFN-1 gene is regulated at the level of transcription. (A) 5x105 MDDCs were seeded in 24-
well plate and the next day either left untreated or treated with DMSO (0.1%) or actinomycin D (1g/ml).  
30 minutes later they were either left untreated or stimulated with 100ng/ml of LPS. Cells were 
subsequently harvested and IFN-1 mRNA levels were analysed by real-time PCR 2-standard curve 
method.  Data are presented as mean +/- S.D. of one representative out of two independent experiments, 
each performed in triplicate.  (B) 7x106 MDDCs were seeded in 10cm dishes and the following day 
stimulated with 100ng/ml of LPS. Cells were then fixed and nuclear extracts subjected to sonication before 
immuno-precipitation with an anti-RNA polymerase antibody.  DNA fragments were purified and analysed 
using the indicated primers.  Data are presented as mean +/- S.E.M. of two independent experiments and 
normalised against the level of RNA polymerase II recruitment at 0h.  (C) 5x105 MDDCs were seeded in 
24-well plate and the next day either left untreated or treated with DMSO (0.1%) or cyclohexamide 
(10g/ml).  30 minutes later they were either left untreated or stimulated with 100ng/ml of LPS. Cells were 
subsequently harvested and IFN-1 mRNA levels were analysed by real-time PCR 2-standard curve 
method in triplicate.  Data are presented as mean +/- S.D. of one representative out of two independent 
experiments, each performed in triplicate.  
 
 
4.2.3 NF-κB and IRF3 undergo rapid nuclear translocation in MDDCs 
Studies from murine myeloid cells suggest that IRF3 and NF-κB are involved in TLR4-
mediated IFN-β expression (Doyle et al., 2002; Honda et al., 2005b; Sakaguchi et al., 
2003). Since it was hypothesised that IFN-λ1 and IFN-β are regulated by a common 
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mechanism, the ability of these transcription factors to undergo nuclear translocation was 
assessed (figure 4.3).   
 
                    
Figure 4.3 LPS stimulation of MDDCs results in nuclear translocation of NF-κB and IRF3.  107 
MDDCs were seeded in 10cm dishes and the following day stimulated with 100ng/ml of LPS for the 
indicated time points.   Cells were then collected and nuclear and cytoplasmic extracts were prepared and 
analysed by western blotting with antibodies against the indicated proteins.  One representative out of two 
independent experiments is shown. 
 
It had previously been reported that in human MDDCs, all 5 NF-κB subunits undergo 
translocation following LPS treatment, although the kinetics of RelB and p52 are slower 
than RelA, c-Rel and p50 (Saccani et al., 2003).  I also observed that the nuclear levels of 
RelA and p50 were substantially increased within 30mins, and at subsequent time points.  
By contrast, translocation of RelB and p52 did not occur until between 2h and 8h.  This 
observation is in line with the fast acting canonical NF-κB signalling pathway which 
mainly liberates RelAp50 containing dimers, compared to the slower acting non-
canonical pathway that acts on RelBp52 dimers.  c-Rel was only examined 2h and 8h 
after activation, but at both time points substantial levels were found in the nucleus 
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whereas only minimal amounts were seen prior to TLR4 activation (data not shown).  It 
should be noted that there appeared to be a strong induction of Rel proteins following 
LPS-stimulation, which is consistant with the study of Saccani et al. who used the same 
cell system (Saccani et al., 2003).  IRF3 was also found to undergo rapid translocation, 
similar to RelA and p50.  It was readily detected in the cytoplasm of naïve MDDCs, 
while only minimal amounts were seen in the nuclei.  However, after stimulation the 
amount of nuclear IRF3 protein significantly increased within 30 mins and peaked around 
2h.  The membranes were subsequently reprobed for actin to ensure equal protein 
loading.  
             
 
4.3 Characterising TLR-expressing 293 cells as a model system to 
understand IFN-λ1 transcriptional regulation 
Due to their ability to produce large amounts of IFN-λ1, primary human myeloid cells are 
the most physiologically relevant cells in which to study IFN-λ1 transcriptional 
regulation.  However, there are some drawbacks with using this system, such as the 
limited numbers of cells available, and the fact their behaviour can vary widely from 
donor to donor.  These limitations make primary human myeloid cells ill-suited for 
certain applications, such as the optimisation of specific techniques.  To overcome these 
practical difficulties, a model human cell-line system was sought in which IFN-λ1 
transcriptional regulation could be investigated.   
 
4.3.1 IFN-λ1 is inducible in TLR-expressing 293 cells 
I therefore assessed the ability of HEK-293 cells that had been engineered to stably 
express high levels of TLR4/CD14/MD2 (TLR4-293s) to produce IFN-λ1.  In addition, 
HEK-293s that stably express high levels of TLR3 (TLR3-293s) were examined, since 
IFN-β induction in response to LPS is believed to be mediated largely via the TRIF-
dependent pathway, which is utilised by TLR3 (Oshiumi et al., 2003).  These cell lines 
were purchased from Invivogen.  They had been transfected with a plasmid encoding the 
respective receptors and selected for the highest expressing clones.  Each cell line was 
treated with the appropriate ligand (LPS for TLR4-293s; pI:C for TLR3-293s) for 
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different amounts of time and IFN-λ1 mRNA levels were measured by real-time PCR 
(figure 4.4A).  The kinetics of IFN-λ1 mRNA induction in both cell types were similar to 
that of LPS- stimulated MDDCs, with peak levels being measured between 1h and 4h  
                   
Figure 4.4 Kinetics of induction of IFN-1 in TLR3-293s and TLR4-293s.  5x104 cells were seeded in a 
24-well plate.  The following day they were stimulated with the appropriate ligand for the indicated time.  
25g/ml and 1g/ml of p:IC and LPS respectively were used.  (A) Cells were harvested and IFN-1 mRNA 
levels were measured using real-time Ct method.  Data are presented as mean +/- S.D. of one 
representative out of two independent experiments, each performed in triplicate.  (B) Supernatants were 
collected and IFN-1 protein concentration was measured by ELISA. Data are presented as mean +/- S.D. 
of one representative out of two independent experiments, each performed in triplicate.  
 
post-stimulation.  It was slightly surprising to note that compared to TLR4-293s, TLR3-
293s had higher basal levels (approximately 500 times), since these cell lines are derived 
from the same parental line.  In addition they had greater inducibility (approximately 800 
Chapter 4  Results 
 146 
times compared to 200 times) and a more sustained production of IFN-λ1 mRNA.  
Supernatants were also collected and analysed for IFN-λ1 protein levels by ELISA 
(figure 4.4B).  TLR3-293s supernatants contained approximately 1,000 pg/ml of protein 
8h after stimulation, rising to 4,000 pg/ml after 24h.  Conversely, IFN-λ1 proteins was 
undetectable, even in stimulated TLR4-293s, which is in line with the lower levels of 
basal and inducible IFN-λ1 mRNA expression compared to TLR3-293s.   
 
4.3.2 TLR3/4-293s express NF-κB and IRF3  
To further validate TLR3-293s and TLR4-293s as a model system, these cell lines were 
screened for the presence of NF-κB subunits and IRF3 by western blotting.  Both cell 
lines contained RelA, RelB, c-Rel, p50, p52 and IRF3.  Again, it was slightly surprising 
to note that TLR4-293s contained higher levels of the aforementioned transcription 
factors, with the notable exception of IRF3 and p105/p50 (figure 4.5A).   
 
The ability of these transcription factors to undergo stimulus-dependent nuclear 
translocation was subsequently examined (figure 4.5B).  TLR3-293s and TLR4-293s 
were stimulated with the appropriate ligand for different lengths of time, and then nuclear 
and cytoplasmic extracts were prepared.  I then examined the sub-cellular location of the 
5 NF-κB subunits and IRF3 by western blotting.  Only minimal amounts of NF-κB 
proteins were detected in the nuclei of unstimulated TLR3-293s.  Nuclear levels of RelA, 
c-Rel, p50 and p52 were all substantially increased 1h post-stimulation, whereas nuclear 
RelB did not increase until 4h post-stimulation.  IRF3, on the other hand, was present in 
both the nuclei and cytoplasm of unstimulated TLR3-293s, and only a modest increase in 
IRF3 levels could be detected in the nuclei of activated cells.  A similar pattern of 
stimulus-dependent nuclear translocation was observed in TLR4-293s.  The membranes 
were subsequently re-probed for actin and tubulin, which confirmed equal protein 
loading.  It is noteworthy that the ratio of nuclear and cytoplasmic IRF3 is approximately 
equal in TLR4-293s in unstimulated cells, whereas in TLR3-293s more IRF3 can be seen 
in the nucleus.  This may explain the reason for the relatively high basal levels of IFN-λ1 
in TLR3-293s.  It would also have been interesting to assess the sub-cellular localisation 
of IRF3 in parental 293 cells.  This would indicate if the nuclear presence of IRF3 in 
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TLR3/TLR4-293s is an inherent property of these cells, or a consequence of receptor 
over-expression, which may drive specific signalling pathways.  Altogether, these 
experiments showed that the IFN-λ1 gene is induced upon stimulation in TLR3-293s and  
           
Figure 4.5 NF-κB subunits and IRF3 are expressed and undergo stimulus –dependent translocation 
in TLR3- and TLR4-293s.  (A) 3x105 cells were plated in a 24-well plate.  The following day whole cell 
extracts were prepared and equal amounts of protein were resolved by SDS-PAGE.  Proteins were then 
transferred the presence of the indicated proteins was assessed by immuno-blotting.  One representative out 
of two independent experiments is shown.  (B) 5x106 cells were seeded in 10cm dishes and the following 
day stimulated with 25g/ml of pI:C or 1g/ml of LPS for the indicated time points.   Nuclear and 
cytoplasmic extracts were then  prepared, and analysed by western blotting using antibodies against the 
indicated proteins.  Data are representative of two independent experiments.  
 
TLR4-293s, and that all 5 NF-κB subunits and IRF3 are present in these cells.  Although 
IRF3 was present in the nuclei of resting cells and had minimal translocation after 
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stimulation, all five NF-κB subunits underwent stimulus-dependent translocation with 
similar kinetics compared to LPS-treated MDDCs.  I therefore concluded that 
TLR3/TLR4-293s would serve as a suitable model system to investigate the potential role 
of these transcription factors in the regulation of IFN-λ1. 
 
 
4.4 siRNA-mediated knockdown of RelA and IRF3 inhibits IFN-λ1 
induction 
 
4.4.1 Optimisation of siRNA to knockdown specific NF-κB and IRF proteins in 
TLR3-293s 
A siRNA-mediated knockdown approach was used to systematically assess the functional 
contribution of individual NF-κB subunits and IRF3 in the induction of IFN-λ1.  This 
approach was optimised in TLR3-293s for two reasons.  Firstly, these cells have a high 
transfection efficiency, thus the likelihood of achieving a high percentage of protein 
knock-down was increased.  Secondly, since TLR3-293s produce detectable amounts of 
IFN-λ1 protein upon stimulation, they provided a convenient system to screen functional 
effects of NF-κB and IRF protein knockdown on IFN-λ1 induction.  Cells were 
transfected with Dharmafect on target plus siRNA oligonucleotides pools targeting RelA, 
RelB, c-Rel, p105 (the precursor protein for p50), p100 (the precursor protein for p52) or 
IRF3.  Additionally, as a negative control, cells were also transfected with a control 
siRNA oligonucleotide pool whose sequences should not target any known transcripts 
within the human genome.  72h after transfection cells were harvested and analysed by 
western blotting.  The extent of protein knockdown was estimated semi-quantitatively by 
loading serial dilutions of the negative control on the same gel (figure 4.6).  The cells 
transfected with siRNA oligonucleotides targeting RelA, RelB, p100/p52 and IRF3 
showed a knockdown of greater than 75%, while siRNA oligonucleotides targeting cRel 
and p105/p50 led to a reduction of approximately 50%.  As controls, a siRNA-mediated 
knock down of IRF5 and IRF7 was also attempted in these cells; however it was not 
possible to alter the levels of these proteins to any significant extent (data not shown).  In 
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summary, it was possible to specifically knockdown the levels of all 5 NF-κB subunits 
and IRF3 by at least 50% in TLR3-293s using siRNA.   
                                            
Figure 4.6 Efficient knock-down of NF-κB subunits and IRF3 in TLR3-293s by siRNA.  104 cells were 
seeded in a 96-well plate and the following day transfected with the specified Dharmacon on target plus 
siRNA pool using RNAiMAX transfection reagent.  Transfections were performed in triplicate.  Following 
overnight incubation the media was aspirated and replaced with standard culture media.  72h later cells 
were harvested, triplicate transfections were pooled and then subject to western blotting.  All Dharmacon 
on target plus siRNA pools were transfected at a final concentration of 10nM.  Data are representative of at 
least 3 experiments.  Control sample serial dilutions were prepared for semi-quantitative estimation of 
efficiency of depletion of target proteins.  SiC = control siRNA 
 
 
4.4.2 Functional effect of NF-κB/IRF3 knockdown on IFN-λ1 induction in TLR3-
293s  
The functional effect of knocking down specific NF-κB subunits and IRF3 on IFN-λ1 
induction was subsequently analysed in TLR3-293s (figure 4.7A).  As negative controls, 
cells were either left untreated, treated with the transfection reagent RNAiMAX or 
transfected with a non-targeting siRNA oligonucleotide pool.  Upon stimulation with 
pI:C the levels of IFN-λ1 protein observed in these 3 control groups was similar, i.e. 
approximately 1,200 pg/ml.  On the other hand, transfection of cells with siRNA 
oligonucleotides pools targeting RelA and IRF3 led to a statistically significant reduction  
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Figure 4.7  Knockdown of RelA and IRF3 significantly inhibits IFN-1 induction in TLR3-293 cells.  
10 cells were seeded in a 96-well plate and the following day transfected with the specified Dharmacon on 
target plus siRNA pools using RNAiMAX transfection reagent.  72h later cells were stimulated with 
25g/ml of pI:C for 8h.  Supernatants were then collected and IFN-1 protein concentrations were 
determined by ELISA. All siRNA pools were transfected at a final concentration of 10nM.  Transfections 
and ELISA measurements were performed in triplicate.  Data are presented as (A) average +/- S.E.M of 
raw IFN-1 protein concentration, or as (B) a percentage of SiC treated cells.  Three stars indicate p value 
< 0.005; two stars indicates p value < 0.01; 1-way ANOVA   
 
in the amount of IFN-λ1 produced.  By contrast, depletion of p100/p52 or RelB had 
minimal effect on IFN-λ1 levels compared to the controls.  While siRNA 
oligonucleotides pools targeting c-Rel and p105/p50 did cause a decrease in the amount 
of IFN-λ1 produced, this difference was not statistically significant.  Even when the data 
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are presented in terms of a percentage of control cells (i.e. the measured IFN-λ1 protein 
concentrations are normalised to untreated cells being 100%) the levels of inhibition 
induced by the c-Rel and p105/p50 knockdown are still not statistically significant 
compared to the unspecific siRNA oligonucleotide pool (figure 4.7B).  However it can be 
seen more clearly that the level of inhibition by RelA and IRF3 is approximately 85% 
and 98% respectively.  MTT assays indicated that the observed differences in IFN-l1 
expression were not due to cytotoxic effects of the siRNA transfection process (data not 
shown).  This result suggested that RelA and IRF3 are key transcription factors 
controlling the transcriptional induction of IFN-λ1 in TLR3-293s.   
                  
 
4.4.3 Functional effect of NF-κB/IRF3 knockdown on IFN-λ1 induction in TLR4-
293s  
These experiments were also performed in TLR4-293 cells.  In these cells, a similar level 
of knock-down of NF-κB subunits and IRF3 was achieved compared to TLR3-293s 
(figure 4.8A).  Moreover, the effect this knock-down had on IFN-λ1 mRNA induction 
also mirrored the observation with TLR3-293s (figure 4.8B).  Again, knock-down of 
RelA and IRF3 led to a substantial inhibition of IFN-λ1 induction after treatment with 
LPS, while p100/p52 or RelB had only minimal effect compared to the controls.  As in 
TLR3-293s, depletion of c-Rel and, to a lesser extent, p100/p52, also inhibited IFN-λ1 
induction, although the inhibition was not statistically significant.  However, this 
inhibition was less pronounced when compared to RelA or IRF3. Taken together, these 
results suggested RelA and IRF3 are key transcription factors controlling the 
transcriptional induction of IFN-λ1 in TLR3-293s and TLR4-293s.   
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Figure 4.8 RelA and IRF3 knock-down inhibits IFN-1 induction in TLR4-293s. (A) 104 cells were 
seeded in a 96-well plate and the following day transfected with the specified Dharmacon on target plus 
siRNA pools using RNAiMAX transfection reagent.  Following overnight incubation, the media was 
aspirated and replaced with standard culture media.  72h later cells were harvested and subject to western 
blotting.  All siRNA pools were transfected at a final concentration of 10nM.  (B) NF-κB subunits and 
IRF3 were depleted by siRNA in TLR4-293s as described above.  Cells were then treated with 1 g/ml of 
LPS for 4h and then IFN-1 mRNA levels were measured by real-time PCR.  Data are presented as mean 
+/- S.E.M. of three independent experiments, each performed in triplicate.  One star indicates p value 
<0.05; two stars indicates p value < 0.01; 1-way ANOVA. 
 
 
 
Chapter 4  Results 
 153 
4.4.4 Validation of RNAi knockdown 
As stated, the experiments shown in figure 4.6, 4.7 and 4.8 were performed using a pool 
of 4 different siRNA oligonucleotides that target 4 distinct sequences on the desired 
mRNA.  These experiments showed that transfection of siRNA oligonucleotide pools 
targeting RelA and IRF3 inhibited IFN-λ1 induction.  To ensure that the effects of these 
siRNA oligonucleotide pools were specific, the individual siRNA oligonucleotides were 
independently transfected into TLR3-293s and the induction of IFN-λ1 was assessed by 
ELISA.  It was found that for both RelA (figure 4.9A) and IRF3 (figure 4.9B) the 
individual siRNA oligonucleotides caused a similar reduction in IFN-λ1 production 
compared to the pool.  This implied that the siRNA oligonucleotides pools targeting RelA 
and IRF3 were specific, and the inhibition of IFN-λ1 production was not via off-target 
effects. 
       
 
Figure 4.9  Validation of involvement of RelA and IRF3 in IFN-1 induction in TLR3-293s using 
multiple siRNA reagents. 10 cells were seeded in a 96-well plate and the following day transfected with 
the indicated siRNA oligonucleotides using RNAiMAX.  72h later cells were stimulated with 25g/ml of 
pI:C for 8h.  Supernatants were then collected and IFN-1 protein concentrations were determined by 
ELISA.  Transfections and ELISA measurements were performed in triplicate.  Data are presented as mean 
+/- S.D. of a representative experiment, each performed in triplicate. 
 
4.4.5 IFN-λ1 induction is dependent on RelA and IRF3 in MDDCs 
The next question that I asked was whether RelA and IRF3 are necessary factors for 
induction of IFN-λ1 human MDDCs, since they are a more physiologically relevant cell 
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type for interferon production.  A major problem with this system is that the transfection 
efficiency of siRNA oligonucleotides into MDDCs is substantially lower compared to 
cell lines.  Despite this, an optimised protocol developed by Dr. Fui Goon Goh in my 
research group facilitated considerable reduction in the concentrations of target proteins.  
Using this protocol, it was possible to consistently reduce the levels of RelA in these cells 
by more than 50% compared to control cells (figure 4.10A).  Similarly, IRF3 protein 
levels could be consistently decreased by just less than 50% (figure 4.10B). 
         
Figure 4.10 IFN-1 induction in response to LPS is dependent on RelA and IRF3 in MDDCs. 4x105 
MDDCs were seeded in a 24-well plate and the following day were transfeted with the indicated siRNA 
oligonucleotides using Dharmafect 1.  72h later whole cells lysates were prepared and equal amounts of 
protein were resolved by SDS-PAGE.  Proteins were then transferred and the levels of (A) relA or (B) IRF3 
were assessed by immuno-blotting .  Data are representative of at least 3 experiments. RelA and IRF3 were 
depleted by siRNA in MDDCs as described above and then cells were treated with 10 ng/ml of LPS for 4h.  
The levels of (C) IFN-1 and (D) IFN-β mRNA were then measured by real-time PCR.  (A) and (B) are 
representative of at least 3 experiments. (C) and (D) are presented as mean +/- S.E.M. of 3 independent 
experiments.  One star indicates p value <0.05; students T-test. 
 
The effect of RelA and IRF3 protein knockdown on IFN-λ1 in MDDCs was subsequently 
analysed in three independent donors (figure 4.10C).  Within each donor, the data were 
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normalised so that cells transfected with non-specific siRNA oligonucleotides equalled 
100%, and then averaged.  It was found that LPS-induced IFN-λ1 mRNA levels were 
decreased by approximately 50% in RelA depleted MDDCs, while IRF3 depleted cells 
showed a similar level of inhibition.  As a positive control, the concentrations of IFN-β 
mRNA were also examined in the same samples.  Again the level of inhibition observed 
when IRF3 had been knocked down was approximately 50% compared to control cells.  
Interestingly, however, when IFN-β mRNA levels were measured in RelA depleted 
MDDCs, the level of inhibition was only approximately 25% (figure 4.10D).  Taken 
together, these results suggested that in MDDCs, the induction of IFN-λ1 and IFN-β in 
response to LPS were equally dependent on IRF3.  However, IFN-λ1 seemed have a 
greater dependency on RelA compared to IFN-β in MDDCs, since its level in induction 
was inhibited to a greater extent when RelA was depleted.   
 
 
4.5 Validation of role of RelA and IRF3 in IFN-λ1 gene induction in 
MDDCs 
In all 3 cell systems analysed, the siRNA-mediated depletion of RelA and IRF3 
specifically inhibited the expression of IFN-λ1.  In order to further validate this result I 
attempted to inhibit the activity of RelA and IRF3 by additional means.  RelA is most 
commonly found in a complex with p50, and the activity of these complexes is 
predominately regulated through inhibitory interactions with IκBα.  Therefore, to reduce 
RelA activity, MDDCs were infected with an adeno-virus expression construct encoding 
a dominant negative version of IκBα.  On the other hand, I attempted to inhibit the 
activity of IRF3 by over-expression of a dominant negative version of the protein that 
was unable to bind DNA and therefore unable to initiate gene transcription. 
  
4.5.1 IκBα DN inhibits IFN-λ1 gene induction 
The dominant-negative variant of IκBα carries a serine to alanine mutation in serines 
32/36 which causes resistance to signal induced phosphorylation and degradation, and 
therefore acts as a super repressor of canonical NF-κB signalling (IκBαSR).  This reagent 
had been previously generated and widely used with the Kennedy Institute, and was 
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kindly gifted Dr Alessandra Lanfrancotti.  Western blot analysis using an IκBα antibody 
clearly showed increased levels of IκBα in IκBαSR infected MDDCs compared to control 
virus (figure 4.11A).  The inhibitory action of the IκBαSR protein was confirmed by co-
infection of the IκBαSR construct or control virus with a luciferase gene reporter driven 
by a tandem repeat of 4 consensus NF-κB sites (figure 4.11B).  Upon treatment with LPS, 
MDDCs infected with control virus showed a significant increase in luciferase activity.  
However, MDDCs that had been infected with the IκBαSR construct the activity of NF-
κB was reduced to less than background levels (compare IκBαSR 0h and 6h, with control 
virus 0h). 
 
Having confirmed that the IκBαSR was functional, the effect of its over-expression on 
TLR4-mediated IFN-λ1 induction was analysed.  Therefore, MDDCs were either infected 
with IκBαSR, control virus or left uninfected, and the effect on IFN-λ1 mRNA 
expression after 1h of LPS treatment was analysed (figure 4.11C).  Compared to 
uninfected cells, cells infected with control virus showed ~2-fold increase in the levels of 
IFN-λ1 mRNA following LPS treatment, which was probably caused by the virus 
activating an interferon response.  Nevertheless, IFN-λ1 induction was inhibited by more 
than 90% when cells were infected with the IκBαSR construct.  The effect of IκBαSR 
over-expression on IFN-β induction was also assessed (figure 4.11D).  Cells infected 
with the control virus contained slightly increased levels of IFN-β compared to 
uninfected cells, but again over-expression of IκBαSR inhibited IFN-β induction by 
~75%.  It is interesting to note that the level of inhibition observed in IFN-β expression 
using IκBαSR over-expression was again less than that of IFN-λ1, and is consistent with 
the effects seen using siRNA.  Altogether, these data support the hypothesis that RelA 
plays a crucial role in the induction of LPS-induced IFN-λ1 in human MDDCs. 
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Figure 4.11 Over-expression of IBSR inhibits LPS-induced IFN-1 induction in MDDC.  (A) 105 
MDDC were seeded in a 96-well plate and the following day were infected with IκBαSR or control virus at 
an MOI of 50.  48h later cells were harvested and analysed by western blotting using an anti-IκBα 
antibody.  Blots were stripped and re-probed using an anti-actin antibody.  (B) 105 MDDC were seeded in a 
96-well plate and the following day were co-infected with either control virus, or virus encoding IBSR, 
and a luciferase reporter containing 4xNF-κB consensus binding sites.  48h later cells were either left 
untreated or stimulated with 100ng/ml of LPS then analysed by luciferase assay.  Data are presented as 
mean luciferase units +/- st dev.  (C) & (D) 105 MDDC were seeded in a 96-well plate and the following 
day were infected with IBSR or control virus at the inducated MOI.  2 days later cells were either left 
untreated or stimulated with 100ng/ml LPS.  RNA was extracted and (C) IFN-1 and (D) IFN- mRNA 
levels were analysed by real-time PCR.  Data are presented as mean +/- S.D. of one representative of two 
independent experiments, each performed in triplicate. 
 
 
4.5.2 Generation of IRF DN constructs 
The data generated from the siRNA experiments also strongly implicated IRF3 in the 
regulation of IFN-λ1.  However, during the course of my project there were no additional 
reagents available, either commercial or in-house, that could support this result.  I 
therefore aimed to inhibit IRF3 by generating an expression construct encoding a 
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dominant negative version of IRF3 (DN IRF3) which lacked the first 133 amino acids 
containing the DNA-binding domain.  The domains of IRF proteins are schematically 
illustrated in fig. 4.12A.  The N-tereminal domain contains a highly conserved DNA-
binding domain of ~120 amino acids, while the C-terminus contains a regulatory domain 
that is neccassary for homo/hetero-dimerisation.  The extreme C-terminus contains a 
serine rich region, which is undergoes inducible phosphorylation and is thought to be 
important for interactions with additional cofactors such as CBP/p300 (Yang et al., 
2002).  The rationale of the DN IRF3 construct was that the exogenously expressed DN 
IRF3 would be able to dimerise with, and sequester, endogenous IRF3, but would be 
unable to bind to the promoters of target genes since it lacked the DNA-binding domain.  
This DN IRF3 construct was based on a previously published reported which showed that 
RANTES gene induction in response to viral infection was inhibited in cells over-
expressing DN IRF3 (Lin et al., 1999).  It should be noted that a potential limitation of 
this method is that DN IRF3 may not specifically inhibit IRF3, by virtue of hetero-
dimerisation with other IRF proteins.  Details of this cloning procedure can be found in 
section 2.3.8.1.  As controls, DN versions of IRF5 and IRF7 were also generated by 
deletion of amino acids 2-136 and 2-277 respectively.  IRF7 has been shown to be 
essential for induction of type I IFNs in response to viral infection (Honda et al., 2005b), 
whereas genetic studies revealed that IRF5 is mainly involved in pro-inflammatory 
cytokine production (Takaoka et al., 2005). 
 
After identifying positive clones that contained the correct DNA sequence encoding 
dominant negative versions of IRF3, 5 and 7, I then confirmed that they expressed the 
desired product.  To do this, the constructs were transfected into HEK-293 cells, and the 
cells were analysed by western blotting using an anti-HA antibody (4.12B).  Cells 
transfected with dominant negative IRF3 and IRF5 expression constructs showed good 
levels of stably expressed proteins. However, expression of constructs carrying full 
length or dominant negative mutants of IRF-7 produced only a weak signal, with multiple 
bands, suggesting a propensity to degradation.   
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Figure 4.12 Generation of IRF DN expression constructs.  (A) Schematic representation of IRF DN 
constructs lacking DNA-binding domain.  HA-tagged cDNAs encoding IRF3, 5 and 7 lacking the DNA-
binding domain were cloned into pENTR plasmid.  DBD = DNA-binding domain; NES = nuclear export 
signal; RD = regulatory domain; SRR = serine rich domain.  (B)  104 HEK-293 cells were seeded in a 96-
well plate and the following day transfected with expression constructs encoding DN IRF3, 5 or 7.  Cells 
were harvested and then analysed by western blotting using an anti-HA antibody.  (C)  104 TLR3-293s were 
seeded in a 96-well plate and the following day co-transfected with the indicated expression constructs and 
the IFN-1 -5086 luciferase reporter construct.  2 days later cells were either left untreated or stimulated 
with 25g/ml of pI:C for 8h then analysed by luciferase assay.  Data are presented as mean fold induction 
+/- SEM of 3 independent experiments.  Two stars indicates p value <0.01; 1-way ANOVA. 
 
In order to determine if these protein functioned as dominant negatives, I co-transfected 
them into TLR3-293s with a reporter construct containing the IFN-λ1 promoter (this IFN-
λ1 promoter construct is discussed in detail in the following chapter) (figure 4.12C).  As 
a positive control, a plasmid encoding a dominant negative version of IκB, that is 
resistant to ubiquitin-mediated degradation, was also used.  Following stimulation, the 
activity of the IFN-λ1 gene reporter was significantly reduced when co-transfected with 
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both the DN IκB and DN IRF3 expression constructs respectively.  On the other hand, the 
DN IRF7 construct had only minimal effect on the reporter compared to the control 
plasmid, which may have been due to the low levels of expression of the protein.  The 
activity of the IFN-λ1 reporter was also inhibited when co-transfected with the DN IRF5 
plasmid, although the difference was not statistically significant.  Thus, the dominant 
negative IRF3 and IRF5 construct expressed high levels of protein and the IRF3 seemed 
to function as a dominant negative as it inhibited the activity of the gene reporter. 
 
4.5.3 Effect of DN IRF constructs on IFN-λ1 induction in MDDCs 
I then investigated if over-expression of the DN IRF constructs inhibited IFN-λ1 
induction in MDDCs.  Since MDDCs are notoriously difficult to transfect with plasmid 
DNA, the constructs were first recombined into adeno-viral backbones.  The large scale 
grow-up and purification of the adeno-viral constructs were kindly performed by Ms 
Helen Banks at the Kennedy Institute.  After the purified viruses were prepared, I first 
checked that they expressed in MDDCs (figure 4.13A).  As a control „M-CSF‟ 
macrophages were also infected, since they are known to have a higher infection 
efficiency.  Western blot analysis showed that DN IRF3 and DN IRF5 proteins were 
expressed in MDDCs, although at considerably lower levels compared to in „M-CSF‟ 
macrophages.  DN IRF7 protein, on the other hand, was not detected and was therefore 
not included in further experiments.   
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Figure 4.13 Effect of DN IRF3 and DN IRF5 over-expression on LPS-induced IFN-1 expression in 
MDDCs.  (A) 5x105  MDDCs or „M-CSF‟ macrophages were plated in a 96-well plate and the following 
day infected with the indicated expression constructs.  2 days later cells were analysed by western blotting 
using an anti-HA antibody.  Data are representative of two experiments.  (B)  105 MDDCs were plated in a 
96-well plate and the following day infected with the indicated expression constructs.  2 days later cells 
were stimulated with 10ng/ml of LPS for 24h.  Supernatants then were collected and IFN-1 concentration 
was assessed by ELISA.  Infections and ELISA measurements were performed in triplicate.  Data are 
presented as mean +/- st dev.  2 representative out of at least 4 independent experiments are shown. 
 
I next examined the effect of DN IRF3 and DN IRF5 over-expression on TLR4-mediated 
IFN-λ1 induction in MDDCs as measured by ELISA in at least 4 donors.  Compared to 
control virus, no consistent effect on IFN-λ1 production was observed.  The results from 
two representative donors are shown (figure 4.13B).  It is possible that the discrepancy 
between the effect of DN IRF3 between 293 cells and MDDCs was due to the differences 
in expression of the DN IRF3 protein.  However, an understanding of how the expression 
of DN IRF3 compared to endogenous levels of IRF3 in MDDCs would be required to 
sustain this conclusion.   
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4.6 Over-expression of specific NF-κB and IRF proteins to investigate 
IFN-λ1 induction 
In this chapter so far, I have described various strategies that were employed to inhibit the 
activity of NF-κB and IRF proteins in order to assess their role in IFN-λ1 induction.  To 
complement these experiments, I also investigated the effect on IFN-λ1 production when 
these factors were over-expressed.  Expression constructs encoding all 5 NF-κB subunits 
were already available within my group.  In addition, I generated expression constructs 
encoding wild-type, HA-tagged IRFs 3, 5 and 7.  Details of the cloning strategy used to 
generate these constructs can be found in section 2.3.8.1.  I confirmed that the constructs 
expressed the desired protein by transfecting them into HEK-293 cells, and then 
performing an anti-HA western blot.  A strong, single band was clearly detected in the 
lanes corresponding to the IRF3 and IRF5, and, to a lesser extent, IRF7 transfected cells 
(data not shown).   
 
4.6.1 RelA, IRF3 and IRF7 over-expression induces IFN-λ1 production in TLR3-293 
cells 
The effect of over-expressing individual NF-κB and IRF proteins on IFN-λ1 production 
was subsequently examined in TLR3-293s (figure 4.14A).  Cells were transfected with 
the appropriate expression constructs, or a control plasmid which lacked any cDNA, and 
IFN-λ1 protein secretion was measured using ELISA.  On average, approximately 
400ng/ml of IFN-λ1 protein was detected in the supernatants of cells transfected with the 
control plasmid, even in the absence of any stimulation.  It is possible that the IFN-λ1 
observed in the control cells was the result of an interferon response triggered by the 
transfection plasmid DNA.  Nonetheless, it was clear that, in this system, RelA, IRF3 and 
IRF7 specifically upregulated the production of IFN-λ1.  Cells over-expressing RelA, and 
cells over-expressing IRF3 or IRF7 produced approximately 2,000 pg/ml and 1,200pg/ml 
of IFN-λ1 protein respectively.  This difference in the levels of IFN-λ1 protein was found 
to be statistically significant compared to control cells.  On the other hand, cells 
transfected with expression constructs encoding RelB, c-Rel, p50, p52 or IRF5 showed a 
similar level of IFN-λ1 protein secretion compared to control cells.    Thus, in TLR3-293s 
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over-expression of RelA, IRF3 and IRF7 was sufficient to drive activation of the IFN-λ1 
gene.   
 
4.6.2 RelA can weakly synergise with IRF3 and IRF7 respectively 
Induction of IFN-β in response to viral infection is believed to require the coordinate 
activation of the NF-κB and IRF3/7 signalling pathways, which act synergistically at the 
IFN-β gene promoter (Thanos and Maniatis, 1995b). The same pathways are also 
activated via LPS-induced TLR4 signal transduction (Rowe et al., 2006). Therefore, the 
next question that was addressed was whether RelA could act synergistically with IRF3 
or IRF7 respectively in the context of IFN-λ1 gene regulation (figure 4.14B).  If these 
transcription factors were synergistic, then the amount of IFN-λ1 produced when RelA 
and IRF3 or IRF7 were co-transfected into TLR3-293s would be greater than the sum of 
single transfections of the respective expression constructs.  Indeed, co-transfection of 
both RelA and IRF3, and RelA and IRF7, respectively, led to approximately 50% more 
IFN-λ1 production compared to the additive values of single transfections.  However, 
while the former was found to be statistically significant, the latter was not.  Taken 
together, these observations suggested that the actions of RelA/IRF3 and RelA/IRF7 were 
only weakly synergistic with regard to IFN-λ1 production in TLR3-293s. 
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Figure 4.14 (A) RelA, IRF3 and IRF7 selectively upregulate IFN-1 protein expression in TLR3-
293s.  104 cells were seeded in a 96-well plate and the following day transfected with expression constructs 
encoding the indicated proteins or the control plasmid pBent.  2 days later supernatants were collected and 
IFN-1 protein concentration was assessed by ELISA. Data are presented as mean +/- S.E.M. of 3 
independent experiments, each performed in triplicate.  Two stars indicate p value<0.01; 1-way ANOVA.  
(B) RelA does not efficiently synergise with IRF3/7 at the IFN-1 gene in TLR3-293s.  104 cells were 
seeded in a 96-well plate and the following day transfected with the indicated expression constructs. 2 days 
later supernatants were collected and IFN-1 protein levels were measured by ELISA. Data are presented 
as mean +/- S.E.M. of 3 independent experiments, each performed in triplicate.  pBent = control plasmid; 
RelA + IRF3 = additive value of single RelA transfection + single IRF3 transfection; RelA/IRF3 = co-
transfection of RelA and IRF3 expression constructs; RelA + IRF7 = additive value of single RelA 
transfection + single IRF7 transfection; RelA/IRF7 = co-transfection of RelA and IRF7 expression 
constructs.  One star indicates p value<0.05; students T-test . 
 
 
4.6.3 Effect of over-expressing RelA and IRF3 in MDDCs 
Over-expression of RelA, IRF3 and IRF7 in TLR3-293s was sufficient to drive 
expression of the IFN-λ1 gene.  In order to determine if these factors could drive the 
expression of IFN-λ1 in MDDCs, these constructs were recombined into adeno-viral 
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expression vectors.  As a negative control, an adeno-viral construct of IRF5 was also 
generated.  The large scale grow-up and purification of the adeno-viral constructs were 
kindly performed by Ms Helen Banks and Dr. Alessandra Lanfrancotti at the Kennedy 
Institute.  The level of expression of these proteins in MDDCs was first analysed.  
Western blot analysis revealed that relatively low levels of IRF3, IRF5, and RelA 
expression could all be detected using an anti-HA antibody.  On the other hand, the 
expression HA-tagged IRF7 was not detected, and was therefore not included in future 
experiments (data not shown).  
 
The effect of over-expressing RelA, IRF3 and IRF5 on IFN-λ1 production in MDDCs 
from three different donors was then examined.  Cells were infected with the above 
expression constructs, control virus or left uninfected.  Two days later they were either 
left untreated or treated with LPS for 8h and IFN-λ1 protein concentration in the cell 
supernatants were determined by ELISA.  In the absence of LPS treatment, no IFN-λ1 
protein was detected in any of the donors (data not shown).  However, IRF3 over-
expression led to a statistically significant increase in the amount of IFN-λ1 produced in 
the presence of TLR4 signalling (figure 4.15).  By contrast, IRF5 over-expression only 
had minimal effect on IFN-λ1 expression compared to control cells.  Surprisingly, RelA 
over-expression also had negligible effect on IFN-λ1 expression.  A possible explanation 
for this observation is that the levels of endogenous RelA expression in MDDCs are 
already under saturating conditions, therefore the addition of exogenous RelA would 
have little impact on gene expression. 
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Figure 4.15 Over-expression of IRF3 significantly increases LPS-induced IFN-1 protein expression 
in MDDCs. 105 cells were seeded in a 96-well plate and the following day subjected to overnight 
incubation in serum-free media with adeno-viral constructs encoding RelA, IRF3 or IRF5 at a M.O.I. of 50.  
As negative controls were also either left un-infected, or infected with the non-encoding adeno-virus 
pENTR.  The following morning the media was replaced with standard culture medium.  48h later cells 
were either left unstimulated, or stimulated with 100ng/ml of LPS for 8h.  Supernatants were then collected 
and IFN-λ1 protein levels were measured by ELISA. Data are presented as mean +/- S.E.M. of 3 
independent experiments, each performed in triplicate.  Two stars indicate p value<0.01; 1-way ANOVA 
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4.7 Discussion 
Type III IFNs or IFN-s are a novel group of cytokines that are distantly related to type I 
IFNs and display similar antiviral properties.  Although most cell types are capable of 
producing these molecules following viral infection, DCs are the major producers in vivo.  
In addition to viral infection, their expression can also be induced by activation of 
specific TLRs, although underlying molecular mechanisms are poorly understood.   
 
In this chapter I have presented data that shows a key role for NF-κB and IRF3 in TLR4-
mediated expression of the novel IFN, IFN-λ1, in human MDDCs.  It was previously 
shown that in human MDDCs, LPS treatment caused the rapid and transient induction of 
IFN-λ1 and IFN-β (Coccia et al., 2004), a result which I confirmed.  The same 
manuscript also showed a similar kinetics of induction in response to TLR3 stimulation.  
However, data obtained from another member within my group contradicted this result, 
which revealed pI:C treatment induced a delayed and sustained induction (Dr. F. Goh, 
personal communication).  The reason for this discrepancy is unclear, although is 
possibly due to endotoxin contamination in the published studies.  In support of this idea, 
we found that some commercially bought pI:C batches were contaminated with traces of 
endotoxin, and resulted in a similar mRNA expression profile as compared with LPS.  
Moreover, there was no mention in the manuscript of Coccia et al of endotoxin testing. 
 
The induction of most cytokines in response to TLR stimulation is regulated at the level 
of transcription.  I therefore examined if this was the case for the human IFN-λ1 gene in 
MDDCs using two independent means.  I found that blocking transcription using 
actinomycin D dramatically inhibited the TLR4-mediated IFN-λ1 mRNA expression.  I 
also analysed the recruitment of RNA polymerase II to the IFN-λ1 transcription start site 
and intergenic region following LPS treatment.  Following stimulation, an increase of ~2-
fold and 3-fold was respectively observed.  The slightly delayed peak of RNA 
polymerase II recruitment to the IFN-λ1 locus was consistent with the lag observed in 
mRNA expression compared to IFN-β in TLR4 activated MDDCs.  This may appear at 
first sight like a modest level of recruitment considering the magnitude of gene 
expression.  However, the levels seen at the IFN-λ1 locus were comparable to those 
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observed at the IFN-β promoter, which is known to be regulated at the level of 
transcription.  While these results are consistent with the idea that IFN-λ1 induction is 
regulated mainly at the level of transcription, they do not rule out possible post-
transcriptional regulatory mechanisms.  In fact, analysis of the 3‟ region of the IFN-λ1 
transcript revealed the presence of 3x AUUAU elements, which are known to important 
regulators of mRNA stability (Espel, 2005).  It would therefore be of interest to assess the 
half life of IFN-λ1 mRNA in response to TLR4 activation.  This could be achieved by 
performing an actinomycin D chase experiments (Alford et al., 2007) or using the 
tetracycline-responsive reporter system (Lasa et al., 2000).    
 
The rapid induction of IFN-λ1 also suggested that all the necessary signalling molecules 
and transcription factors were already present within resting MDDCs.  This hypothesis 
was tested by blocking protein synthesis with cyclohexamide, and then measuring the 
effect on IFN-λ1 induction.  Interestingly, IFN-λ1 expression was not inhibited by 
cyclohexamide pre-treatment.  On the contrary, level of amplitude of expression after 4h 
of LPS treatment was greater than seen in control cells.  I therefore conclude that protein 
synthesis is required for deactivation, but not activation of the IFN-λ1 gene.  Although I 
did not explore the mechanism of IFN-λ1 gene deactivation, an obvious candidate is 
IκB, which is RelA dependent gene whose re-synthesis after LPS-treatment is essential 
for prompt termination of NF-κB activity (Arenzana-Seisdedos et al., 1995).   
 
The transcription factors NF-κB and IRF3 are known targets of TLR4 signalling (Kaisho 
and Tanaka, 2008), and are constitutively expressed in immature MDDCs.  Furthermore, 
a prerequisite for rapid IFN-λ1 transcription in MDDCs would be the rapid nuclear 
translocation of these factors.  Indeed significant nuclear levels of RelA, p50 and IRF3 
can be observed within 30 mins of TLR4 activation.  In contrast to other TLRs which 
only activate the canonical NF-κB pathway, TLR4 signalling in MDDCs leads to 
activation of both canonical and non-canonical NF-κB pathways (Saccani et al., 2003).  
Although the translocation of RelB and p52 did not occur until after 2h of LPS treatment, 
the possibility that they contributed to the late phase of IFN-λ1 expression cannot be 
excluded.   
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During the course of my project, two reports were published that also indicated a role for 
IRF3 and RelA in the regulation of IFN-λ1 (Onoguchi et al., 2007; Osterlund et al., 
2007).  Osterlund et al. showed that over-expression of IRF3 or RelAp50 was able to 
drive a luciferase gene reporter down-stream of the IFN-λ1 promoter.  Moreover, when 
IRF3 or RelAp50 over-expression was coupled with SV infection even greater activity of 
the reporter construct was observed.  On the other hand, Onoguchi et al. demonstrated 
that over-expression of a constitutively active form of IRF3 was sufficient to drive the 
expression of IFN-λ1 transcription.  Of interest, the same paper also showed that IRF3 or 
TBK1 deficient MEFs had impaired production of IFN-λ2 in response to Newcastle 
disease virus infection (IFN-λ1 is not expressed in mice).   
 
The experiments presented in this chapter both confirmed and extended these findings.  I 
was able to show, for the first time, that siRNA-mediated knock-down of RelA and IRF3 
significantly inhibited IFN-λ1 expression in stimulated TLR3-293s and TLR4-293s.  On 
the other hand, siRNA-mediated depletion of other NF-κB subunits had no significant 
effect on IFN-λ1 expression.  Importantly, the specificity of RelA and IRF3 inhibition 
was confirmed by using individual On Target Plus siRNAs, which shows the observed 
inhibition was specific.   
 
To the author‟s knowledge, this is the first instance description of a role for IRF3 and 
RelA in IFN-λ1 regulation in human myeloid cells, which are more physiologically 
relevant for interferon production compared to cell lines.  While knock-down in the cell 
lines almost completely abolished IFN-λ1 induction, a more modest, yet statistically 
significant inhibition was observed in MDDCs.  This discrepancy most likely reflects the 
levels of knock-down between the cell lines and myeloid cells, which is a consequence of 
the lower transfection efficiency of the latter.   
 
IκBαSR over-expression also dramatically inhibited IFN-λ1 transcription in MDDCs.   
Although this technique is less specific than siRNA, since the activity of other NF-κB 
subunits are likely to be affected, it still adds further support for the importance of RelA 
in IFN-λ1 gene activation.  In contrast, RelA over-expression in MDDCs had only 
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minimal effect on TLR4-mediated IFN-λ1 production compared to control cells.  Since 
DCs produce large amounts of inflammatory cytokines following infection, they express 
high endogenous levels of RelA.  It is tempting to speculate therefore that the addition of 
exogenous RelA has little impact on gene expression as the cells may already be under 
saturating concentrations.  This explanation seems likely, given that RelA over-
expression in TLR3-293s led to a significant increase in IFN-λ1 production. 
 
On the contrary, I found that over-expression of IRF3 in MDDCs significantly 
augmented LPS-induced IFN-λ1 production.  Moreover, this augmentation was specific, 
as IRF5 over-expression had a negligible effect compared to control cells.  Consistent 
with the results from Onoguchi et al, I also found that over-expression of IRF3 was 
sufficient to drive IFN-λ1 expression in resting TLR3-293s.  In addition, IRF7 was also 
able to activate the IFN-λ1 gene in these cells.  Unfortunately, due, to low expression 
levels, it was not possible to ascertain whether IRF7 could drive IFN-λ1 production in 
MDDCs.  To obtain further evidence for the involvement of IRF3 in IFN-λ1 regulation, a 
DN expression construct was generated that lacked the DNA binding domain.  
Transfection of this construct into TLR3-293s significantly inhibited the activity of the 
IFN-λ1 -5086 gene reporter (discussed in detail in chapter 5).  Moreover, the level of 
inhibition observed was similar to that of IκBα over-expression.  By contrast, DN IRF7 
had negligible effect on reporter activity, which reflected the weak expression of this 
protein in these cells.  However, infection of MDDCs with DN IRF3 had no discernable 
effect on LPS-induced IFN-λ1 production.  Although the reasons for this were not clear, 
it possible that there was not a sufficient amount of DN IRF3 expressed in these cells to 
inhibit the activity of endogenous IRF3. 
 
It should be noted that the study of IFN-l1 gene induction presents an obvious technical 
challenge.  In the absence of small molecule inhibitors that specifically target proteins of 
interest, manipulation of signaling pathways by delivery of wild-type or dominant 
negative expression constructs, or the delivery of siRNA oligonucleotides to knock-down 
putative transcription factors involved in IFN-l1 activation, must be used.  The delivery 
of these nucleic acids into the cells runs the risk of mimicking viral infection, which 
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would lead to activation of interferon genes, and could thus lead to results which are an 
artifact of the experimental system.  This is particularly true in human MDDCs, which 
are highly specialised to detect viral infection and produce large amount of interferons.  
However, all experiments included proper controls (either empty adeno-viral vector or 
scrambled siRNA oligonucleotides) and, as mentioned previously, no detectable amounts 
of IFN-l1 or IP-10 could be detected in control cells. 
 
The ability of RelA and IRF3/7 to synergistically drive IFN-λ1 expression was also 
assessed.  My results showed that RelA and IRF3 are only weakly synergetic at the IFN-
λ1 promoter.  Comparing to the summation of single transfections, co-transfection in 
TLR3-293s showed that IFN-λ1 production was only increased by 50%.  Although by 
strict definition this increase is synergetic, it could not be described as a strongly 
synergetic interaction.  For example, it was reported that co-treansfection of plasmids 
encoding RelA and IRF7 in resting 293 cells led to a 150-fold increase in the expression 
of the RANTES gene, whereas single transfections only led to a 5-30-fold increase in 
expression (Genin et al., 2000).  However, it is worth noting that the concentrations of 
exogenous RelA and IRF3 may not have been optimal.  By titrating the amount of 
plasmid used in single transfection experiments, it was clear that the IFN-λ1 gene was 
concentration dependently activated.  However, no such titrations were performed in co-
transfection studies.  It would have been interesting to examine if titrating down the 
concentrations of plasmid RelA and IRF3/7 would have resulted in a stronger synergy. 
 
An interesting observation from these results was the apparent greater dependency of 
IFN-λ1 on RelA compared to IFN-β in LPS-treated MDDCs.  This trend was observed 
both when IκBαSR was over-expressed, and when RelA was depleted using siRNA 
(while IRF3 affected both genes similarly).  In fact, there have been conflicting reports on 
the role of RelA in IFN-β induction, as its involvement seems to vary between cell types 
and/or species.  Early studies showed that IFN-β gene activation in virally infected 
human fibroblasts was dependent upon the formation of a multi-protein, in which RelA 
was a crucial component (Thanos and Maniatis, 1995b).  However, RelA knock-out 
MEFs displayed only a modest reduction in IFN-β expression following viral infection, 
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suggesting only a minor role for RelA in this system (Wang et al., 2007b).  The results 
shown herein extend the knowledge of IFN-β gene regulation, by demonstrating that 
RelA does contribute to TLR4-mediated IFN-β expression in human MDDCs. 
 
The major theme of the two previous publications on the induction of IFN-λ1 
transcription was that IFN-λ1 and IFN-β were regulated by a common mechanism 
(Onoguchi et al., 2007; Osterlund et al., 2007).  The results presented in this chapter 
broadly agree with these conclusions, in that RelA and IRF3 are both strongly implicated 
in the activation of both genes in response to TLR4 stimulation.  However, the greater 
dependency of IFN-λ1 compared to IFN-β on RelA in LPS-treated MDDCs suggested 
that subtle, quantitative differences may exist in the underlying regulatory mechanisms. 
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Functional B sites in the IFN-1 promoter are 
embedded in transposable elements 
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5.1 Introduction 
The initial studies of IFN- gene regulation (published while this work was in progress) 
relied heavily on a comparative analysis with the well characterized type I IFN gene 
system (Onoguchi et al., 2007; Osterlund et al., 2007).  Induction of the human IFN- 
gene in response to viral infection requires the coordinate activation of the transcription 
factors NF-B, AP-1 and IRF3/7 (Thanos and Maniatis, 1995b).  A search for the cis-
regulatory elements in the proximal ~600 nucleotides (nt) of the IFN-1 gene promoter 
revealed a cluster of IRF binding sites and a B site, reminiscent of the IFN-β gene 
proximal promoter, suggesting that IFN-1 and IFN- might be regulated by a common 
mechanism. This possibility was further supported by co-transfection experiments with 
various IRF expression constructs with IFN-1 or IFN-3 proximal ~600nt promoter 
driven gene reporter constructs, which suggested that  the IFN-1 gene was regulated by 
virus-induced IRF3 and IRF7, and resembled the IFN- gene (Osterlund et al., 2007).  
Moreover, Onoguchi et al. reported that mutation of some of these sites led to an 
inhibition of IFN-λ1 promoter activity in gene reporter assays (Onoguchi et al., 2007).  
By contrast, the IFN-2/3 genes, which are expressed at significantly lower levels, were 
found to be mainly controlled by IRF7, similar to the IFN- genes. 
 
Results presented in chapter 4 clearly pointed to a major role for the transcription factors 
RelA and IRF3 (and IRF7) in TLR4-mediated IFN-λ1 expression in human MDDCs.  To 
better understand the molecular mechanism of IFN-λ1 gene expression, the structure of 
the IFN-λ1 genomic locus and the locations of functional RelA and IRF3 regulatory 
elements were systematically investigated using a combination of biochemical and 
bioinformatic approaches. Contrary to the published reports (Onoguchi et al., 2007; 
Osterlund et al., 2007), our results suggest that the architecture of the IFN-λ1 and IFN-β 
promoter markedly differ, and help to explain why IFN-λ1 has a greater sensitivity to the 
nuclear levels of RelA as discussed in chapter 4.   
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5.2 Distal regulatory elements are required for maximal IFN-λ1 gene 
activation 
 
5.2.1 Rationale for design of IFN-λ1 reporter constructs 
To begin to understand the where the RelA and IRF3 binding sites controlling IFN-λ1 
induction are located, luciferase gene reporter constructs were generated.  At that time 
there were no reports regarding the transcriptional regulation of IFN-λ1.  The Osterlund 
and Onoguchi (Osterlund et al 2007, Onoguchi et al 2007) manuscripts that were 
published during the course of this study utilised IFN-λ1 reporter constructs containing 
~600 nt of upstream region, although it was unclear how they how they  came to select 
this region for analysis.  By contrast, this investigation undertook a systematic approach 
to identify regulatory elements regulating IFN-λ1 induction that relied on three 
assumptions:  
 
1) Regulatory elements can be located several kilobases (kB) away from the 
transcription start site of genes  
 
2) That the majority of regulatory elements would be located 5‟ to the IFN-λ1 
transcription start site. 
 
3) That the majority of regulatory elements would be located within regions that 
have been evolutionary conserved (Pennacchio and Rubin, 2001). 
 
Therefore the regions of interspecies conservation upstream of the human IFN-λ1 gene 
were analysed using the UCSC hg18 human genome assembly and sequence comparison 
features (http://genome.ucsc.edu/) (figure 5.1).  The multiple alignments of 28 vertebrate 
species were generated using Multiz and PhastCons by the UCSC/Penn State 
Bioinformatics comparative genomics alignment pipeline and viewed as the islands of 
conservation in the UCSC Genome Browser.  Of interest, the transcription start site 
(TSS) of the IFN-λ1 gene was defined as -97 nt upstream of the translation start site 
(TLSS), according to the ensemble genome browsing website (www.ensembl.org).  The 
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primers used to generate the IFN-λ1 reporters were based on this data, and the 5‟ of the 
reverse primer was located -23 nt upstream of the IFN-λ1 TLSS.  However, during the 
course of this investigation, Onoguchi et al (Onoguchi et al., 2007), reported that their 
RACE experiments indicated that the TSS of IFN-λ1 was located only -15 nt upstream of 
the TLSS.  The size of the IFN-λ1 reporter constructs are therefore in relation to the TSS 
as defined by Onoguchi et al (shown in figure 5.5).  Nevertheless, only limited 
conservation was observed in the promoter region proximal to the transcription start site 
(TSS).  However, punctuated regions of conservation could be seen between 
approximately 2kB and 5kB upstream of the TSS.   
 
        
Figure 5.1  Rationale for design of IFN-λ1 gene reporter constructs.  Genomic features of the human 
IFN-λ1 locus were analysed using the UCSC Genome Browser website (http://genome.ucsc.edu/).  The 
diagram shows the IFN-λ1 gene, which is indicated by the red line, and more than 5ΚB of upstream region.  
Also shown are regions of inter-species conservation (indicated by the vertical blue lines) and the positions 
of repetitive and transposable elements (indicated by the black horizontal bars).  A schematic representation 
of the regions encompassing IFN-λ1 -5086 and -1901gene are shown underneath the diagram. The 
transcription start site is located -15 upstream of the IFN-λ1 translation start site.  
 
To examine the functional consequences of the intergenic sequence conservation I 
generated two gene-reporter constructs: (1) driven by the upstream region of 5068 nt, and 
thus encompassing all conserved islands, and (2) driven by 1106 nt encompassing the 
conserved region most proximal to the gene. To facilitate the delivery of the gene-
reporter constructs into macrophages and MDDCs, which are notoriously difficult to 
transfect, I recombined them into adenoviruses.  Large scale adeno-viral purification was 
kindly performed by Ms Helen Banks, Kennedy Institute of Rheumatology.  The 
efficiency of DNA delivery by adenoviruses approached 100% (as judged by GFP 
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expression) and there was no significant effect on the resting cells (measured by 
endogenous IFN-1 and IP-10 response, data not shown). The generation of the IFN-λ1 
reporter constructs is described in more detail in section 2.3.8.2. 
 
5.2.2 Positive regulatory elements are located within 5ΚB upstream of the IFN-λ1 
TSS 
The -5068 nt and -1106 nt IFN-λ1 promoter driven reporter constructs were infected into 
primary human myeloid cells.  Three different cell types from at least 4 different donors 
were used: MDDCs, M-CSF macrophages and GM-CSF macrophages.  The activity of 
the reporters, in the presence or absence of LPS, were then analysed by a luciferase assay 
(figure 5.2)  Both constructs demonstrated an inducible luciferase reporter activity, but 
the LPS-induced response was significantly stronger for the longer -5068 construct in all 
myeloid cell types tested.   
            
 
Figure 5.2  IFN-λ1 -5086 reporter construct had significantly more activity than the -1106 reporter 
construct in (A) MDDCs, (B) M-CSF macrophages and (C) GM-CSF macrophages.  105 cells were 
seeded in a 96-well plate and the following day incubated overnight with the indicated adeno-viral 
construct at an M.O.I. of 50 in serum free media.  The following morning, the media was replaced with 
standard culture media and 2 days later were either stimulated with 100ng/ml of LPS for 8h or left 
unstimulated, before being subjected to luciferase assay.  Infections and luciferase measurements were 
performed in triplicate.  Data are presented as mean fold induction +/- S.E.M of n independent experiments, 
each performed in triplicate.  One star indicates p value <0.05; three stars indicate p value <0.005; T-test. 
 
Thus, the most proximal region of 1106 base pairs was not sufficient for maximal levels 
of IFN-λ1 induction in response to LPS.  This suggested that the region between -1106 
and -5068 upstream of the gene may contain essential regulatory elements.   
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5.2.3 Regulatory elements essential for IFN-λ1 gene induction are located within the 
first -1901 nt upstream of the TSS 
To dissect the contribution of various segments between the -5068 nt and -1106 nt 
upstream of the TSS, we generated two intermediate luciferase reporter constructs, driven 
by 3209 nt and 1901 nt of the upstream region. The deletion set was transfected into 
TLR4-293 cells, in which a robust and transient expression of endogenous IFN-1 
mRNA was detected following LPS-stimulation (Chapter 4). The basal activity of the 
IFN-λ1 -5068, -3209 and -1901 reporter constructs were similar, and at least 4 times 
greater than the -1106 construct.  Furthermore, upon stimulation with LPS, the activity of 
the three longer IFN-λ1 reporter constructs was at least 10-fold greater compared to the 
IFN-λ1 -1106 reporter (figure 5.3A). A similar trend was observed in TLR3-293 cells 
stimulated with pI:C (figure 5.3B).   
 
       
Figure 5.3  IFN-λ1 -1901 reporter has significantly more activity compared to the -1106 reporter 
construct in (A) TLR4-293s and (B) TLR3-293s.  104 cells were seeded in a 96-well plate and the 
following day co-transfected with the indicated IFN-λ1 gene reporter construct and a control plasmid 
expressing renilla.  2 days later cells were stimulated with the indicated ligand for 8h and then analysed by 
luciferase assay.  Data are presented as mean +/- S.E.M. of 3 independent experiments, each performed in 
triplicate.  Two stars indicate p value<0.05; 1-way ANOVA. 
 
These observations implied that the majority of positive regulatory elements regulating 
the induction of the IFN-λ1 gene lie within the first -1901 nucleotides upstream of the 
TSS. 
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5.2.4 Validation of IFN-λ1 -1901 reporter as a model of the endogenous IFN-λ1 gene  
Gene reporter constructs can be extremely useful tools when beginning to characterise the 
features of specific promoters.  It is, nonetheless a reductionist and relatively artificial 
system, which, in some instances, can generate artifactual results that do not reflect the 
real biology of the endogenous gene.  Therefore, the behaviour of the IFN-λ1 -1901 nt 
reporter construct was assessed to ensure that it reflected behaviour of the endogenous 
gene.  To do this, the said reporter was co-transfected into TLR3-293s with individual 
NF-κB and IRF expression constructs, and the activity of the reporter was assessed by 
luciferase assay.  The activity of the reporter under these different conditions was then 
compared to effect of NF-κB and IRF over-expression on the endogenous IFN-λ1 gene, 
assessed by ELISA (figure 5.4A).  Over-expression of RelA clearly induced the strongest 
induction of the IFN-λ1 -1901 reporter construct, while IRF3 and IRF7 over-expression 
activated the reporter to a similar extent.  On the other hand, over-expression of IRF5, or 
the other 4 NF-κB subunits, respectively, had minimal effect on reporter activity, as 
compared with the control plasmid (figure 5.4B).  Over-expression of individual NF-κB 
and IRF proteins had a similar effect on endogenous IFN-λ1 production (figure 5.4A).   
 
The fact that the behaviour of IFN-λ1 -1901 reporter closely mirrored that of the 
endogenous gene in this system, suggested that it was indeed a useful tool for 
understanding the transcriptional regulation of IFN-λ1. Another important conclusion 
was that contrary to the initial assumption that regulatory elements often occur within the 
evolutionary conserved regions, in the case of the IFN-λ1 gene essential regulatory 
elements were human-specific.   
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Figure 5.4 The behaviour of the IFN-λ1 -1901 reporter is similar to the endogenous IFN-λ1 gene in 
response to NF-κB and IRF protein over-expression in TLR3-293s.  104 cells were plated in a 96-well 
plate and the following day co-transfected with the indicated expression constructs, the IFN-λ1 -1901 
reporter and a plasmid encoding renilla.  2 days later cells supernatants were collected and IFN-λ1 protein 
concentration was determined by ELISA, and IFN-λ1 -1901 reporter activity was determined by luciferase 
assay.  (A) Data are presented as mean IFN-λ1 protein concentration +/- S.D. of a representative 
experiment out of 3 independent experiments, each performed in triplicate.  (B) Data are presented as mean 
luciferase/renilla units +/- S.D. of a representative experiment out of 3 independent experiments, each 
performed in triplicate.  
 
 
5.3 Identification of putative NF-κB and IRF binding sites within the -
1901 nucleotides upstream of the IFN-λ1 gene 
The data generated in chapter 4 suggested that the critical events regulating the induction 
of IFN-λ1 in response to LPS are the binding of RelA and IRF3 to regulatory elements 
within the IFN-λ1 promoter. Thus, the nucleotide sequence of the 5068 nt promoter 
region was inspected for the presence of putative NF-κB and IRF binding sites, using 
transcription factor binding sites searching software, such as JASPAR 
(http://jaspar.cgb.ki.se/ )(Vlieghe et al., 2006) and rVista (http://rvista.dcode.org/) (Loots 
and Ovcharenko, 2004). Specific focus was given to the first 1901nt upstream of IFN-λ1, 
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since this region seemed to contain the majority of regulatory elements required for LPS 
induction (figure 5.5).  Altogether, six putative NF-κB and 6 IRF binding sites were 
identified in the IFN-λ1 promoter region encompassing the -1901 reporter.  Interestingly, 
only two of these NF-κB binding sites were located within the -1106 IFN-λ1 reporter 
construct, while the other four were positioned between -1106 and -1901 nucleotides 
upstream of the transcription start site.  In contrast, five of the IRF binding sites were 
located within the proximal IFN-λ1 promoter region, while only one was identified more 
than -1106 nucleotides upstream of the gene.  Taken together, this bioinformatic analysis 
suggests that RelA binding to the predicted cluster of NF-κB sites between -1106 and -
1901 of the promoter region may mediate the extra LPS-inducibility of the IFN-λ1 -1901 
reporter construct compared to the -1106 construct.  
 
     
Figure 5.5  Four putative NF-κB binding sites are located between -1106 and -1901 upstream of the 
IFN-λ1 transcription start site.  The DNA sequence containing the IFN-λ1 -1901 reporter construct was 
analysed for putative NF-κB and IRF binding sites using the JASPAR database (http://jaspar.cgb.ki.se/).  
Putative κB sites shown in grey; putative ISRE sites shown in yellow; transcription start site defined by 
ensembl shown in green italics; transcription start site defined by Onoguchi et al. shown in green bold; 
translation start site shown in red; reverse primer used to generate IFN-λ1 reporter constructs shown in 
blue.  
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5.4 RelA binding to the distal cluster of κB sites is a key regulatory 
event in TLR4-mediated IFN-λ1 gene activation  
 
5.4.1 RelA-mediated IFN-λ1 induction is mediated mainly via the distal promoter 
region between -1106 and-1901 nucleotides upstream of the TSS 
The hypothesis that RelA acts via the putative distal cluster of NF-κB sites between    -
1106 and -1901 upstream of the IFN-λ1 gene, while IRF3/7 acts via the proximal 
promoter region, was subsequently investigated.  First, the IFN-λ1 -1106 luciferase 
reporter was co-transfected into TLR4-293s with either the expression construct encoding 
RelA, IRF3, IRF7 or a control plasmid respectively.  The luciferase signal measured 
under these conditions was then compared with the signal generated when the IFN-λ1 -
1901 luciferase reporter was co-transfected with the same expression constructs (figure 
5.6A).  RelA activated the -1901 reporter construct ~148-fold but the -1106 reporter only 
22-fold.  This 7-fold difference suggested the major elements responsible for the RelA 
response were located between -1901 and -1106 upstream of the IFN-λ1 gene.  On the 
other hand, IRF3 and IRF7 over-expression resulted in a similar level of activation of the 
IFN-λ1-1901 and -1106 reporter constructs.  A similar trend was observed in TLR3-293s 
(figure 5.6B).   
 
Taken together, these results support the notion that the extra activity of the IFN-λ1-1901 
reporter construct compared to the -1106 reporter is due, at least in part, to the binding of 
RelA to the putative NF-κB binding sites located between -1901 and -1106 upstream of 
the IFN-λ1 TSS.  Moreover, IRF3/7 activity seems to be confined to the proximal 
promoter region within the first -1106 nucleotides upstream of the transcription start site. 
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Figure 5.6 RelA and IRF3/7 activate IFN-λ1 via spatially separated (distal and proximal) promoter 
elements in (A) TLR4-293s and (B) TLR3-293s. 104 cells were plated in a 96-well plate and the 
following day co-transfected with the indicated expression constructs, the IFN-λ1 -1901 reporter or the 
IFN-λ1 -1106 reporter, and a plasmid encoding renilla.  Two days later cells were analysed by luciferase 
assay.  Data are presented as mean luciferase/renilla units +/- S.D. of a representative out of 2 independent 
experiments, each performed in triplicate.  The levels of fold-induction of RelA, IRF3 and IRF7 normalised 
against the activity of the empty control plasmid pBent are indicated above the corresponding bar. 
 
 
5.4.2 Mutation of individual putative κB sites does not diminish IFN-λ1 -1901 
reporter activity  
To examine the contribution of individual B sites to LPS induction of the IFN-1 gene, 
a set of gene-reporter constructs, carrying site-specific mutations in the B sites in the 
background of -1901 nt construct were generated. In addition to the κB sites in the distal 
cluster, the predicted κB2 site, and the predicted ISRE2 site were also subject to 
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mutation, since they had been reported to bind RelA and IRF3 respectively (Onoguchi et 
al., 2007). The mutant promoter constructs were transfected into TLR4-293 cells, and the 
luciferase reporter activities measured following LPS induction. The level of activity was 
then compared to the wild-type IFN-λ1 -1901 and IFN-λ1 -1106 reporter constructs.  By 
comparing the activity of the mutant constructs to the wild-type constructs, it would be 
possible to determine whether the identified putative κB sites conferred the extra activity 
upon the -1901 reporter in response to RelA.  None of the mutations had a significant 
effect on the basal activity of the reporter constructs compared to the wild-type reporter.  
In line with previous observations, the signal generated by the wild-type IFN-λ1 -1901 
reporter was approximately 10-fold greater than the -1106 reporter in response to LPS 
(figure 5.7).  In addition, the construct bearing the ISRE2 mutation was approximately 
2.5-fold less responsive to LPS compared to the IFN-λ1 -1901 reporter construct.  
However, the activity of the IFN-λ1 -1901 reporter constructs whose predicted κB sites 
had been mutated, were similar to the wild-type IFN-λ1 -1901 reporter.   
 
Therefore the ISRE2 site appeared to play a critical role in converting the LPS signal into 
IFN-λ1 gene activation, whereas loss of individual NF-κB sites had no significant impact 
in this system.  There are at least two possible explanations for the latter observation: (1) 
the mutation of the predicted NF-κB sequence did not sufficiently disrupt NF-κB-DNA 
complexes; (2) the sites are functionally redundant, and the loss of an individual κB site 
was compensated for by the remaining ones.   
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Figure 5.7 Mutation of individual NF-κB binding sties does not diminish IFN-λ1 -1901 reporter 
activity in TLR4-293s.  104 cells were seeded per well and the following day co-transfected with the 
indicated wild-type or mutated IFN-λ1 reporter constructs and a plasmid encoding renilla.  The relative 
positions of the NF-κB sites and ISRE site are indicated by the green box; mutated sites are indicated by the 
red cross.  2 days later cells were stimulated with 1mg/ml of LPS and then analysed luciferase assay.  Data 
are presented as mean luciferase/renilla units +/- S.E.M. of 3 independent experiments, each performed in 
triplicate.  Two stars indicate p value<0.01; three stars indicate p value<0.005; 1-way ANOVA compared 
to -1901 wt reporter.   
 
5.4.3 Mutation of multiple putative NF-κB binding sites inhibits IFN-λ1 -1901 
reporter activity 
In order to test if the distal cluster of putative κB elements in the distal IFN-λ1 promoter 
region were functionally redundant two further reporter constructs were generated.  In the 
first construct the κB3 and κB4 sites were mutated, while the κB5 and κB6 sites were 
mutated in the second construct.  The activities of the reporters harbouring mutations in 
two distinct distal κB sites were then compared to the wild-type IFN-λ1 -1901 reporter by 
luciferase assay.  It was observed that the activity of the IFN-λ1 -1901 reporter constructs 
that carried mutation at either sites κB5&6 or κB3&4 were approximately 3-fold less than 
the wild-type in response to LPS (figure 5.8).   
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Figure 5.8 Mutation of two NF-κB binding sties in the IFN-λ1 distal promoter region inhibits IFN-λ1 
-1901 reporter activity in TLR4-293s.  104 cells were seeded per well and the following day transfected 
with the indicated wild-type IFN-λ1 reporters or reporters whose putative NF-κB sites had been mutated. 
The relative positions of the κB sites are indicated by the green box; mutates sites are indicated by the red 
cross. 2 days later cells were stimulated with 1mg/ml of LPS and then analysed by luciferase assay.  Data 
are presented as mean luciferase/renilla units +/- S.E.M. of 3 independent experiments, each performed in 
triplicate.  Two stars indicate p value<0.01; three stars indicate p value<0.005; 1-way ANOVA compared 
to -1901 wt reporter. 
 
Overall, the cluster of predicted κB sites in the distal IFN-λ1 promoter region contributes 
to the transcriptional induction of IFN-λ1 in response to LPS accounting for the greater 
inducibility observed in the IFN-λ1 -1901 reporter construct compared to the IFN-λ1 -
1106 reporter construct.  Furthermore, κB sites in this distal cluster appear to be 
somewhat functionally redundant. It has been shown that in a homotypic cluster, the 
disruption of individual binding sites can be tolerated, as the presence of other sites 
compensate. On the other hand, all sites may contribute to the overall sensitivity of the 
transcriptional response (Segal et al., 2008). 
 
5.4.4 Design of primer sequences to analyse the IFN-λ1 promoter by chromatin 
immuno-precipitation 
The results described in the above imply that RelA mediates a large amount of its activity 
through binding to the distal κB sites located between -1106 and -1901 base pairs 
upstream of the IFN-λ1 gene to activate transcription.  However, since these experiments 
were performed in TLR4-293s using gene reporter constructs, they may not be reflective 
of the mechanism that occurs in LPS-treated MDDCs.  I therefore analysed the 
recruitment of RelA to the proximal and distal IFN-λ1 promoter regions using chromatin 
Chapter 5  Results 
 187 
immuno-precipitation (ChIP), which has the advantage of measuring the interactions of 
endogenous proteins with endogenous promoters.  Designing primers sequences that 
efficiently amplify the genomic region of interest is a fundamental aspect of ChIP.  
Primers were designed under the following stringent conditions: 
 
 Amplicon of 100-200 base pairs 
 primer length 20-27 base pairs 
 GC content of 40-60% (optimal 50%) 
 Tm 63-67°C (optimal 65°C) 
 Similar TM of forward and reverse primer (no greater than 1°C) 
 Primers should not have a complementary sequence of more than 2 bases at the 3‟ 
end 
 Complementary sequence of more than 3 bases should not exist within the primer 
 3‟ of primers should be G or C 
 
Primers sequences that met these criteria were tested on genomic DNA that had been 
subjected to ChIP conditions (i.e. paraformaldehyde-fixed and sonicated).  Only primers 
that had efficient and specific amplification, as judged by a Ct value of less than 25 and 
melt curve analysis respectively, were deemed suitable for ChIP experiments.  However, 
initial attempts to design primers to interrogate the IFN-λ1 promoter region resulted in 
primer sequences that were either not efficient or, more commonly, not specific (data not 
shown).  Closer inspection of the ~2κB IFN-λ1 promoter region revealed, that aside from 
the most proximal ~250 base pairs, it was almost exclusively comprised of repetitive 
elements, which was likely to hinder specific amplification of the region.  It is 
noteworthy that all four distal κB sites were also located with repetitive elements, three of 
them within ERVL LTR repeats and one within an AluSx repeat (figure 5.9A).  To 
overcome the problem of primer specificity, the IFN-λ1 2κB promoter was systematically 
divided into 5x400 base pair segments, and three primer pairs were designed for each 
chunk (figure 5.9A).  Out of these 15 primer pairs tested, only six showed a high level of 
efficiency and specificity (figure 5.9B & C).   
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Figure 5.9 Primer design for analysis of IFN-λ1 promoter region by chromatin immuno-
precipitation.  (A) 2κB of IFN-λ1 promoter region was divided into 5x400 base pair „chunks‟ and 3 primer 
sets were designed per chunk.  Gery highlight = putative κB sites; green highlight = TSS from Onoguchi et 
al; red highlight = translation start site; green text = GA(n) repeat; red text = MLT2B2 repeat; blue text = 
AluSx repeat; pink text = FLAM_C repeat; brown text = AluSq repeat; orange text = AluSg/x repeat.  (B) 
Melt curve analysis of primers using sonicated gDNA as a template.  (C) Summary of primer analysis.  
Green = suitable melt curve and Ct value; Red = unsuitable melt curve/Ct value. 
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All three primer sets that amplified the most proximal IFN-λ1 promoter region, which is 
largely devoid of repetitive elements, showed an adequate level of specificity and primer 
set N was selected for future experiments.  By contrast, only three out of nine sets within 
the more distal promoter regions showed sufficiently specific amplification.  One of 
these, primer set H, was located within the middle of the distal cluster of κB sites, and 
was therefore to analyse RelA recruitment to this region.   
 
5.4.5 RelA is rapidly recruited to the distal κB cluster in LPS-treated MDDCs 
Recruitment of RelA to the proximal and distal IFN-λ1 promoter regions in LPS-treated 
MDDCs was subsequently analysed by ChIP.  After one hour of LPS stimulation, RelA 
was efficiently recruited to the distal IFN-λ1 promoter region but not to the proximal 
IFN-λ1 promoter, whereas by four hours post-stimulation the level of RelA enrichment 
was similar between the two regions (data not shown).  In order to control for the 
heterogeneity between blood donors the data was normalised to fold-induction of RelA 
recruitment compared to unstimulated cells.  This showed that recruitment of RelA to the 
distal cluster of κB sites was rapid and transient peaking at 1 hour of LPS treatment, 
whereas the recruitment to the proximal promoter region appeared to be delayed until 
after 4 hours post stimulation (figure 5.10).  As a positive control, RelA recruitment to 
the IFN-β enhanceosome region was also assessed and showed a strong and rapid 
recruitment of RelA, similar to the one at the IFN-λ1 distal region.   
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Figure 5.10 RelA is rapidly recruited to the distal cluster of B sites in the IFN-1 promoter region.  
7x106 MDDCs were seeded in 10cm dishes and the following day were either left untreated, or stimulated 
with 100ng/ml of LPS for either 1h or 4h.  Cells were then fixed and nuclear extracts subjected to 
sonication.  Samples were then incubated with anti-RelA antibodies or anti-Ig antibodies.  Immuno-
complexes were collected, DNA fragments purified and analysed by real-time PCR with preimer sets H 
(distal) and N (proximal) or the IFN- promoter respectively.  Data are presented as mean fold enrichment 
+/- S.E.M. of four independent experiments, each performed in triplicate.  One star indicates p value<0.05; 
two stars indicate p value<0.01; 1-way ANOVA.  
 
 
5.4.6 Multiple AluS elements containing κB sites are present within the IFN-λ1 
genomic locus 
Taking into account the independence of NF-B activating signalling and the fact that 
distal B sites appear to originate by the insertion of the Alu Sx and ERVL LTR repeats 
(figure 5.9), the whole IFN-1 genomic region was inspected in more detail for the 
presence of other transposable elements.  At least ten elements of Alu S subfamilies were 
found in 5‟ and 3‟ regions of the gene, as well as in its introns (Figure 5.11), six of which 
were Alu Sx repeats carrying B sites either identical to the B5 in Alu Sx_2 or 
containing point mutations in the positions unlikely to affect NF-B binding.  
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Alu sub-type Position   Coordinates   κB site 
 
AluSx_0  5‟   44474245-44474522  GGTGAAACCC 
AluSx_1  5‟   44475349-44475652  GGTGAAACCC 
AluSx_2  5‟   44477244-44477539  GGTGAAACCC 
AluSq_0  5‟   44478084-44478388  AGTAAAACCC 
AluSg/x  5‟    44478394-44478557  - 
AluSx_3  intron   44479791-44480099  AGTGAAACCC 
AluSq_1  3‟   44481391-44481702  GGTGAAACCC 
AluSp_0  3‟   44481725-44482023  GGAGAAACCC 
AluSx_4  3‟   44482822-44483114  GGTGAAACCC 
AluSx_5  3‟   44483779-44484078  GGCGAAACTC 
 
Figure 5.11 Alu S subfamily elements in the IFN-1 gene locus.   
 
Of particular interest, the AluSx element located in the second intron of the IFN-1 gene 
produces a rare island of sequence conservation in this genomic region. In contrast, there 
was no additional MLT2B2 LTR element carrying similar B binding sites in the region. 
Moreover, when a sequence similarity search with the fragment encompassing B3 and 
B4 sites of the MLT2b2 in the IFN-1 promoter was conducted genome-wide using 
Ensembl Blastview platform, only 52 ERV sequences in the human genome aligned with 
this region, and only 3 of them comprised the intact B3 site (data not shown). 
Interestingly, the corresponding region of the IFN-β locus contains no insertions from the 
Alu or or LTR subfamilies (data not shown).   
 
Therefore, the whole IFN-1 locus appears to have sequestered a large number of B site 
containing Alu S elements, potentially providing additional binding sites for NF-B 
complexes.  
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5.5 Biochemical characterisation of distal cluster of putative NF-κB sites 
 
5.5.1 Five of six κB sites in the IFN-λ1 promoter region efficiently bind RelAp50 
complexes 
The relative binding affinities of the 6 predicted κB sites within the IFN-λ1 ~2κB 
promoter region were investigated using EMSA.  A schematic representation of the 
locations of the radio-labelled DNA probes relative to the IFN-λ1 transcription start site 
is shown (figure 5.12A).  The probes were incubated with recombinant RelAp50, since 
this heterodimer is the most common form of NF-κB in vivo.  These proteins were 
generated from a bacterial protein expression system with high purity (figure 5.12B).  As 
a positive control, the κB4 site from the 3‟ downstream of TNF gene was used, as it has 
been shown to bind RelAp50 complexes with high affinity (Kuprash et al.).  With the 
exception of the B4 probe, which was located in the distal IFN-λ1 promoter, all the 
probes tested were able to efficiently bind RelAp50 complexes (figure 5.12C).  
Furthermore, under these conditions of excess probes and excess RelAp50, the binding 
efficiencies appeared similar to that of the TNF B4 probe.   
 
Thus, the two B sites in the proximal IFN-λ1 promoter region (κB1 and κB2), and three 
of four B sites in the distal IFN-λ1 promoter region (κB3, κB5, κB6), were able to 
efficiently bind recombinant RelAp50 complexes in vitro. 
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Figure 5.12 Most putative NF-κB binding sites in the IFN-λ1 promoter region can efficiently bind 
RelAp50.  (A) Schematic diagram of the IFN-λ1 locus with putative NF-κB sites annotated by green boxes.  
(B) Recombinant RelA and p50 subunits were purified from a mammalian expression system.  (C) Radio-
labelled NF-κB probes were incubated with the recombinant RelA and p50 and their ability to interact was 
assessed by EMSA. 
 
 
5.5.2. κB sites bind RelAp50 complexes with similar affinities 
Under saturating conditions the binding affinities of IFN-λ1 κB sites 1-3; 5 and 6 seemed 
similar.  Therefore, to understand if there were more subtle differences in the affinities of 
these probes, the concentration of recombinant RelA protein was titrated down and the 
binding affinities were quantified (figure 5.13).  When RelAp50 was used at the highest 
concentration of 100nM, the strongest binding was observed using the κB3 and κB5 
probe, which was only approximately 50% greater than the κB1 probe.  The κB2 and κB6  
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Figure 5.13 Distal κB sites bind RelAp50 more efficiently then proximal κB site in the IFN-λ1 
promoter region.  (A) Schematic diagram of the IFN-λ1 locus with putative NF-κB sites annotated by 
green boxes.  (B,C) The relative binding of κB sites were estimated by quantifying the ratio of RelAp50 
bound and free radioactive probe using serial dilutions of the protein.  
 
probes showed an intermediate level of affinity.  At a lower RelA concentration of 24nM, 
there was a greater difference between the relative affinities of the probes.  The binding 
affinity of the κB2 and κB1 probes was at least 4-fold weaker than the κB3 probe, and at 
least 2-fold weaker than the κB5 and κB6 probes respectively.  However, each of the κB 
probes showed negligible binding when RelAp50 was used at a concentration of 6nM.  It 
was therefore concluded that the κB sites identified in the IFN-λ1 promoter region had 
similar affinities, when the concentrations RelAp50 complexes were saturating (i.e. 
100nM) or not sufficiently high (i.e. 6nM).  However, at the intermediate concentration 
of 24nM, the κB sites 3, 4 and 5, which were located on the distal promoter region, had a 
stronger affinity for RelAp50 complexes, compared to the κB1 and κB2 sites, which were 
located in the proximal IFN-λ1 promoter region.   
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Thus, these results suggested that the three distal κB sites bind RelAp50 with a higher 
affinity than the proximal κB sites.   
 
5.5.3 Five of six κB sites in the IFN-λ1 promoter region efficiently NF-κB complexes 
in LPS-induced MDDCs 
Having established that five out of six putative κB sites could bind recombinant RelAp50 
proteins with high affinity, their ability to bind RelAp50 complexes from LPS-activated 
MDDCs was subsequently investigated.  Therefore, the appropriate κB probes were 
incubated with nuclear extracts from cells that had been stimulated with LPS for 1 hour 
or had been left untreated (figure 5.14B).  When the five different κB probes were 
respectively incubated with nuclear extracts from untreated MDDCs, several weak bands 
could be observed on the gel.  However, when nuclear extracts from LPS-activated 
MDDCs were used, two of these bands became markedly darker, particularly in the lanes 
corresponding to κB probes 3, 5 and 6.  Furthermore, when the samples were treated with 
antibodies that recognise RelA and p50 (the main NF-κB species in the nuclei of MDDCs 
1 hour post LPS stimulation – figure 4.3) the bands were supershifted. Based on the 
migration pattern of the complexes in comparison to the previously characterised TNF 
κB4 (Kuprash et al., 1995) and the results of the supershift, the composition of the EMSA 
bands was defined as RelAp50 (upper) and p50p50 (lower) (figure 5.14B).  
 
Thus, NF-κB specific protein complexes derived from MDDC nuclear extracts were able 
to bind to each of the five κB probes in a LPS-dependent manner.  Furthermore, in 
comparison to the probes representing κB sites 1 and 2, sites 3, 5 and 6 seemed to have a 
stronger affinity for the protein complexes, which is consistent the pattern observed using 
recombinant proteins (figure 5.13). 
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Figure 5.14 Distal κB sites bind NF-κB in LPS-induced MDDCs.  (A) Schematic diagram of the IFN-λ1 
locus with putative NF-B sites annotated by green boxes.  (B) 107 MDDCs were plated in a 10cm dish and 
the following day stimulated with 100ng/ml of LPS for 0h or 1h.  Nuclear extracts were then prepared and 
incubated with radio-labelled NF-B probes and analysed by EMSA.  Supershift antibodies against RelA 
and p50 were used to determine if these proteins were bound by the probes.  One representative out of two 
independent experiments is shown. 
 
5.5.4 ISRE2 site efficiently binds IRF3 
The ability of the two ISRE sites proximal to the IFN-λ1 transcription start site to interact 
with IRF3 were also investigated using EMSA (figure 5.15A).  Recombinant IRF3 was 
purified by Dr Alessandra Lanfrancotti (Kennedy Institute) from a mammalian 
expression system with high purity (figure 5.15B).  It was seen that the ISRE2 site 
efficiently bound IRF3, whereas no interaction was detected with the ISRE1 site.  
Interestingly, ISRE2 site contained three tandem core ISRE sequences (x3 GAAA), in 
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contrast to the other putative ISRE sites in the region which only contained a maximum 
of one GAAA. No IRF3 binding was detected at the three putative ISRE sites in the TNF 
promoter.  
 
          
 
Figure 5.15 ISRE2 site efficiently binds recombinant IRF3 in vitro.  (A) Schematic diagram of the IFN-
λ1 locus with putative NF-κB sites annotated by red ovals. (B) Recombinant IRF3 was purified from a 
mammalian expression system.  (C) Radio-labelled ISRE probes were incubated with the recombinant 
IRF3 and their ability to interact was assessed by EMSA.  One representative out of two independent 
experiments is shown. 
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5.6 Discussion 
In this chapter the molecular mechanisms leading to IFN-1 gene expression in LPS-
stimulated MDDCs were investigated and revealed the modular organisation of the IFN-
1 enhancer. Specifically, the IFN-1 gene expression is mediated via spatially separated 
promoter elements that independently interact with IRF and NF-B. The activity of IRF3 
(and possibly IRF7) seems to occur through binding to the proximal IFN-λ1 promoter 
region.  By contrast, maximal induction of IFN-λ1 is dependent upon RelA binding to 
multiple κB sites within both the proximal and distal IFN-λ1 promoter region. 
Remarkably, the distal cluster of B sites, which were shown to be required for maximal 
levels of LPS induction, were introduced into the IFN-1 locus by insertion of Alu Sx 
and ERVL LTR repeats.  
 
 
Stimulation of human MDDCs with LPS results in a strong and rapid increase of IFN-1 
and IFN- gene expression, while no other type I IFNs are induced (Coccia et al., 2004). 
Moreover, the kinetics of their expression largely mirrors each other, peaking between 1 
and 4 hours and returning to the basal level by 24 hours post induction (figure 4.1). As in 
the case of IFN-, both NF-B RelA and IRF3/7 play key and direct role in the 
transcriptional regulation of the IFN-1 gene (Figures 4.10 & 4.14). How does the 
enhancer of IFN-1 operate? Is it similar to the IFN-enhancer? The enhancer of the 
IFN- gene is one of the best characterized compact enhancers in the human genome and 
provides a model of a highly coordinated and cooperative assembly of distinct TFs: in 
response to virus infection in fibroblasts both NF-B and IRF3/7 are assembled into a 
multifactorial complex (enhanceosome) that recruits the basal transcriptional machinery 
to the promoter. A less integrative but more flexible form of information processing is 
through a modular enhancer that functions as an ensemble of separate elements that can 
independently affect gene expression (Arnosti and Kulkarni, 2005). The observed 
independence of NF-B and IRF3 signalling in both endogenous gene and -1901 nt gene-
reporter activation and the high number of B sites distributed across the promoter, 
favour the later model. Importantly, in other types of analysis (such as specific activation 
by RelA, IRF3 and IRF7 or the lack of strong synergism between RelA and IRF3/7) the 
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behaviour of -1901 gene-reporter also reflected that of the endogenous IFN-λ1 gene. 
Moreover, the modular model predicts a level of redundancy in function of independent 
elements, which we also observe in the activity of the IFN-1 B sites.  
 
RelA binding to the distal cluster of κB sites seemed to be essential for maximal 
activation of IFN-λ1 gene.  Indeed ChIP analysis of LPS-treated MDDCs revealed a 
faster and stronger recruitment of RelA to the distal cluster of κB sites compared to the 
κB sites in the proximal IFN-λ1 promoter region. However, a trend in accumulation of 
RelA activity 4 hours post LPS stimulation was observed at the proximal IFN-λ1 region, 
pointing out to possible re-distribution of RelA in the region (Figure 5.10). It is 
interesting to speculate that NF-κB sequestered at the distal cluster of κB sites can 
directly influence IFN-λ1 gene expression at the early stages of the response, but can also 
deliver it to the proximal promoter and thus potentiate gene transcription at later hours. 
This hypothesis requires further investigation but it is worth noting that the maximum 
levels of IFN-λ1 mRNA expression and PolII recruitment to the TSS were observed at 4 
hours post LPS stimulation.  
 
One interesting feature of the modular enhancer is that the separate sub-elements could 
be represented by either single binding sites or small groups of binding sites that may 
function together, even forming local enhanceosome-like structures (Arnosti and 
Kulkarni, 2005). In the IFN-1 promoter, sites PRD1, ISRE and B1, B2 are 
interspersed within the first 300 nt of the promoter region, with B1 and PRD1 being 
adjacent to each other. This proximity could suggest a mechanism similar to that of the 
IFN- enhanceosome, at least in the proximal promoter region.  In fact, both Onoguchi et 
al and Osterlund et al suggested that IFN-1 might indeed be regulated via the 
enhanceosome mechanism (Onoguchi et al., 2007; Osterlund et al., 2007). However, the 
removal of B2 binding site by mutagenesis does not significantly affect gene reporter 
activity in response to LPS (Figure 5.7), contradicting the enhanceosome model which 
states that failure to mobilize any one of the participating factors should abrogate gene 
transcription entirely (Maniatis et al., 1998). On the other hand, the PRD1 site does not 
bind IRF3 (Figure 5.15), ruling out the possibility of complex formation at the PRD1-
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B1 element. The formal analysis of IRF3 recruitment to the ISRE sites at the proximal 
promoter region in LPS-stimulated MDDCs has not been achieved during the course of 
this study due to the lack of antibodies that had sufficient levels of immuno-precipitation 
under ChIP conditions. Future work will attempt to address this issue.  
 
The observed differences in sequence organization of IFN- and IFN-1 promoters are 
likely to affect their sensitivity to activation and reflect on their distinct physiological 
roles. For instance, IFN- can be induced in virtually all cells, acting as a molecular 
signal for viral infection. As such, it must be strongly regulated and activated only in 
response to a clear signal. At the same time the input signal can then be amplified by the 
fixed arrangement of binding sites as in biological bipolar junction transistors 
(Papatsenko and Levine, 2007). For example, in fibroblasts, NF-B and IRF3/7 appear to 
exist at suboptimal concentrations limiting the input signal to IFN-, which results in 
only in a fraction of cells expressing the gene (stochastic expression), while the 
overexpression of RelA in these cells can significantly increase the number of IFN- 
producing cells (Apostolou and Thanos, 2008). In contrast, in MDDCs, RelA can be 
found in the nuclei of all cells within 30 min of LPS-stimulation, thereby ensuring the 
availability of the activating signal. In this situation, recruitment of RelA to target 
promoters is likely to provide an activation signal based on the number of available B 
binding sites and independently of promoter occupancy by other transcription factors 
(Bosisio et al., 2006). Consequently, the robustness and sharpness of the IFN-1 
expression is ensured by the array of B sites in its promoter.  
 
It would be extremely interesting to investigate whether the IFN- gene expression in 
LPS-induced MDDCs is regulated via the enhanceosome assembly similar to its 
regulation in fibroblasts. In fact data from my group suggests that transcription of IFN-β 
in response to TLR4 stimulation of MDDCs follows RelA activation and recruitment to 
the IFN-β genomic locus, which occurs at multiple κB sites within and outside the well-
characterised proximal promoter region (F Goh et al, manuscript in preparation). These 
findings provide new insights into the complexity of IFN-β induction in primary immune 
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cells and suggest that the assembly of the IFN-β enhanceosome itself may be a cell- and 
stimulus-specific rather than general phenomenon. 
 
Recent comparative genomics studies have shown that a substantial proportion of 
sequence constrained elements unique to mammals arose from mobile elements, pointing 
to transposons as a major force in the evolution of mammalian gene regulation  (Lowe et 
al., 2007; Mikkelsen et al., 2007). The IFN-1 genomic locus appears to have 
accumulated a high number of transposable elements, raising the possibility that they 
might be a part of ongoing evolutionary selection and primate specification of IFN-s 
(Pestka et al., 2004). In fact, although the ERVL-Alu Sx-ERVL element transposition 
into the region can be detected as early as in marmosets, it is not found in the 
corresponding sequence of the chimpanzee genome, and is only partially present in the 
genomes of orang-utan and rhesus monkeys.   
 
Interestingly, the distal cluster of κB sites in the distal IFN-λ1 promoter region were 
embedded within transposable elements of the ERV LTR and Alu families.  ERV LTRs 
comprise about 8% of the human genome, but are usually not found in gene-rich regions, 
as they can have an affect on gene expression (Medstrand et al., 2005; van de Lagemaat 
et al., 2006). However, those elements that do become fixed are more likely than other 
transposable elements to assume a role in gene regulation via exaptation of functional 
elements in the ERV LTRs to the host.  For example, Wang et al have shown that a 
significant fraction of p53 site-containing class 1 ERVs may have been exapted as 
regulatory sequences to expand the p53 transcriptional network (Wang et al., 2007a). The 
class L ERVs, however, are one of the older families of ERVs, present in all placental 
animals but have undergone a major burst in amplification in primates (Benit et al., 
1999). Consequently these elements are characterised by a high level of sequence 
divergence. Indeed, the results of our genome-wide analysis of ERVL sequences, which 
align them to the κB-containing MLT2b2 in the IFN-λ1 promoter, confirmed their high 
sequence divergence. This conclusion is supported by the previously described analysis 
of another ERVL in the 3GAL-T5 promoter, containing functional NHF-1 binding site 
(Dunn et al., 2005).  
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In contrast to ERVs, primate-specific Alu repeats, which comprise more than 10% of the 
human genome, are often found in gene-rich regions (Chen et al., 2002). Their genome 
distribution appears to be non-random, clustering in genes of signalling, metabolic and 
transport proteins (Grover et al., 2003). Consequently, Alu elements have been 
implicated in diverse functions including transcriptional regulation, mainly by providing 
new enhancer signals to neighbouring genes (Brosius, 1999). Most of the Alu elements 
found in the promoters and harbouring putative regulatory sites belong to the older Alu 
subfamilies, such as Alu S expansion, which occurred about 55 Mya., indicating that they 
might have evolved to become accessory sites for PolII transcription (Shankar et al., 
2004). A number of TFBS (AP-1, Estrogen responsive element, Liver X receptor etc) 
have been previously shown to function in the Alu elements, and when analysed 
computationally revealed positional conservation in all subfamilies (Shankar et al., 
2004). However, with a notable exception of a study describing an insertion of a 
functional κB site via Alu Sg element in the promoter of the IFN- gene (Ackerman et 
al., 2002) and the recent study by Apostolou and Thanos implicating Alu Sx elements in 
the interchromosomal interaction with the IFN-β promoter (Apostolou and Thanos, 
2008), there is no information regarding the function of NF-κB binding sites in the Alu 
repeats. It is interesting to speculate that Alu S repeats interspersed in the genome may 
function as NF-κB-specific anchors that can sequester NF-κB and either directly 
influence expression of the nearby genes or distribute it to the promoters of selected 
genes via interchromosomal interaction  (Apostolou and Thanos, 2008). 
 
Altogether, ten elements of the Alu S subfamily were identified in the 10 Κb of the IFN-
λ1 locus, six of which are Alu Sx elements carrying κB sites identical or similar to the 
site κB5. The reason for such a high number of transposable elements carrying putative 
κB sites in this genomic region is not clear, especially in view of the fact that some of 
them are not detected in other primate genomes. Future studies will address the role of 
these elements in the transcriptional regulation of IFN-λ1. The first attempts have already 
been made to design primer sets to the corresponding repeat region for subsequent ChIP 
analysis. The human evolutionary lineage has experienced a repeat-driven genome 
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expansion of 30 Mb since the divergence from chimpanzees (Liu et al., 2003). It is 
therefore possible that the transcription factor binding sites, which translocated into this 
region with the transposable elements, may contribute to the regulatory divergence 
between species.  The functional relevance of thousands of mobile elements carrying 
transcription factor binding sites, e.g. Alu S repeats with B sites, as well as the evolution 
of the TF binding repertoire via transposable elements, is a fascinating subject that 
warrants further investigation. 
 
In summary, the molecular architecture of the IFN-1 promoter appears to be markedly 
different from the well described compact enhancer of the IFN- gene, despite their 
similar levels and kinetics of expression in MDDCs in response to virus infection and 
LPS. In these cells, the expression of IFN-1 senses high levels of nuclear RelA via the 
distal cluster of B sites, integrated into this region together as a part of mobile genetic 
elements transposition. An independent signal transmitted by IRF3/7 via the proximal 
promoter region, distantly similar to the IFN- enhancer, may represent the remnants of 
the type I IFN regulatory system and contribute to a fine-tuning of gene expression.  
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6.  Concluding discussion 
IFN-λs are novel members of the class II cytokine family, which also comprises type I 
IFNs, type II IFN (IFN-), IL-10 and IL-10 related factors.  Although this cytokine family 
contains only limited sequence homology, key motifs are strongly conserved which 
accounts for the high level of structural homology between the ligands and receptors of 
this family.  Members of the class II cytokine regulate a highly diverse range of 
immunological functions that impact on both innate and adaptive immunity.  The IFN-λs, 
like type I IFNs, have been shown to possess anti-viral and anti-tumour activities, 
however, it was unclear if they possessed additional immuno-regulatory functions. 
 
Chapter three examined the role of IFN-λ1 in both acute and chronic inflammation.  I 
found that IFN-λ1 was strongly induced in human MDDCs and monocyte-derived 
macrophages, in response to the inflammatory stimulus LPS.  I also observed low levels 
of IFN-λR1 and minimal IFN-λ1-induced signal transduction in these cells.  
Consequently IFN-λ1 was unable to modulate LPS-induced inflammatory cytokine 
production in MDDCs and M-CSF macrophages.  Similarly, chronically inflamed 
synovial membranes derived from RA patients were also unresponsive to IFN-λ1 due to 
limited levels of IFN-λ receptor expression and signal transduction.  In addition, 
spontaneous production of IFN-λ1 relatively low in these samples, indicating that IFN-λ1 
plays a limited role in synovial joint destruction in the late stages of RA.  However, given 
that the IFN-λ receptor is highly expressed in pDCs, it will be of interest to examine the 
role of type III IFNs in the early stages of RA.  Moreover, it will also be of great interest 
to examine the role of IFN-λ1 in inflammatory diseases that primarily affect epithelial 
tissues, such as psoriasis and colitis, such epithelial cells also express high levels of IFN-
λR.  For this the IFN-λR1 knock-out mice that were recently acquired will provide an 
invaluable tool.   
 
It is quite possible that IFN-λ1 may be of great benefit clinically.  The anti-viral and anti-
tumour activities of type I IFNs have been used to treat a variety of cancers and chronic 
viral infections for more than two decades.  Although they can be very effective at 
treating these conditions, a major drawback associated with type I IFN therapy is the 
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potential development of side-effects which can severely reduce the patients quality of 
life.  These can include headaches, fatigue, anorexia, mood disorders and clinical 
depression (Weiss, 1998).  In extreme cases, IFN-α therapy has been reportedly induced 
the development of auto-immune diseases including systemic lupus erythematosus and 
thyroid disease (Gota and Calabrese, 2003; Tomer et al., 2007).  Since IFN-λ1 and IFN-α 
execute similar gene expression programs, it is possible that IFN-λ1 therapy may also be 
effective at treating cancers or infections of epithelial cells, but would result in reduced 
side-effects due to the cell-type specific nature of the receptor expression.  In fact, 
ZymoGenetics is currently conducting clinical trials of PEGylated IFN-λ1 for the 
treatment of chronic Hepatitis C infection (Fox et al., 2009).   
 
Chapter four investigated the role of NF-κB and IRF proteins in IFN-λ1 expression.  It 
showed that, similar to IFN-β, IFN-λ1 expression was dependent on RelA and IRF3 in 
LPS-stimulated MDDCs, since siRNA knock-down of these proteins inhibited IFN-λ1 
expression.  However, IFN-λ1 seemed to have a greater dependency on RelA compared 
to IFN-β, whereas both genes were equally dependent on IRF3.  Recently the genomes of 
several teleost fish species have been sequenced, which has allowed the identification and 
cloning of fish IFN genes and components of the IFN-induction pathways.  Interestingly, 
many of the components of the IFN pathway in teleost fish are similar to mammals 
suggesting the IFN pathway has been long established in vertebrate evolution.  
Mammalian homologues of the viral sensors RIG-I, MDA5, TLR3 and TLR7 have been 
identified in the genomes of Atlantic salmon (Sun et al., 2009), in addition to the TLR 
adaptor TRIF (Fan et al., 2008).  Another study found that Atlantic salmon contain a 
homologue of IRF7, which, similar to mammalian IRF7, was upregulated following 
stimulation with pI:C and recombinant Atlantic salmon IFN (Kileng et al., 2009).  
Furthermore, IRF3 and IRF7 have both been identified in rainbow trout (Holland et al., 
2008).  Therefore mechanisms leading to IFN induction appear to be to have evolved 
early in vertebrate evolution and have been evolutionary conserved. 
 
In chapter five I examined the locations of the RelA and NF-κB regulatory elements that 
controlled IFN-λ1 induction.  I found that the IFN-λ1 promoter contains a proximal 
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IFR3/7 regulatory element and spatially separated κB binding sites that extend at least 
2κBp upstream of the gene.  Therefore, the molecular architecture of the IFN-λ1 
promoters is significantly different from the IFN-β promoter, which contains a highly 
compact enhancer proximal to the transcription start site comprising NF-κB and IRF3/7 
regulatory elements.  Moreover, the greater number of NF-κB binding sites in the IFN-λ1 
promoter explains, at least in part, the greater dependency of IFN-λ1 on RelA compared 
to IFN-β.   
 
As stated in the aims, thesis set out to characterise the role of IFN-1 in inflammation 
and test the hypothesis that IFN-1 will act as an anti-inflammatory cytokine (similar to 
IL-10) to limit the level of pro-inflammatory gene expression.  The results generated 
during the course of this work did not provide evidence in support of this hypothesis.  As 
summarised above, IFN-l1 was unable to down-regulate inflammatory cytokine 
expression in a manner similar to IL-10.  However, analysis of the mechanism of LPS-
induced IFN-l1 gene expression in primary human myeloid cells revealed the IFN-l1 
promoter contains functional kB sites embedded within repetitive elements of the Alu and 
LTR families.  This observation has led to a revised hypothesis that repetitive elements 
harbour kB elements that impact on NF-kB-mediated inflammatory gene expression. 
 
Understanding how class II cytokines evolved should shed light on the complexity of the 
regulation and function of these molecules.  Only a few studies have investigated the 
promoters of fish IFNs in any great detail.  Computational analysis has revealed that all 
fish IFNs promoters studied so far contain at least two IRF binding sites in the proximal 
promoter region (Bergan et al., 2006; Chen et al., 2005; Sun et al., 2009).  Interestingly, 
some, but not all, fish IFN promoters also contain NF-κB binding sites (Sun et al., 2009), 
similar to mammalian IFN promoters where NF-κB sites are present in IFN-β and IFN-λ1 
promoters, but absent from IFN-α promoters (Civas et al., 2006; MacDonald et al., 
1990).  It is worth noting that the mammalian IFN genes that are regulated by NF-κB all 
contain NF-κB sites that have been directly or indirectly associated with Alu repeats.  It 
has been demonstrated that the human IFN-γ promoter contains a functional NF-κB 
binding site ~800 nt upstream of the gene which was inserted by an Alu element 
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(Ackerman et al., 2002).  In the case of IFN-γ, it appears the Alu repeat brought only a 
partial NF-κB binding site when it inserted into the IFN- locus 22-34 million years ago.  
Phylogenetic analysis indicated that a series of substitution mutations led to the formation 
of a high affinity NF-κB binding site prior to radiation of the great apes more than 20 
million years ago.  As shown in this thesis, the IFN-λ1 promoter also contains a 
functional NF-κB site which is embedded in an Alu repeat and lies ~1500 nt upstream of 
the gene.  It appears that the insertion of the Alu repeat into human genomes occurred 
relatively recently in evolution, since it is absent from chimpanzee genomes (see figure 
5.1).  In addition, a recent publication showed that NF-κB can be delivered to the IFN-β 
enhanceosome via associations with NF-κB sites on distinct chromosomes (Apostolou 
and Thanos, 2008).  Remarkably, these NF-κB sites on distinct chromosomes were also 
embedded within Alu repeats. 
 
These findings raise the intriguing question of when IFNs first arose in evolution and 
how they have evolved during vertebrate evolution.  At present it is not clear exactly 
when the ancestral IFN gene arose during evolution.  However, analysis of the genomes 
of sea squirts (C. intestinalis and C. savignyi), which are classified as invertebrate 
chordates, indicates the presence of a gene which shows limited homology to the human 
IFN-αR1 gene (Krause and Pestka, 2005).  Importantly, the locations of splice site 
junctions and conserved cysteine residues of these genes are consistent with mammalian 
class II cytokine receptors.  By contrast, the purple sea urchin (S. purpuratus), which is 
classified as a non-chordate deuterostome, seems to have no significant sequences that 
are characteristic of class II cytokines.  This suggests the ancestral IFN system appeared 
during early chordate evolution.   
 
As stated IFN genes have been identified in the genomes of all teleost fish species so far 
examined, and one report has recently identified IFN genes in the Xenopus genome.  
Interestingly, all genes so far identified encoding IFNs in fish and Xenopus contain 5 
exons, similar to mammalian IFN-λs (Zou et al., 2007).  In addition, the IFN receptor 
chains are structurally more similar to the IFN-λ receptor complex, which has led to the 
suggestion by some authors that the IFN-λs represent the ancestral IFN system (Levraud 
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et al., 2007).  However, several studies have shown that on the basis of peptide 
homology, fish IFNs are closer to mammalian type I IFNs (~41-46%) than mammalian 
IFN-λs (~36%) (Altmann et al., 2003; Robertsen et al., 2003).  The pattern of cysteine 
residues in fish IFNs are also more closely resembles type I IFNs (two or four) than IFN-
λs (six).  Furthermore, fish group II IFNs contain a CAW motif, which is conserved 
exclusively amongst mammalian IFN-αs (Zou et al., 2007).  Therefore it is not possible 
to presently assign mammalian type I IFNs or mammalian IFN-λs as the ancestral IFN 
system.   
 
It remains unclear at what point mammalian type I IFNs and mammalian IFN-λs radiated 
in evolution.  However, the presence of IFN-λR1 homologue in Xenopus genomes 
(Krause and Pestka, 2005) implies this event occurred prior to the diversification of 
amphibians and reptiles/birds.  It is interesting to consider that the transition from a water 
based habitat to a land based habitat would obviously require significant adaptations and 
induce new stresses upon the host.  In particular, the scaly exterior of fishes was replaced 
with mucosal exteriors in amphibians, which may, one can imagine, be more susceptible 
to viral infections.  It is therefore tempting to speculate that the tissue-specific nature of 
IFN-λ anti-viral activity originally arose to protect amphibians from contracting viral 
infections via their skin. 
 
As stated above, all known Xenopus IFNs are encoded by genes containing 5 exons 
whereas avian and mammalian type I IFNs are intronless. This implies a genetic event 
occurred whereby spliced RNA was reincoperated into the genome as a retrotransposition 
during early tetrapod evolution and gave rise to modern type I IFNs.  Again it remains 
unclear when this event happened, but the sequencing and annotation of reptilian 
genomes would be helpful in this respect.  However, it is apparent that following the 
retrotransposition event, there has been a tendency for type I IFN genes to duplicate.  
Analysis of chicken genomes indicates the presence of 11 IFN genes, which can be split 
into two subgroups based on peptide homology and structure (Sick et al., 1998; Sick et 
al., 1996).  Annotation of monotreme and marsupial genomes has only been undertaken 
recently.  It was estimated that echidnas contained about four IFN genes (Harrison et al., 
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2003), although this number could well increase with more thorough analysis, while six 
IFN genes were reportedly present in platypus (Zou et al., 2007).  The marsupial species 
opossum and wallaby were found to contain 9 and 16 IFN genes respectively (Harrison et 
al., 2003; Zou et al., 2007).  As with chickens the IFNs identified in monotremes and 
marsupials were divided into two subgroups.  However, the tendency for type I IFN 
genes to duplicate is most apparent in eutherian mammals, which encode at least seven 
subgroups of type I IFNs: ,  and However, not all subtypes are present in 
all species, for example IFN-t is present only in ruminants.  Moreover, the gene 
duplication of each subgroup varies considerably between species such that humans 
contain 13 IFN- genes compared with 11 in mice.  Similarly, while most species contain 
only a single copy of IFN-, several IFN- genes are present in cows. 
 
There is also evidence to suggest that the IFN-λ species, similar to type I IFNs, have 
undergone recent duplication events following the speciation of eutherian mammals.  A 
recent analysis of 23 mammalian species found that the number of IFN-λ genes ranged 
from one (in bush baby genomes), to potentially nine (in shrew genomes) (Fox et al., 
2009).  In several species that contained multiple IFN-λ genes, these genes were more 
closely related to each other than IFN-λ genes of another species, suggesting that 
diversification of these species preceded the duplication of the genes.  Interestingly, some 
of the species analysed, including horse and dog, had an IFN-λ gene encoded by a single 
exon.  Moreover, in these species, the single exon IFN-λ gene was located on different 
chromosome from the multi-exon IFN-λ genes, strongly suggesting the duplication was 
the result of a retrotransposition event, similar to the formation of type I IFNs.  However, 
as the authors noted many of the genomes they analysed are only in draft format, which 
may have led to the false positive hits such as pseudo-genes.  Therefore a more thorough 
analysis is required to understand the full repertoire of IFN-λ genes within mammalian 
genomes. 
 
The significance of type I IFN and, to a lesser extent, IFN-λ gene duplication during 
tetrapod evolution remains unclear; however it presumably must confer some sort of 
evolutionary advantage.  It has been suggested that the lack of intron sequences placed a 
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selection pressure on duplication of type I IFN genes, since the possibility to generate 
different proteins through alternative splicing was lost.  Consistent with this idea, the 
presence of alternatively spliced IFN mRNAs has been reported to occur in several fish 
species (Levraud et al., 2007; Long et al., 2004).  Alternatively gene duplication may 
allow the flexibility to combat rapidly evolving pathogens during evolution.  For example 
the inducibility of IFN-λ1 and IFN-β, but not IFN-αs in response to LPS suggests that 
these genes have evolved to combat bacterial, in addition to viral infections.  
Accordingly, the IFN-λ1 promoter has acquired multiple NF-κB binding sites in its 
promoter region which amplify the signal from TLR4 resulting in robust gene expression.  
Of interest, recent work from my lab has identified a novel cluster of distal NF-κB 
binding sites in the IFN-β locus, which also seem to contribute to robust expression of 
IFN-β in response to LPS (Dr. F Goh, manuscript in preperation). 
 
An interesting feature of the class II cytokine ligand clusters in humans is the correlation 
between genes within the cluster and cellular co-expression.  For instance, IFN-λs are 
clustered on chromosome 19, and are produced mainly by DCs; type I IFNs, chromosome 
9, can be produced by most cell types; IFN-γ, IL-22 and IL-26, chromosome 12, 
produced by activated T-cells, IL-10, IL-19, IL-20, IL-24, chromosome 1, mainly 
produced by monocytes/macrophges in addition to T-cells.  These cluster co-expressions 
may be the result of similar patterns of regulatory elements in the promoters, as a 
consequence of gene duplication events.   
 
Another interesting and complementary possibility is that epigenetic modifications of the 
cluster loci are important determinants of cellular expression.  The fundamental unit of 
chromatin is the nucleosome; ~147 nt of DNA wrapped around a histone octamer 
containing two copies of the four histone proteins with adjacent nucleosomes linked by a 
DNA region of ~10-80 nt.  Histone proteins typically form a physical barrier to 
transcription as they inhibit the binding of transcription factors.  However, the N-terminal 
tails protrude from the histone core and are subject to a wide variety of post-translational 
modifications, including acetylation and methylation.  These modifications can affect 
gene transcription either by altering chromatin structure to make regulatory elements 
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accessible/inaccessible or by creating novel binding sites for chromatin remodelling 
enzymes that slide or remove the histone proteins. 
 
IL-4, IL-5 and IL-13 are members of the class I cytokine family that are closely clustered 
on human chromosome 5 and characteristic cytokines of Th2 cells.  It has been 
demonstrated that during the differentiation of naïve T cells into Th2 cells the region 
encompassing the IL-4/IL-5/IL-13 cluster acquire histone modifications that are typically 
associated with transcriptionally active genes, such as acetylation and methylation of 
specific lysine residues on histone 3 (Ansel et al., 2006).  By contrast, the differentiation 
of naïve T-cells into Th1 cells has been shown to induce the acquisition of 
transcriptionally repressive histone modifications at the IL-4 gene cluster.   
 
Very few studies have addressed the role of histone modifications in the regulation of 
class II cytokines.  An exception is IFN-γ, which has been shown to acquire histone 
modifications associated with transcriptionally active genes such as histone-3 acytlation 
and histone-3 lysine-9 methylation during the differentiation of Th1 cells (Chang and 
Aune, 2007).  Interestingly, these modifications extend as far as ~70κBp upstream of the 
IFN-γ gene.  Since the IL-26 gene is located ~50κBp upstream of IFN-γ, the IL-26 locus 
is presumably subject to the same epigenetic modifications as IFN-γ, although this point 
was not highlighted by the authors.  It would be interesting to assess if the same 
modifications are observed at the IL-22 gene, which lies ~100κBp upstream of the IFN-γ.  
Furthermore, it would be of great interest to examine whether other class II cytokine gene 
clusters are similarly subject to wide ranging epigenetic changes during cellular 
differentiation.  For example, does the IFN-λ locus acquire histone acytlation/methylation 
marks during the differentiation of monocytes into DCs?  Does the IL-10 gene cluster 
acquire epipgenetic modifications during the differentiation of CD34+ haematopoietic 
progenitors into monocytes?   
 
In summary, this thesis has investigated the regulation and function of the novel class II 
cytokine IFN-λ1.  It has shown IFN-λ1 is unable to modulate LPS-induced inflammatory 
cytokine production in human myeloid cells and spontaneous cytokine production in 
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synovial tissue derived from RA patients.  This correlated with low levels IFN-λ receptor 
expression and minimal IFN-λ1 mediated signal transduction in these cells.  It also found 
the IFN-λ1 gene is strongly expressed in MDDCs following TLR4 activation, and is 
dependent on the transcription factors RelA and IRF3.  These factors act via spatially 
separated regulatory elements, with IRF3 binding to the proximal IFN-λ1 promoter 
region, while RelA binds to elements in both the proximal and distal IFN-λ1 promoter 
region.  Remarkably, the distal NF-κB binding sites have been delivered to the IFN-λ1 
gene by transposable elements of the Alu and LTR families. 
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